Směrnice Xxxxxx 2000/32/XX
xx xxx 19. xxxxxx 2000,
xxxxxx xx xx xxxxxxx xxxxx přizpůsobuje xxxxxxxxxxx xxxxxxx směrnice Xxxx 67/548/XXX x xxxxxxxxxx xxxxxxxx a xxxxxxxxx předpisů týkajících xx xxxxxxxxxxx, balení x xxxxxxxxxx nebezpečných xxxxx [1]
(Text x xxxxxxxx xxx EHP)
KOMISE XXXXXXXXXX XXXXXXXXXXXX,
x xxxxxxx xx Smlouvu o xxxxxxxx Xxxxxxxxxx společenství,
s xxxxxxx xx xxxxxxxx Xxxx 67/548/EHS xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, balení a xxxxxxxxxx xxxxxxxxxxxx xxxxx [2], naposledy xxxxxxxxxx xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 1999/33/XX [3], a xxxxxxx xx xxxxxx 28 xxxxxxx xxxxxxxx,
xxxxxxxx x xxxxx xxxxxxx:
(1) Příloha X xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx společně x xxxxxxxxxx xxxxx x xxxxxxxxxxx x označování xxxxx xxxxx. Xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxx, xx xx měl být xxxxxx nebezpečných xxxxx x uvedené příloze xxxxxxxxxxx. Některé xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx určitých xxxxxx xxxxxxxxx a tabulky X v xxxxxxx X.
(2) Příloha III xxxxxxxx 67/548/EHS xxxxxxxx xxxxxx xxx udávajících xxxxxx xxxxxxxxxx rizik xxxxxxxxx x xxxxxxxxxxxx xxxxxxx x xxxxxxxxx. Xxxxxxx IV xxxxxxxx 67/548/XXX obsahuje xxxxxx xxx x xxxxxxxxxxxxxx xxxxxx týkajícími se xxxxxxxxxxxx látek a xxxxxxxxx. Příloha VI xxxxxxxx 67/548/XXX obsahuje xxxxx xx xxxxxxxxxxx x x označování xxxxxxxxxxxx látek x xxxxxxxxx. Některé jazykové xxxxx xxxxxxxx vyžadují xxxxxx určitých xxxxxx xxxxxx XXX, XX x VI.
(3) V xxxxxxx X xxxxxxxx 67/548/XXX se xxxxxxx xxxxxx xxx xxxxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxx, xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxx. Xx xxxxxxxx přizpůsobit xxxx xxxxxxx xxxxxxxxxxx pokroku.
(4) Xxxxxxx XX xxxxxxxx 67/548/XXX xxxxxxxx předpisy xxxxxxxx se xxxxxxx xxxxxxxx xxxxx otevření xxxxx. Tyto xxxxxxxx xx xxxx xxx xxxxxxxxxxxx x xxxxxxxxxxxxx. Xx xxxxxxxx xxxxxxxx xxxxxx, kde xx xxxxxxx xxxxxx proti xxxxxxxx xxxxx xxxxxxxxx.
(5) Xxxxxxxx této xxxxxxxx xxxx x xxxxxxx xx xxxxxxxxxxx Xxxxxx xxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx xxx xxxxxxxxxx technických překážek xxxxxxx xx xxxxx xxxxxxxxxxxx látek x xxxxxxxxx,
XXXXXXX TUTO SMĚRNICI:
Xxxxxx 1
Směrnice 67/548/XXX xx mění xxxxx:
1. Xxxxxxx X xx xxxx xxxxx:
x) odpovídající xxxxxxxx x xxxxxxxxx xx nahrazuje poznámkou X x xxxxxxx 1X této xxxxxxxx;
x) xxxxxxxxxxxx xxxxx x xxxxxxx X xx xxxxxxxxx xxxxx x xxxxxxx 1B xxxx xxxxxxxx;
x) odpovídající položky xx xxxxxxxxx xxxxxxxxx x xxxxxxx 1X xxxx směrnice;
d) xxxxxxxx xx xxxxxxx x xxxxxxx 1D xxxx xxxxxxxx.
2. Odpovídající xxxx x xxxxxxx III xx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxx specifickou xxxxxxxxxx v příloze 2 této směrnice.
3. Xxxxxxx XX xx xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxx x příloze XX xx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx v xxxxxxx 3X této xxxxxxxx;
x) odpovídající xxxxxx x xxxxxxx XX xx nahrazují xxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxx 3B xxxx xxxxxxxx.
4. Část B xxxxxxx V se xxxx xxxxx:
x) xxxxxxxx X.10 xx nahrazuje xxxxxx v xxxxxxx 4X xxxx směrnice;
b) xxxxxxxx X.11 xx xxxxxxxxx xxxxxx x xxxxxxx 4X této xxxxxxxx;
x) xxxxxxxx B.12 xx xxxxxxxxx xxxxxx x příloze 4X xxxx směrnice;
d) kapitoly X.13 a X.14 xx xxxxxxxxx xxxxxx x příloze 4X xxxx xxxxxxxx;
x) xxxxxxxx X.17 se nahrazuje xxxxxx v xxxxxxx 4X xxxx směrnice;
f) xxxxxxxx B.23 xx xxxxxxxxx textem v xxxxxxx 4X xxxx xxxxxxxx. Xxxxx xxxxxxxx X.23 xx vysvětlivce xx xxxx xxxxxxxxxxxxx xxxxxxxx;
x) vkládá se xxxx x xxxxxxx 4X xxxx xxxxxxxx.
5. Xxxxxxx xx xxxxxx xxxxxxx xxxxxxxx xxxxx x xxxxx X xxxxxxx V.
6. Xxxxxxxxxxxx xxxxx x xxxxxxx XX se xxxxxxxxx xxxxx v příloze 5 xxxx xxxxxxxx.
7. Xxxxxxx IX se xxxx xxxxxxxx xxxxxxxx x příloze 6 xxxx xxxxxxxx.
Článek 2
1. Xxxxxxx xxxxx xxxxxx x xxxxxxxx právní a xxxxxxx předpisy nezbytné xxx xxxxxxxx souladu x touto xxxxxxxx xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x nich xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxx xxx xxxxxx xxx xxxxxx xxxxxxx xxxxxxxxx. Xxxxxx odkazu si xxxxxxx členské xxxxx.
2. Xxxxxxx xxxxx sdělí Xxxxxx xxxxx hlavních xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx, které xxxxxxx x xxxxxxx působnosti xxxx xxxxxxxx, x xxxxxxxxxx xxxxxxx mezi xxxxxxxx a přijatými xxxxxxxxxxxxxx xxxxxxxxxxxx.
Článek 3
Tato xxxxxxxx xxxxxxxx v xxxxxxxx xxxxxx xxxx xx xxxxxxxxx x Úředním xxxxxxxx Evropských společenství.
Xxxxxx 4
Xxxx xxxxxxxx xx xxxxxx xxxxxxxx xxxxxx.
X Xxxxxxx xxx 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Přijato po xxxxxxxxxxxx po xxxxxxx xxxxx.
[2] Xx. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. věst. X 199, 30.7.1999, x. 57.
XXXXXXX 1X
XXXXXXXXX X XXXXXXX X
Xxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx x označování xxxxx
(Xxxxxx xx českého xxxxx)
XXXXXXX 1X
"XXXXXXX A
|
Z |
Symbol |
ES |
DA |
DE |
EL |
EN |
FI |
FR |
IT |
NL |
PT |
SV |
|
18 |
Ar |
Argón |
Argon |
Argon |
Αργό |
Argon |
Argon |
Argon |
Argon |
Argon |
Árgon |
Argon |
|
64 |
Gd |
Gadolinio |
Gadolinium |
Gadolinium |
Γαδολίνιο |
Gadolinium |
Gadolinium |
Gadolinium |
Gadolinio |
Gadolinium |
Gadolínio |
Gadolinium" |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx k látkám |
Číslo XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x přípravkům |
|
006–011–00–7 |
karbaryl (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. kat. 3; X40 Xx; R22 X; X50 |
Xx; X X: 22–40–50 S: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (ISO) natrium-N-methyldithiokarbamát |
205–293–0 |
137–42–8 |
Xn; X22 X31 X; X34 R43 X; X50–53 |
X; X X: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
206–354–4 |
330–54–1 |
Xxxx. xxx. 3; X40 Muta. xxx. 3; R40 Xx; R22–48/22 X; X50–53 |
Xx; X X: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- isopropoxyfenyl-N-methylkarbamát |
204–043–8 |
114–26–1 |
T; X25 N; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
xxxxxxxx (XXX) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 T; X24 N; X50–53 |
X+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
xxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; R24/25 N; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
xx-xxxxx (XXX) X-(2,3-xxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–961–1 |
2303–16–4 |
Xxxx. xxx. 3; X40 Xx; X22 X; R50–53 |
Xn; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
barban (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-xxxxxxxxxx)xxxxxxxx |
202–930–4 |
101–27–9 |
Xx; R22 X43 N; R50–53 |
Xn; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
merkaptodimethur (XXX) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; X22 Xx; X38 X; X51–53 |
Xx; X X: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
karbofuran (XXX) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 N; X50–53 |
X+; X R: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
dinobuton (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-xxx-xxxxx-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx |
213–546–1 |
973–21–7 |
X; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
dioxakarb (XXX) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; R25 X; X51–53 |
X; X R: 25–51/53 X: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-chlor-4-methoxyfenyl)-1,1-dimethylmočovina |
243–433–2 |
19937–59–8 |
N; X50–53 |
X X: 5 0/ 5 3 S: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
pirimikarb (XXX) 2-(xxxxxxxxxxxxx)- 5,6-dimethyl xxxxxxxxx-4-xx-X,X-xxxxxxxxxxxxxxxx |
245–430–1 |
23103–98–2 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
xxxxxxxxx (ISO) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-xxxxxxxxxx-X,X-xxxxxxxxxxxxxxxxxxxxxx |
X |
202–388–9 |
95–06–7 |
Xxxx. xxx. 2; R45 Xx; X22 N; X50–53 |
X; X R: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
tri-allát (ISO) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; R22–48/22 X43 X; X50–53 |
Xx; N X: 22–43–48/22–50/53 X: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (ISO) 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
205–766–1 |
150–68–5 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X R: 22–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
monuron-TCA 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; R36/38 Karc. xxx. 3; R40 X; X50–53 |
Xx; X X: 36/38–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) methyl-N-[(N-methylkarbamoyl)oxy]thioacetimidát |
240–815–0 |
16752–77–5 |
T+; X28 N; X50–53 |
X+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
bendiokarb (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; X23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
xxxxxxxxx (XXX) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx x 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; R24/25 N; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
xxxxxxxxxxxx (XXX) 2-[(ethylsulfanyl)methyl]fenyl-N-methylkarbamát |
249–981–9 |
29973–13–5 |
Xn; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-fenyl-1,1-dimethyluronium-trichloracetát |
— |
4482–55–7 |
Xi; R38 X; X50–53 |
Xx; X X: 38–50/53 S: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (XXX) 2-xxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–114–6 |
2631–40–5 |
Xx; X22 N; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xx; X21 N; X50–53 |
X+; X R: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 X; X51–53 |
Xx; N X: 22–51/53 X: (2-)24-61 |
|||
|
006–060–00–4 |
xxxxxxxxxxx (XXX) 2-methyl-4,4-dioxo-5,6-dihydro-4λ4-1,4-oxathiin-3-karboxanilid |
226–066–2 |
5259–88–1 |
Xn; R22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (ISO) 1,2-xx[3-(xxxxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx |
245–740–7 |
23564–05–8 |
Xxxx. xxx. 3; R40 X; X50–53 |
Xx; N X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx X-xxxxxxxxxx-X-xxxxxxx-2,5-xxxxxxxx-3-xxxxxxx |
262–302–0 |
60568–05–0 |
Xxxx. xxx. 3; X40 N; X50–53 |
Xx; X X: 40–50/53 S: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) ethyl-N -[({[(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)xxx]xxxxxxxx}xxxxxxxxxxx)xxxxxxxx]-X-xxxxxxxxx-β-xxxxxxxx(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)-X-({[2-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxxxxxx}xxxxxxxx)-X-xxxxxxxxxxxxxx |
— |
82560–54–1 |
X; X23/25 N; R50–53 |
T; X R: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
X,X-xxxxxxxxxxxxxxxx 1,1-xxxxxxxxxxxxxxxx |
X |
200–316–0 |
57–14–7 |
X; X11 Xxxx. kat. 2; X45 X; X23/25 C; X34 X; X51–53 |
X; X; X R: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
X,X-xxxxxxxxxxxxxxxx 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; X45 X; R23/24/25 X; X51–53 |
X; X X: 45–23/24/25–51/53 X: 53–45–61 |
C ≥ 25 %: X; R45–23/24/25 3 % &xx; X &xx; 25 %: X; X45–20/21/22 0,01 % < X &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx fluorovodíková … % |
B |
231–634–8 |
7664–39–3 |
T+; R26/27/28 X; X35 |
X+; X X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: T+; C; X26/27/28–35 1 % ≤ X &xx; 7 %: T; X23/24/25–34 0,1 % ≤ C &xx; 1 %: Xx; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (ISO) O,O-dimethyl-S -[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
201–676–1 |
86–50–0 |
X+; R26/28 X; X24 X43 X; X50–53 |
X+; X X: 24–26/28–43–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (XXX) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; R40 X; R23–48/25 Xx; X21/22 N; X50–53 |
X; X X: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
azinfos-ethyl (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; X24 X; X50–53 |
X+; N X: 24–28–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
xxxxxxxxx (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; R23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
chlorid xxxxxxx |
234–129–0 |
10545–99–0 |
X14 X; X34 X; X50 |
X; X X: 14–34–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; R36/37/38 |
||
|
016–014–00–5 |
chlorid xxxxxxxx |
— |
13451–08–6 |
X14 X; X34 N; X50 |
X; N X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; R34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; R45 Xxxx. xxx. 3; X40 X+; X26 X; X25 X; X34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; R45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; R45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: T; R45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: T; X45–22–23–43 1 % ≤ X &xx; 3 %: X; X45–23–43 0,1 % ≤ X &xx; 1 %: X; X45–20 0,01 % ≤ X < 0,1 %:X; R45 |
|
|
016–024–00-X |
dimexano (XXX) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 X; X50–53 |
Xx; X R: 22–50/53 S: (2-)60-61 |
|||
|
016–071–00–6 |
3-amino-6,13-dichlor-10-[(3-{[4-chlor-6-(2-sulfonatoanilino)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx trisodný |
410–130–3 |
136248–03–8 |
R43 |
Xi X: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
xxxxxxx xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 C; R34 |
C X: 14-34 X: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: X; R34 5 % ≤ X < 10 %: Xx; R36/37/38 |
||
|
030–004–00–8 |
dimethylzinek [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; R17 X; X34 X; X50–53 |
X; X; X R: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
xxxxxxxxx (XXX) xxxxxxxxxxxxx(xxxxxxx)xxxxxxx xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx |
236–049–1 |
13121–70–5 |
Xx; X20/21/22 X; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] xxxxx(xxxxxxxxxxxxx)xxxxxxx [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; X20/21/22 X; X50–53 |
Xx; N X: 20/21/22–50/53 X: (2-)26–28–60–61 |
X ≥ 1 %: Xx; R20/21/22 |
1 |
|
|
050–017–00–2 |
fenbutatinoxid (XXX) 1,1,1,3,3,3-xxxxxxx(2-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxx |
236–407–7 |
13356–08–6 |
X+; X26 Xx; X36/38 N; X50/53 |
X+; X X: 26–36/38–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
xxxx (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Yellow 34 (XX 77603) XX xxxxxxxxxx žluť 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Karc. kat. 3; R40 Xxxx. xxx. 1; R61 Xxxx. xxx. 3; X62 R33 X; X50–53 |
X; N R: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
xxxxxx (xxxxxxx-xxxxxxxxxx-xxxxx xxxxxxxx) CI Xxxxxxx Xxx 104 (XX 77605) XX xxxxxxxxxx červeň 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. kat. 3; X40 Xxxx. xxx. 1; R61 Xxxx. kat. 3; X62 X33 N; X50–53 |
X; N X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
601–024–00-X |
xxxxx [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; X65 Xx; X37 X; R51–53 |
Xn; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
xxxxx[x]xxxxx xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; X45 Xxxx. xxx. 2; X46 Xxxx. kat. 2; X60–61 X; X50–53 |
X; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
benzo[e]acefenanthrylen |
205–911–9 |
205–99–2 |
Karc. kat.2; X45 X; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-dichlorbenzen x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 X; X50–53 |
Xx; X X: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-xxxxxxx-1-xx allyljodid |
209–130–4 |
556–56–9 |
R10 X; X34 |
X R: 10-34 X: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
xxx-2-xx-1,4-xxxx |
203–788–6 |
110–65–6 |
X; X23/25 Xx; X21–48/22 X; R34 |
T X: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
C ≥ 50 %: X; R21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ C &xx; 25 %: Xx; R20/22–48/22 3 % ≤ X &xx; 10 %: Xx; X20/22 |
||
|
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; X8 Xx; R22 Xx; X36 |
X; Xx R: 8–22–36 S: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 X; X51–53 |
Xx; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-xxxxxxxxxxxxxxxx-2-xx xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 X52–53 |
Xx X:36–52/53 X: (2-)26-61 |
|||
|
603–117–00–0 |
propan-2-ol xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; X11 Xx; X36 X67 |
X; Xx X: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
xxxxxxx-2-xx 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (XXX) |
201–993–5 |
90–43–7 |
Xx; R36/37/38 X; X50 |
Xx; X X: 36/37/38–50 S: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx xxx xxxxxxx-2-xxxxxxxxxxxx 2-bifenylát xxxxx xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; R22 Xi; X37/38–41 X; X50 |
Xx; X X: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-methylpentan-2,2-diyl)difenol 2,2-xxx(4-xxxxxxxxxxxx)-4-xxxxxxxxxxxx |
401–720–1 |
6807–17–6 |
Xxxx. xxx. 2; X60 Xx; R36 N; X50–53 |
X; X X: 60–36–50/53 X: 53–45–60–61 |
|||
|
604–041–00–0 |
xxxxxxxxxxx [1] acifluorfen-natrium [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; X22 Xx; X38–41 X; X50–53 |
Xx; X R: 22–38–41–50/53 S: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx hydrochinonmonobenzylether 4-(xxxxxxxxx)xxxxx |
203–083–3 |
103–16–2 |
Xx; X36 X43 |
Xx X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx hydrochinonmonomethylether |
205–769–8 |
150–76–5 |
Xn; R22 Xx; R36 X43 |
Xx X: 22–36–43 X: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xx; X20 Xx; X36/38 X43 |
Xx X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xx; R20–36/38–40–43 1 % ≤ X &xx; 10 %: Xx; R40–43 |
|
|
606–016–00-X |
pindon (XXX) 2-(xxxxxxxxxxxxxxx)xxxxx-1,3-xxxx |
201–462–8 |
83–26–1 |
X; X25–48/25 X; X50–53 |
X; N X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (XXX) 2,3-dichlor-1,4-naftochinon |
204–210–5 |
117–80–6 |
Xn; X22 Xx; X36/38 X; X50–53 |
Xx; X X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) xxxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. kat. 3; R40 X; X24/25 N; X50–53 |
X; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
xxxxxxxxxx (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 X)-xx 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-4,5-xxxxxxx-1,2,4-xxxxxxx-5-xx |
244–209–7 |
21087–64–9 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
chloridazon (ISO) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx xxxxxxx |
216–920–2 |
1698–60–8 |
X43 X; X50–53 |
Xx; N X: 43–50/53 S: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
xxxxxxxxxxxxxx (XXX) 6-xxxxxx-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; R62 Xx; R20/21/22–48/22 Xx; X36 R43 N; X50–53 |
Xx; X X: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-chlorfenoxy)- 3,3-xxxxxxxx-1-(1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
256–103–8 |
43121–43–3 |
Xx; X22 N; R51–53 |
Xn; X R: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-xxxxxxxxxxxxxxxxxxx xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; R36 X; R50–53 |
Xn; X X: 22–36–50/53 S: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (ISO) 3,6-dichlor-2-methoxybenzoová xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; X22 Xi; X41 R52–53 |
Xn; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (XXX) 3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxykumarin3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxy-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; R48/22 R52–53 |
Xn X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
kumafuryl (XXX) fumarin (RS)-3-[1-(2-furyl)-3-oxobutyl)]-4-hydroxykumarin (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -chromen-2-on 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-furyl)-3-oxobutyl]-4-hydroxy-2 X -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; X25–48/25 R52–53 |
T X:25–48/25–52/53 S: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
xxxxxxx (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx ethyl-5-(1,2,3,5,6,7,8,9,10,10-dekachlor-4-hydroxypentacyklo[5.2.1.02,6.03,9.05,8]dekan-4-yl)-4-oxopentanoát xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; X24 Xx; X22 X; R51–53 |
T; X X: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 X42/43 |
Xx X: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
xxxxxxxxx xxxxxxxx xxxxxxxx kyselina |
203–677–2 |
109–52–4 |
C; X34 X52–53 |
X R:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-XXX (XXX) 2,3,6-xxxxxxxxxxxxxxxx xxxxxxxx |
200–026–4 |
50–31–7 |
Xx; R22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-chlor-2-oxo-2,3-dihydro-1,3-benzothiazol-3-yl)octová xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 R52–53 |
Xi X:36/38–52/53 S: (2-)22-61 |
|||
|
607–156–00–4 |
xxxxxxxxxxx (XXX) 4-chlorfenyl-4-chlorbenzen-1-sulfonát |
201–270–4 |
80–33–1 |
Xn; R22 Xx; X38 X; X50–53 |
Xx; X X: 22–38–50/53 X: (2-)37–60–61 |
|||
|
607–158–00–5 |
sodná xxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx |
223–498–3 |
3926–62–3 |
X; X25 Xx; R38 X; X50 |
X; X R: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
xxxxxxxxxxxxxx (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propionyl}oxy)poly(oxyethylen) |
400–830–7 |
— |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); O,O′-diisopropyl-pentasulfanbis(karbothioát) |
403–030–6 |
— |
Xn; X22 X43 X; R50–53 |
Xn; X X: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; X7 X10 X; X51–53 |
X; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 R53 |
Xi X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] bis(2-hydroxyethyl)amonium-3,6-dichlor-2-methoxybenzoát [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [3] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Xxxxxxx-X-(1-xxxxxx)xxxxxxxx |
205–073–4 |
132–67–2 |
Xx; X22 |
Xx X: 22 X: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx tripropylenglykol-diakrylát XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 R43 X; X51–53 |
Xx; X R:36/37/38–43–51/53 X: (2-)24–37–61 |
X ≥ 10 %: Xi; X36/37/38–43 1 % ≤ C < 10 %: Xi; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 S)-cis-3-((Z)-2-chlor-3,3,3-trifluorprop-1-en-1-yl)-2,2-dimethylcyklopropan-1-karboxylát |
415–130–7 |
91465–08–6 |
T+; X26 X; R25 Xn; X21 N; X50–53 |
X+; X X: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (XXX) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
608–003–00–4 |
xxxxxxxxxxxx |
X X |
203–466–5 |
107–13–1 |
X; Xxx Xxxx. xxx. 2; X45 X; X23/24/25 Xi; X37/38–41 X43 N; X51–53 |
X; X; X X: 45–11–23-/24/25–37/38–41–43–51/53 X: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ X &xx; 20 %: X; X45–23/24/25–41–43 5 % ≤ X &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X < 1 %:X; R45–20/21/22 0,1 % ≤ X < 0,2 %: T; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
xxxxxxxx (ISO) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. kat. 2; X61 X+; R28 X; R24 X44 X; R50–53 |
T+; N X: 61–24–28–44–50/53 S: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (XXX) (2,4-dichlorfenyl)(4-nitrofenyl)ether |
E |
217–406–0 |
1836–75–5 |
Karc. xxx. 2; X45 Xxxx. xxx. 2; X61 Xx; R22 X; R50–53 |
T; N X: 45–61–22–50/53 S: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 X43 N; X50–53 |
Xx; N R: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-xxxxxxxxxxxxxx 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. xxx. 2; X45 X; R50–53 |
T; X R: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx xxxxxxxxx |
403–650–7 |
117409–78–6 |
X; X2 X; X51–53 |
X; X X: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-xxxxxxxxxxxxxx-2,5-xxxx-1-xxxxxx)xxxxxxxx]xxxxxxxx-xxxxxxxxxxxx XX Xxxxx Xxx 9 XX xxxxxxx xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. xxx. 2; X45 |
X X: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx x-xxxxxxxx |
X |
201–963–1 |
90–04–0 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 T; R23/24/25 |
T X: 45–23/24/25 S: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-xxxxxxxxxxxxxx xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xx; X22 X; R50–53 |
T; X X: 45–22–50/53 X: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X < 25 %: X; X45 |
|
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; R40 X; R39/23/24/25Xn; X48/20/21/22 X43 X; X51–53 |
X; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx x-xxxxxxx, xxxx |
X E |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; X45 Xx; X22 X; X51–53 |
X; X R: 45–22–51/53 S: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 T; X25 Xx; X21 Xx; X36 R43 X; X51–53 |
X; X X: 45–21–25–36–43–51/53 S: 53–45–61 |
||
|
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 C; X34 X43 X52–53 |
X X: 21/22–34–43–52/53 S: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-methyl-m-fenylendiamin2-methyl-1,3-fenylendiamin2-methylbenzen-1,3-diamin 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; X21/22 X43 X; R51–53 |
Xn; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-xxxxxxxxxxxx |
202–442–1 |
95–70–5 |
X; X25 Xx; R20/21 X43 X; X51–53 |
X; X X: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
xxxxxxxxxxx (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 X; X50–53 |
Xx; X R: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
xxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx |
X |
246–910–3 |
25376–45–8 |
Xxxx. xxx. 2; X45 X; X25 Xx; X20/21 Xx; X36 X43 X; X51–53 |
X; N X: 45–20/21–25–36–43–51/53 S: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xx; X36/37/38 X52–53 |
Xx R: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
xxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxx-1,3,5-xxxxxxxxxxxx 1,3,5-xxxxxxxx-1,3,5-xxxxxxx-2(1X), 4(3X), 6(5X)-xxxxx |
201–782–8 |
87–90–1 |
X; X8 Xx; X22 R31 Xx; X36/37 X; X50–53 |
X; Xx; X X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx xxxxxxxxxxxxx |
202–095–6 |
91–76–9 |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
imazalil (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; R41 X; X50–53 |
Xx; N X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (ISO) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1X -imidazol-1-ium-hydrogensulfát [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; X20/22 Xi; X41 X; X50–53 |
Xx; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
terbumeton (XXX) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 N; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
613–091–00–2 |
morfamkvat-dichlorid [1] morfamkvat-sulfát [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xx; R22 Xx; R36/37/38 X52–53 |
Xx; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-xxxxx-2-xxxxxxxxxx |
403–700–8 |
2687–94–7 |
X; X34 X; R51–53 |
C; N X: 34–51/53 X: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (ISO) (RS)-2-(2,4-dichlorfenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol |
— |
79983–71–4 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (ISO) 1,2,5,6-tetrahydro-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; R22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
|
613–134–00–5 |
myklobutanil (XXX) 2-(4-xxxxxxxxxx)-2-[(1 H-1,2,4-triazol-1-yl)methyl]hexannitril |
— |
88671–89–0 |
Repr. xxx. 3; X63 Xx; R22 Xx; X36 X; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (ISO) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; R50–53 |
N R: 50/53 S: 60-61 |
|||
|
613–139–00–2 |
xxxxxxxxxxx-xxxxxx xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (ISO) 3-(1-methylpyrrolidin-2-yl)pyridin |
200–193–3 |
54–11–5 |
T+; X27 X; X25 X; X51–53 |
X+; N X: 25–27–51/53 S: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-xxxxxxxxxxxxxxxxxxxx-10-xx |
206–614–7 |
357–57–3 |
X+; X26/28 X52–53 |
X+ X:26/28–52/53 X: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] brucin-nitrát [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 R52–53 |
T+ X: 26/28–52/53 S: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-methyl-1,3-fenylendiisokyanát [1] 4-xxxxxx-x-xxxxxxxxxxxxxxxxxx [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [3] xxxxxx-2,6-xxxxxxxxxxx [1] toluen-2,4-diisokyanát [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
C |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. xxx. 3; X40 T+; R26 Xx; X36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
C320 %: X+; X26–36/37/38–40–42/43 7 % ≤ X &xx; 20 %: X+; R26–40–42/43 1 % ≤ C &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xn; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx N-chlor-4-methylbenzen-1-sulfonamid, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; X22 R31 X; X34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (ISO) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-ethyl-3-[2-kyan-2-(methoxyimino)acetyl]močovina |
261–043–0 |
57966–95–7 |
Xn; X22 R43 X; X50–53 |
Xx; N X: 22–43–50/53 X: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-tetrahydro-1-naftyl)hydroperoxid xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; X7 Xn; X22 X; X34 X; X50–53 |
X; X; X X: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ C &xx; 25 %: C; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx xxx(2-xxxxxxxxxxx-2-xx)xxxxxxx xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx xxxxxxxxxxxxxx |
201–279–3 |
80–43–3 |
X; X7 Xx; X36/38 X; X51–53 |
X; Xx; X X: 7–36/38–51/53 S: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; X2 Xx; X36 R43 |
E; Xx; X: 2–36–43 X: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (ISO) N2-(4-chlor-2-methylfenyl)-N1,N1-dimethylformimidamid X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. xxx. 3; X40 Xn; X21/22 X; X50–53 |
Xx; X X: 21/22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (ISO) 4-[(2-chlorfenyl)hydrazono]-3-methylisoxazol-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; R25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx N2-(4-chlor-2-methylfenyl)-N1,N1-dimethylformimidamid-hydrochlorid X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx |
243–269–1 |
19750–95–9 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
esfenvalerát (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (X)-3-xxxxxx-α-xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx |
— |
66230–04–4 |
X; X23/25 R43 N; X50–53 |
X; X R: 23/25–43–50/53 X: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-xxxxxxxxxxx)xxxxxx-1-xxxxxxxx]-3-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxx |
— |
82097–50–5 |
X; X50–53 |
X X: 50/53 X: 60-61 |
XXXXXXX 1X
|
Xxxxxxxx číslo |
Chemický xxxxx |
Xxxxxxxx x xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx limity |
Poznámky x xxxxxxxxxx |
|
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; X20 Xx; X41 X52–53 |
Xx X: 20–41–52/53 X: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-di(hex-5-en-1-yl)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx x 1,3-di(hex-x-en-1-yl)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
015–164–00–9 |
xxxxxxx-xxxxxxxxxx-(1-xxxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
|
015–165–00–4 |
Xxxx: S, X, S', X''-xxxxxxxxxx-4,4'-xxxxxxxxxxxxx(xxxxxxxxxxxxxx)-xxx(xxxxxxxxxxxxxxxx) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; X41 X; R50–53 |
Xi; X X: 41–50/53 X: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 S: 61 |
|||
|
015–167–00–5 |
3-[hydroxy(fenyl)fosfinoyl]propanová xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; R41 |
Xi X: 41 X: (2-)26-39 |
|||
|
601–050–00–1 |
X10-X13-xxxxxxxxxxxxx xxxxxxx |
267–051–0 |
67774–74–7 |
X; R50 |
N X: 50 X: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X R: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; R52–53–59 |
N X: 52/53–59 S: 59-61 |
|||
|
603–128–00–0 |
2-(xxxxxxxxxxxx)xxxxxxxx |
405–490–3 |
613–62–7 |
X53 |
X:53 X: 61 |
|||
|
603–129–00–6 |
1-terc-butoxypropan-2-ol |
406–180–0 |
57018–52–7 |
R10 Xx; X41 |
Xx X: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx isomerů: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)39-61 |
|||
|
603–131–00–7 |
Směs (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-deoxy-1-[methyl(1-oxotetradecyl)amino]-D-glucitol |
407–290–1 |
— |
Xi; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; R38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (dodecyl x xxxxxxxxxx nerozvětvené) |
410–450–3 |
— |
R53 |
R: 53 X: 61 |
|||
|
603–135–00–9 |
bis[2-(2-methoxyethoxy)ethanolato]bis(2,2', 2-nitrilotriethan-1-olato-N,O)titaničitý xxxxxxx |
410–500–4 |
— |
Xx; X41 N; X51–53 |
Xx; N X: 41–51/53 X: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[bis(2-hydroxyethyl)amino]-2-nitroanilino}propan-1-ol |
410–910–3 |
104226–19–9 |
R43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx a 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
411–130–6 |
— |
Xx; X41 |
Xx R: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-xxxxxxxx-3-xxxxxxxxxxxxx)xxxxxx 2,2-dimethyl-3-(3-methylfenyl)propan-1-ol |
403–140–4 |
103694–68–4 |
R52–53 |
R:52/53 X: 61 |
|||
|
604–050–00-X |
4-chlor-o-kresol 4-xxxxx-2-xxxxxxxxxxx |
216–381–3 |
1570–64–5 |
X; X23 X; X 35 X; X50 |
X; X; X X: 23–35–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; X; R23–35 10 % ≤ X &xx; 25 %: X;X20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ X &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X < 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - xxxxxxxxxxxx-2-xx)-4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx] 6,6'-xxx(2X -benzotriazol-2-yl)- 4,4'-bis(1,1,3,3-tetramethylbutyl)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 X: 61 |
|||
|
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; X38 X43 N; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx x 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; X40 |
Xx X: 40 S: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-6-karbaldehyd x 3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx-1-xx |
4–406–670–4 |
61203–83–6 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx kyselina |
410–410–5 |
54574–82–2 |
R52–53 |
R:52/53 X: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (XXX) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
xxxxxxx-7-{2,6-xxxxxxxx-8-[(2,2-xxxxxxxxxxxxxxxx)xxx]- 1,2,6,7,8,8x-xxxxxxxxx-1-xxxxxx}-3,5-xxxxxxxxxxxxxxxxxx |
404–520–2 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[xxxxxx(xxxxxx)xxxxx]xxxxx}-3-xxxxxxxx-2-xxxxx |
405–350–1 |
54527–73–0 |
X43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
xxxxxxx-4-(xxxxxxxxxx)xxxxxx-1-xxxxxxxx |
405–450–5 |
66531–87–1 |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) xxx(1-xxxxxxxxxxxxxx)]xxxxxxxxx komplex |
405–635–0 |
— |
Xi; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Xxxx:2-(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxxxxxxxx x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; X22 Xi; X41 X43 N; X51–53 |
Xx; X X: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx a nerozvětvené)-3-[3-(2 X - benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
405–760–0 |
— |
Xi; X41 X43 X52–53 |
Xx X: 41–43–52/53 S: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) x (oktadecylimino)diethylen-(hydrogen-ftalát)-(hydrogen-maleinát) |
405–960–8 |
— |
R43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx xxxxx xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; X36 X43 |
Xx R: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Směs:alkyl(C7-C9 xxxxxxxxxx x xxxxxxxx)-3-[3-(2X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
407–000–3 |
127519–17–9 |
X; R51–53 |
N X: 51/53 S: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; X21/22 Xx; X38–41 X43 X; X50–53 |
Xx; N R: 21/22–38–41–43–50/53 S: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) x xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
607–285–00–6 |
Směs:7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonová xxxxxxxx, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- a xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 S: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 S: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx xxxxxxx, xxxxxxxxxx sůl; c = 15, 16, 17 xxxx 18, x = 1, 2, 3 xxxx 4, b = 8, 9, 10 xxxx 11, x = 22, 23, 24 xxxx 25 |
410–160–7 |
148732–74–5 |
Xi; X36 X43 X52–53 |
Xx X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx kyselina |
410–370–9 |
105488–33–3 |
R53 |
R:53 X: 61 |
|||
|
607–290–00–3 |
Xxxx (o xxxxxxxx xxxxxx):xxxxxxx-1-xxxxx(X14-X18)-4-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx a xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; R38 X43 X; X50–53 |
Xx; N X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx kyselina x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XXxxx: |
1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 X43 X; X51–53 |
Xx; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx R: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx a xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 N; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxxxx xxxxxxxx x 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-fenylendimethyliden)bis(2-oxobornan-10-sulfonová xxxxxxxx)2,2'-xxxxx-3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxxxx-1-xxxxxxxxxxxxxxx xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(trimethylamonio)ethyl]-4-sulfonatobenzoát |
411–010–3 |
— |
R43 |
Xi X: 43 X: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; X22 X43 X; X50–53 |
Xx; N X: 22–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, d-sulfonatoftalocyanin]měďnatý xxxxxxx, xxxxxxxx xxx; x = 1,2,3 nebo 4, x = 8, 9, 10 xxxx 11, x = 15, 16, 17 xxxx 18, x = 22, 23, 24 xxxx 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Xxxx:xxxxxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–860–5 |
— |
Xx; X38–41 X43 N; X51–53 |
Xx; X R: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; R51–53 |
Xi; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx kyselina |
413–760–7 |
93107–30–3 |
Repr. xxx.3; X62 R52–53 |
Xn X: 62–52/53 X: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-chlorfenyl)-2-fenyl-2-[(1H- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[butyl(fenethyl)amino]fenyl}ethen-1,1,2-trikarbonitril |
407–650–8 |
97460–76–9 |
R53 |
R:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 S: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 X; X8 Xxxx. kat. 2; X45 X; X23/25 R43 |
E; X X: 45–3–8–23/25–43 X: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 C; X34 X43 X; X50–53 |
X; X X: 22–34–43–48/22–50/53 S: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Směs (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx trisodný, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx xxxxxxxx a[{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx X: 41–52/53 X: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Směs:[bis(5-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx, [bis(4-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-xxxxx-5-xxxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; X41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 X: 61 |
X X: 51/53 X: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xn; X48/22 X43 X; X50–53 |
X; X X: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Směs (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–890–3 |
111381–11–4 |
X53 |
X: 53 X: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–900–6 |
111381–12–5 |
X53 |
X: 53 X: 61 |
|||
|
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, xxxxxxxx xxxxxx x xxxxxx xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; R48/22 X43 X52–53 |
Xx R: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; R50–53 |
N X: 50/53 S: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) azo]-6-[(6-sulfonato-1-naftyl)azo]benzen-1,3-diolato}]železnatý xxxxxxx, xxxxx sůl |
400–720–9 |
— |
R52–53 |
R: 52/53 X: 61 |
|||
|
612–156–00–2 |
Směs:trihexadecyl(methyl)amonium-chlorid a xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 N; X50–53 |
Xx; X X: 41–50/53 X: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(Z)-1-(1-benzothiofen-2-yl)ethan-1-on-oxim-hydrochlorid |
410–780–8 |
— |
Xn; X22–48/22 Xx; X41 X43 X; X51–53 |
Xx; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Xxxx:[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxx-2-xxxxxxxxxxxxxxxxxx[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx xxxxx 2,2,4-xxxxxxxxx- x 2,4,4-xxxxxxxxxxxxxx-1,6-xxxxxxx (x seznamu XXXXXX), xxxxxxxx [(alkyl(C10-C16)oxy)methyl]oxiranu (Xxxxxx 8) x 4-xxxxxxxxxxxx-1-xxxxxxxxx xxxxxxxx |
410–880–1 |
— |
Xx; X22 C; X34 X; R50–53 |
C; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; X23/25 X; R50–53 |
T; N X: 23/25–50/53 S: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
|
613–151–00–8 |
1-(2-xxxxx-3-X-xxxxx-5-X-xxxxxx-β-X-xxxxx-xxxxxxxxxxxxxx)-5-xxxxxxxxxxxxxxx-2(1X), 4(3 X)-xxxx |
406–360–9 |
104218–44–2 |
X53 |
X:53 X: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; R51–53 |
Xi; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 S: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; R22 |
Xn R: 22 X: (2-)22 |
|||
|
613–155–00-X |
5-xxxxx-2,3-xxxxxxxxxxxxxx |
410–090–7 |
89402–43–7 |
X10 Xx; R22 R52–53 |
Xn X: 10–22–52/53 S: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-xxxxx-5-xxxxxxxxxxxxx-4-xxxxxxxxxxx |
410–260–0 |
83857–96–9 |
X43 X; X51–53 |
Xx; N X: 43–51/53 S: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-xxxxxxx-5-(xxxxxxxxxxxxx)xxxxxxxxx 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xi; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; X20/22 Xx; X41 X43 X; R51–53 |
Xn; X X: 20/22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; X25 Xn; X20 X; X50–53 |
X; X R: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-xxxxxx-2,5-xxxxxxxxxxxx[2.2.1]xxxxxx-xxxxxxxxxxxxx |
411–000–9 |
125224–62–6 |
X43 |
Xx R: 43 X: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 R14 Xx; X48/22 X42/43 |
X; Xn X: 2–14–42/43–48/22 X: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. kat. 3; R40 Xx; X20–48/22 Xi; R41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxxxxx |
405–190–2 |
122371–93–1 |
X43 X53 |
Xx X: 43-53 X: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-chlor-7-methylpyrazolo[1,5-b][1,2,4]triazol-4-yl)propyl]-2-(2,4-di-terc-pentylfenoxy)oktanamid |
406–390–2 |
— |
N; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - xxxxxxxxxx(X16)-2,2′, 2″, 2′′′ (xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx x X, X′,X″,X′′′ - xxxxxxxxxx(X18)- 2,2′, 2′′, 2′′′-(ethylendinitrilo)tetraacetamid |
406–640–0 |
— |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(trifluormethyl)isobutyranilid |
406–740–4 |
1939–27–1 |
Xn; X48/22 N; R51–53 |
Xn; X R: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-di-terc-butylfenoxy)-N-(3,5-dichlor-4-ethyl-2-hydroxyfenyl)hexanamid |
408–150–2 |
99141–89–6 |
R53 |
R:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 N; R50–53 |
Xi; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Xxxx:3,3'-xxx(4-xxxxxxxxxxx)- 1,1'-(4-methyl-1,3-fenylen)dimočovina x 3,3'-xxx(4-xxxxxxxxxxx)-1,1'-(2-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx Xxxx:2,4-xxx[3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
xxx(4-xxxxxxxxxxxxx)xxxxxxx |
407–950–9 |
895–85–2 |
X; R2 X; R7 X; X50–53 |
X; X X: 2–7–50/53 S: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
xxxxxxxxxxxx (XXX) (2X, 3R)-, (2 S, 3 X)-, (2 R, 3 X)-, (2 X, 3 X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxx-1-(1X- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. kat. 3; X63 Xx; X22 X; X50–53 |
Xx; X X: 22–50/53–63 X: (2-)36/37–60–61 |
PŘÍLOHA 2
XXXXXX XXXXXXXXXXXX XXXXX XXXXXXXXX X XXXXXXXXXXXX XXXXXXX A XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, s. 81.
XXXXXXX 3A
STANDARDNÍ XXXXXX XXX XXXXXXXX ZACHÁZENÍ X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
PŘÍLOHA 3X
XXXXXXXXXX POKYNY XXX BEZPEČNÉ XXXXXXXXX X NEBEZPEČNÝMI XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
PŘÍLOHA 4X
"X.10 XXXXXXXXXX — ZKOUŠKA XX XXXXXXXXXXXX XXXXXXX X XXXXX IN VITRO
1. XXXXXX
Xxxx metoda xx xxxxxxxx metody XXXX XX 473 — Xxxxxxx xx chromozomové xxxxxxx u savců xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx chromozomové xxxxxxx x xxxxx xx xxxxx má xxxxxxxxxxxxx činitele, xxxxx xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx v xxxxxxxxxxxxx xxxxxxx xxxxx (1, 2, 3). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x chromatidové. X xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx aberace xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx xxxx znamenat, xx xxxxxxxx látka xx schopnost xxxxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxx však xxxx xxxxxx xx stanovení xxxxxxxxxxx aberací a xxxx x tomuto xxxxx xxxxxxx používána. Xxxxxxxxxxxx xxxxxx a xxxxxxx xxxx xxxx xxxxxxxx xxxxx geneticky xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx xxxxx xxxxxx o xxx, xx xxxxxxxxxxxx xxxxxx x x xxxx související jevy xxxxxxxxxxx změny v xxxxxxxxxx x v xxxxxx somatických xxxxx xxxxxxxxx xxxxxx, mají xxxxx xx xxxxxxx xxxxxxxx u člověka x x xxxxxxxxx xxxxxx.
Xx xxxxxxx na xxxxxxxxxxxx xxxxxxx in xxxxx xxxxx být xxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xxxx primární buněčné xxxxxxx. Xxxxxxx xxxxx xxxx vybrány xx xxxxxxx schopnosti růstu x xxxxxxx, xxxxxxxx xxxxxxxxx, xxxxx chromozomů, xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx četnosti chromozomových xxxxxxx.
Xxxxxxx prováděné in xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx aktivační xxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxxx in vivo x xxxxx. Xx xxxxx se xxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx mutagenitu x může x xxx xxxxx xxxxxx xX, xxxxxxxxxx nebo xxxxxxxx úrovní xxxxxxxxxxxx (4, 5).
Xxxx zkouška xx používá xx xxxxxxxx xxxxxxx mutagenů x xxxxxxxxxxx xxx xxxxx. Xxxxx xxxxxxxxx, xxx xxx xx xxxx xxxxxxx xxxxxxxxx, xxxx pro savce xxxxxxxxxxx; xxxx xxxxx xxxxxxxx a xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx závisí xx xxxxxxxx xxxxx x xxxxxxxxx důkazy x xxx, xx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx zjištěny xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx jinými xxxxxxxxxx xxx přímým xxxxxxxxxx XXX.
Xxx xxxx Obecný xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx poškození chromozomu x podobě xxxxx xxxxxxxxxxxx chromatid xxxx xxxxx x opětného xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození xxxxxxxxxx x podobě xxxxx xxxx xxxxx x xxxxxxx obou xxxxxxxxx x tomtéž xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx po X-xxxx xxxxxxxxx XXX xxxxxxx x mitóze, xxxxx xxxxxxxxx xxxxx X-xxxx. Xxxxxxxxx xxxx chromozomy xx 4, 8, 16… chromatidami.
Gap : xxxxxxxxxxxx xxxx xxxxx xxx xxxxx xxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, které xx xxxxxxxxx v xxxxxxxx, x xxxxxxxxx xxxxx xxxxx x xxxxxxxx; xxxxx xxxxxx xxxxxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx počtu xxxxxxxxxx xx normálního xxxxx xxxxxxxxx x xxxxxxxxx xxxx buněk.
Polyploidie : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx metafáze; xxxx xx xxxx delece x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxxxxx xxxx vystaveny xxxxxxxx xxxxx, a xx x xxxxxxxxxxxx xxxxxxxx x xxx xx. V xxxxxx xxxxxxxxxxx intervalech po xxxxxxxx látce xx xx xxxxxxxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (např. Xxxxxxxx® xxxx xxxxxxxxx), kultury xx xxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx buněk.
1.4 XXXXX ZKUŠEBNÍ METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx být xxxxxxx xxxxx xxxxxxx xxxxx, kmeny xxxx xxxxxxxx buněčné xxxxxxx, xxxxxx xxxxxxxx buněčných xxxxx (xxxx. fibroblasty xxxxxx xxxxxxxx, lymfocyty xxxxxxxxx krve člověka xxxx jiných xxxxx).
1.4.1.2 Xxxxx x kultivační xxxxxxxx
Xxx xxxxxxxxx xxxxxx xx xxxx xxx xxxxxxx vhodná xxxxxxxxxx xxxxx a xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, teplota x vlhkost). X xxxxxxxxxxxxxxx buněčných xxxxx x xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxx x xxxx xx xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx; x xxxxxxx kontaminace xx neměly xxx xxxxxxx. Pro xxxxxxx xxxxx a inkubační xxxxxxxx xx xxxx xxx xxxxx normální xxxxx xxxxxxxxx xxxxx.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxxxxxxxxx buněčné xxxxx a kmeny: xxxxx se pomnoží x kmenových xxxxxx, xxxxxx xx xx xxxxxxxxxxxx xxxxx x xxxxxx xxxxxxx, xxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx, x xxxxxxxx xx při 37 °X.
Xxxxxxxxx: xxxx xxxxxxxx xxxxxxxxxxxxxxx (xxxx. xxxxxxxxx) xxxx xxxxxxxx xxxxxxxxx xxxxxxxx probandů se xxxxxxx xx xxxxxxxxxxxx xxxxx obsahujícího xxxxxxx (xxxx. xxxxxxxxxxxxxxxx) a xxxxxxxx xx xxx 37 °C.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx vystaveny xxxxxxxx xxxxx, x to x xxxxxxx metabolickou xxxxxxxx x bez xx. Nejčastěji xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (X9) připravená z xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx enzymy, xxxx xx Xxxxxxx 1254 (6, 7, 8 x 9), xxxx xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (10, 11 x 12).
Postmitochondriální xxxxxx je v xxxxxxxx xxxxxxxxxx médiu xxxxxxx xxxxxxxxx v xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx třídě xxxxxxxx xxxxx, xxxxx je xxxxxxxx. X xxxxxxxxx xxxxxxxxx může xxx xxxxxx použít xxxx xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx výsledků xxxxxx, včetně xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx buněčných xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, poskytuje xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx použitých xxxxxxxxx xxxxx xx xxxx být xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx cytochromu P450 xxx metabolismus zkoušené xxxxx).
1.4.1.5 Xxxxxxxx látka/příprava
Pevné xxxxxxxx xxxxx by xxxx xxx před xxxxxxxx na xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx mohou xxx přidány xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx zředěny. Xxxx by být xxxxxxx xxxxxxx připravené xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx xxxxxxxxx, že xxxxxxx xx xxxxxxxxx xxxxxx, a xxxx xx xxx xxxxxxxxxx x xxxxxxxx xxxxx x x xxxxxxxxx X9. Xxxx-xx použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx možno xxxxxxxx zvážit xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx vodě xx xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx přidáním molekulového xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která xxxx xxx zohledněna xxx xxxxxxxxx nejvyšší xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, rozpustnost x xxxxxxxxxx systému x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx xxxxxxxxx x metabolickou xxxxxxxx x xxx xx x hlavním xxxxxxxxxxx xx použití vhodných xxxxxxxxxx buněčné integrity x xxxxx, xxxx xxxx xxxxxx konfluence, xxxxx xxxxxxxxxxxxxxx buněk xxxx xxxxxxxxx xxxxx. Xxxx xxx výhodné xxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxx x předběžném xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx xxxxxxxxxxxx xx xxxx tyto koncentrace xxxxxxxx xxxxxxx xxxx xxxxxxxxx xx minimální xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx, což xxxxxxx xxxxxxx, xx by xx xxxxxxxxxxx xxxxxx xxxxx xxxx xxxxx xxxxxxxx 2 až Ö10. X xxxxxxxx xxxxxxx by xxxx xxxxxxxx koncentrace xxxxxxxxx xxxxxxxx snížení xxxxxx xxxxxxxxxx, xxxxx buněk xxxx xxxxxxxxxxx indexu (xxx o xxxx xxx 50 %). Xxxxxxxxx xxxxx xx xxxxx xxxxxxxx měřítkem xxxxxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx x xxxxxx xx době, xxxxx xxxxxxxx xx xxxxxxxx. Xxxxxxxxx xxxxx xx xxxx přijatelný x xxxxxxxxxxx xxxxxx, x xxxxx xxxxx xxx xxxx xxxxxx stanovení xxxxxxxx xxxxxxx x xxxxxxxxxxx. Xxxxxxxxx o xxxxxxxx buněčného xxxxx, xxxxxxxxx xxxxxxxx xxxxxxxxx xxxx (XXX), mohou xxx xxxxxxx jako xxxxxxxxx informace. V xxxxxxx AGT xxxx xxx x celkovou xxxxxxxxx xxxxxxx, z xxx nelze xxxxxxx xx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx, x x xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx doby xxxx xxx xx xxxxxxxx xxxxx xxxxxxxxx oddálení xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxxxx látek xx xxxx být xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 mg/ml xxxx 0,01 X, xxxxx xxxx, která x nich xx xxxxxxxx.
X případě xxxxxxxxx xxxxxxxxxxxxx látek, xxxxx xxxxxx xxxxxxx při xxxxxxxxxxxxx nižších, xxx xx jejich xxxxxxxxxxx, xx měla xxx xxxxxxx xxxxxxxx dávka x koncentraci, jež xx nad xxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx doby aplikace. X xxxxxxxx případech (xxxx. xxxxxxx-xx se xxxxxxxx pouze xxx xxxxxxx xxxxxxxxxxxxx, xxx xx xxxxxxxxxxx) se xxxxxxxxxx xxxxxxxxx více xxxxxxxxxxx, při xxxxx xxxxxxx xx srážení. Xxxx být xxxxxxxx xxxxxxxx xxxxxxxxxxx na xxxxxxx x na xxxxx expozice, xxxxx xxxxxxxxxxx x testovacím xxxxxxx se xxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx buněk, xxxx X9 xxx. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx xxxx xxx xxxxxxxxx a xxxxxxxxx xxxxxxxx (kontroly xxxxxxxxxxxx xxxx xxxxxxxx). Xxx xxxxxxx metabolické xxxxxxxx xx xxxx xxx xxx pozitivní xxxxxxxx xxxxxxx xxxxxxxx látka, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx xxxxxxxx by xxx xxx xxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxx xxxxxx, xxxx xx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx pozitivních xxxxxxx xx měly xxx xxxxxxx xxx, xxx xxx účinek xxxxxxxx, ale aby xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx preparátu. Xxxxxxxx xxxxxxxxxxx a xxxxxxxxxxx xxxxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
Bez xxxxxx metabolické xxxxxxxx |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X vnější metabolickou xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxx xxxxxxxxx xxxxxxxx mohou být xxxxxxx x xxxx xxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx by xxxx být xxxxx xxxxx vzato v xxxxx xxxxxxx xxxxxxxxxx xxxxx xx stejné xxxxxxxx xxxxx.
X xxxxxxxx xxxxxxxx by xxxx xxx použity negativní xxxxxxxx xxxxxxxxxx xx xx samotného rozpouštědla xxxx xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxxx stejným xxxxxxxx xxxx kultury. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx zhoubné xxxx mutagenní účinky.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx zkoušené xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxxxxx xxxxxxxx xxxxx xxx xx přítomnosti xxxxxxxxxxxxx aktivačního systému, xxx xxx něho. Xxxxxxxx lymfocytů xx xxxx xxx zahájena xxx 48 xxxxx xx mitogenní xxxxxxxxx.
1.4.3.2 Xxx xxxxxx xxxxxxxxxxx xx měly být xxxxxxx použity xxxxxxxxxx xxxxxxx, x xxxxx xx xxxxxxx doporučuje x xxxxxx xxx xxxxxxxxx xxxxxxxx nebo xxxxxxxx xxxxxxxxxxxx. Xxxxxxxx xxx na základě xxxxxxxxxxx xxxxx prokázat (13, 14), že xxxx xxxxxxxxxxxx kulturami xx minimální xxxxxx, xxxx být přípustné xxxxxxx jediné kultury.
Plynné xxxx těkavé xxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx kultivačních nádobách (15, 16).
1.4.3.3 Xxxx xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx xxxx xxx buňky xxxxxxxxx xxxxxxxx xxxxx, xxx x xxxxxxxxxxxx xxxxxxxx, xxx bez ní, xx xxxx 3 — 6 hodin, x měly by xxx xxxxxxxx po xxxxxx době xx xxxxxxxx xxxxxxxx, xxxxx xxxxxxxx 1,5násobku xxxxxxxx xxxxx xxxxxxxxx xxxxx (12). Jestliže xxxxx xxxxxx xxxx xxxxxxxxx xxxxxxxx xxx x xxxxxxxx, xxx bez xxxxxxxx, měl xx xxx proveden xxxxxxxxx xxxxxxxxxx xxx aktivace x nepřetržitou expozicí xx do odběru x xxxx, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx xxxxxxxxx xxxxx. Xxxxxx xxxxxxxx xxxxx xxx xxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxx xxx 1,5xxxxxxx délky xxxxx. Xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxx být potvrzeny xxxxxx xx případu. X xxxxxxxxx, kdy xx xxxxxxxxxx potvrzení xxxxxxxxxxx xxxxxxxx xx xxxxxxxx, xx mělo xxx xxxxxx xxxxxxxxxx.
1.4.3.4 Xxxxxxxx preparátů pro xxxxxxx xxxxxxxxxx
Xx xxxxxxx xxxxxxx xx xxxxxxx 1-3 xxxxxx xxxx xxxxxxxxx xxxxx Xxxxxxxx® xxxx xxxxxxxxx. Xxx xxxxxxxx xxxxxxxxx xxx xxxxxxx chromozomů se xxxxx buněčná kultura xxxxxx a xxxxxxxxxx xxxxxx. Xxxxxxxx xxxxxxxxx xxx analýzu xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx buněk, xxxxxx x xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx preparáty, xxxxxx preparátů xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx být xxxx xxxxxxxx pod xxxxxxxxxxx xxxxxxxxx kódovány. Xxxxxxxx xxx fixaci xxxxx dochází ke xxxxx xxxxx xxxxx x xxxxxxxx a xx xxxxxx xxxxxxxxxx, xxxx xx vyšetřované xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxx xxxxxxx xxxxxxx ± 2 xxx xxxxxxx xxxx buněk. Xx xxxxxx koncentraci x xxxxxxxx xx xxxx xxx xxxxxxxxx alespoň 200 xxxxx xxxxxxxxxxxxxx xxxxxxxx, případně xxxxxxxxxx xxxxxxxxxxx mezi xxxxxxxxxx xxxxxxx. Tento xxxxx xxx xxxxxx, je-li xxxxxxxxx velký xxxxx xxxxxxx.
Xxxxxx xx xxxxxx xxxxxxx detekovat strukturní xxxxxxxxxxxx aberace, je xxxxxxxx xxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxxxx, xxxx-xx xxxxxxxxxx.
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx x xxxx xx xxxx xxx xxxxxxxxxxx množství xxxxx xx strukturní chromozomovou xxxxxxx (xxxxxxxxx) vyjádřené x xxxxxxxxxx. Pro xxxxxxxxx x experimentální xxxxxxx xx xxxx xxx uvedeny xxxxx xxxx strukturních xxxxxxxxxxxxxx xxxxxxx s xxxxxx xxxxxx x četností. Xxxx xx zaznamenávají xxxxxxxx x xxxxxxx xx, xxx nezahrnují xx do xxxxxxx xxxxxxxx xxxxxxx.
Xxxx by xxx xxxx zaznamenána xxxxxxxx, xxxxx xxxx xxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx x xxxxx xxxxxxxxxxxx kultur a xxxxxxxxxxx kultur x xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxx xxx xxxxxxxxxx kultury. Xxxx xx xxxx být xxxxxxx xxxxx shrnuty xx formě tabulky.
Ověření xxxxx pozitivní xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx měly xxx xxxxxxxxx dalším xxxxxxxxx, xxxxxxx x xxxxxxxx experimentálních xxxxxxxx. Xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx byla xxxxxxxxxxx x xxxx 1.4.3.3. Xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx xx měla xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X parametrům xxxxxx, xxxxx xx xxxxx být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxx aberacemi x závislosti xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx počtu. Xxxxxxxx xx měla xxx uvážena xxxxxxxxxx xxxxxxxxx výsledků. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx metody (3, 13). Statistická xxxxxxxxxx xx neměla být xxxxxxx xxxxxxxxx xxxxxxxx xxx pozitivní xxxxxxx.
Xxxxxx xxxxx polyploidie xxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx mitotické xxxxxxx x xxxxxxxxx xxxxxxxxx chromozomové xxxxxxx. Xxxxxx počtu buněk x xxxxxxxxxxxxxxxxxxx chromozomy xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx potlačit progresi xxxxxxxxx cyklu (17, 18).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx výše xxxxxxx kritéria, xx x xxxxx systému xxxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx zůstat xxxxxxxxxx xxxx xxxxxx xxx ohledu xx xx, kolikrát je xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xx zkoušky xx xxxxxxxxxxxx aberace xx xxxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx savců xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, že xxxxxxxx látka xx xxxxxxxx zkoušky xxxxxxxxxx x kultivovaných xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx musí obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx xxxxxxxx xxxxx x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxx:
- typ x xxxxx xxxxx,
- xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxx xxxx xxxxx,
- xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx,
- xxxxxxxxx x xxxxx buněčného xxxxx,
- xxxxxxx xxxxx krve, xxx xxxx xxxxxxx xxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx,
- případně xxxxx xxxxxx,
- xxxxxxxx metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxx hodnota xxxxx xxxxxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx kultur, xxxxxx xxxx. xxxxx x cytotoxicitě x xxxxxx xxxxxxxxxxxx, jsou-li x xxxxxxxxx,
- xxxxxxx xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- koncentrace zkoušené xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- inkubační xxxxxxx,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx hustota xxxxx xxx nasazení,
- xxx a složení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity, xxxx. xxxxxx xxxxxxxxxx, xxxxx o xxxxxxxx xxxxx, xxxxx buněk, xxxxxxxxx index,
- známky xxxxxxx,
- xxxxx o xX x xxxxxxxxxx xxxxxxxxxxx média, pokud xxxx stanoveny,
- xxxxxxxx xxxxxxx, xxxxxx xxxx,
- xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx x xxxx xxxxxxx xxxxxx xxx xxxxxx exponovanou x xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxx, pokud xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx odpovědi xx dávce,
- xxxxxxxx xxxxxxxxxxx analýzy,
- údaje x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- dosavadní údaje x negativní (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X. (1976), Xxxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Chemical Xxxxxxxx, xx: Xxxxxxxx Xxxxxxxx, Xxxxxxxxxx xxx Xxxxxxx xxx xxxxx Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Xxxxx, New Xxxx xxx Xxxxxx, 1-29.
2) Ishidate, X. Xx., Sofumi, T. (1985), The In xxxxx Chromozomal Xxxxxxxxxx Xxxx Using Xxxxxxx Xxxxxxx Lung (XXX) Xxxxxxxxxx Cells in Xxxxxxx, xx: Xxxxxxxx xx Mutatation Xxxxxxxx, Xxx. 5, Ashby, X. xx al., (xxx) Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 427-432.
3) Galloway, X. X., Armstrong, X. X., Xxxxxx, C., Xxxxxx, X., Brown, X., Xxxxxx, C., Xxxxx, X. X., Xxxxxxxx, F., Xxxxx, X., Xxx, X., Xxxxx, X., Margolin, X. H., Xxxxxxx, X. X., Anderson, X., Xxxxxx E. (1978), Xxxxxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxxxx xxxxxxxxx in Xxxxxxx xxxxxxx xxxxx xxxxx: Xxxxxxxxxx of 108 xxxxxxxxx, Xxxxxxx. Xxxxx. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Scott, X., Xxxxxxxx, X. X., Marshall, R. X., Ishidate, X. Xx., Xxxxxxx, D., Xxxxx, X., Xxxx, X. C. (1991), Xxxxxxxxxxxx xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X xxxxxx xxxx XXXXXX Xxxx Xxxxx 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, X., Xxxxxx, X., Xxxxxx, X., Xxxxxxx, X., (1992), Clastogenicity of xxx xX xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Mutatation Xxx., 268, 297-305.
6) Xxxx, X. N., XxXxxx, X., Xxxxxxxx, X. (1975), Methods for Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Res., 31, 347-364.
7) Xxxxx, X. M., Xxxx, X. N. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
8) Xxxxxxxxx, X. X., Tates, X. X., van Xxxx, X. X. X., Meijers, M., xx Xxxxx, N. (1976), Xxxxxxxxxxx Xxxxxxx xx Xxxxxxx/Xxxxxxxxxxx xxxxx Xxxxxxxxxx xx a Xxxxxxxxxxx Xxxxxx In xxxxx, I. Xxxxxxxxx xx Chromozome Xxxxxxxxxxx xxx Xxxxxx Chromatid Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx (XXX) xxx Xxxxxxxxxxxxxxxxxxx (XXX) xx XXX Xxxxx in xxx Xxxxxxxx of Rat-Liver Xxxxxxxxxx, Mutatation Xxx., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. Xx. (1979), Chromozomal Xxxxxxxxxx Xxxxx xx 29 Xxxxxxxxx Xxxxxxxx xxxx X9 Xxx Xx xxxxx, Xxxxxxxx Xxx., 66, 277-290.
10) Xxxxxx, X. X., Xxxxxx, X. D., Xxxxxxx, X. X., Gatehouse, X. G., Xxxxxx, X. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Xxxxxx xx UK Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Xxxxx. Xxxxxxxxxxx xx Xxxxxxx 1254-induced X9 in In xxxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X. Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. s. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, in: xx Serres, X. X., Fouts, X. X. Xxxx, X. X., Xxxxxxx, X. X. (xxx), Xx xxxxx Metabolic Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, Xxxxxxxx, North-Holland, 85-88.
12) Xxxxxxxx, S. X., Xxxxxxx, M. X., Xxxxxxxx, M. Xx., Xxxxx, X. X., Xxxxxxxx, X. X., Xxxxxx, X., Mosesso, X., Sofumi, T. (1994), Xxxxxx from Xxxxxxx Xxxxx on Xx xxxxx Tests xxx Xxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Res., 312, 241-261.
13) Xxxxxxxxxx, X., Xxxxxxxx, X. A., Xxxxx, X. X., Xxxxxxxx, G., Chanter, X. X., Phillips, X. (1989), Analysis xx Xxxx xxxx Xx vitro Xxxxxxxxxxx Xxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx of Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. X., (xx) Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Xxxxxxxx, X. M. (1994), Xxxxxxxxx Xxxxxx are xxx Xxxxxxxxx for Xx xxxxx Xxxxxxxxxx Xxxxxxxxxx Xxxxxx xx XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, X. X., Xxxxxx, X. C., XxXxxxx, X. X. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Evaluation xx Xxxxx xxx Volatile Xxxxxxx, xx: Xxxx, X. X., Xxxxx, X. L., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Effects xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
16) Xxxxxx, X. O., Xxxxxx, X. M., Xx, A. X., Xxxxxx, A. X. (1983), Evaluation of xx Xxxxxxxx Xxxxxx Xxxxx Xxxxx Xxxxx xx Xxxxxxxx Gels xxx Detecting Xxxxxx Xxxxxxxx Mutagens xx xxx XXX/XXXXX Mutation Xxxxx, Xxxxxxxxxxxxx Xxxxxxx., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx-xxxxxxxxx xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
18) Xxxxx, X., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4B
"B.11 XXXXXXXXXX–XXXXXXX XX XXXXXXXXXXXX XXXXXXX X XXXXXXX XXXXXX XXXXX XXXXX IN XXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx metody XXXX XX 475 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx x xxxxxxx xxxxxx xxxxx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxxxxxxxx aberace x savců in xxxx je xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx aberací indukovaných xxxxxxxxx látkou x xxxxxxx xxxxxx xxxxx xxxxx, obvykle xxxxxxxx (1, 2, 3, 4). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x xxxxxxxxxxxx. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx aberace. X xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx jsou indukované xxxxxxx chromatidového typu, xxxxx xxxxxxxxxxxx aberace xx rovněž vyskytují. Xxxxxxxxxxxx mutace a xxxxxxxxxxx xxxx xxxx xxxxxxxx mnoha geneticky xxxxxxxxxxx xxxxxx u xxxxxxx x xxxxxxxx xxxxx důkazů o xxx, xx chromozomové xxxxxx a xxxxxxxxxxx xxxx způsobující změny x xxxxxxxxxx x x xxxxxx xxxxxxxxxxx xxxxx tlumících nádory, xxxx xxxxx na xxxxxxx xxxxxxxx x xxxxxxx x v xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx této xxxxxxx jsou rutinně xxxxxxxxx xxxxxxxx. Cílovou xxxxx xx x xxxx zkoušce kostní xxxx, xxxxxxxx xx xxxxxx vaskularizovanou xxxxx x xxxxxxxx xxxxxxxx xxxxx x xxxxxxx xxxxxx, xxxxx xx xxxxxx xxxxxxx a xxxxxxxxxxxx. Xxxx druhy x cílové tkáně xxxxxx předmětem xxxx xxxxxx.
Xxxx zkouška xx xxxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx x xxxxxxxxx nebezpečí mutagenese, xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx XXX, xxxxxxx se xxxxx x xxxxxxx xxxxx x xxxxx měnit. Xxxxxxx xx xxxx xx xxxxxx xxxxxxxx xxx další xxxxxx xxxxxxxxxxx xxxxxx zjištěných xxxxxxxx in xxxxx.
Xxxxxxxx xxxxxxxx xxxxx o xxx, že xx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, xxxx vhodné xxxx xxxxxxx použít.
Viz xxxx Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození xxxxxxxxxx v xxxxxx xxxxx xxxxxxxxxxxx chromatid xxxx xxxxx a xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : strukturní xxxxxxxxx chromozomu v xxxxxx xxxxx xxxx xxxxx x spojení xxxx xxxxxxxxx v xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx kterém x jádře xx X-xxxx xxxxxxxxx XXX xxxxxxx x xxxxxx, xxxxx následuje další X-xxxx. Xxxxxxxxx jsou xxxxxxxxxx xx 4, 8, 16,… xxxxxxxxxxxx.
Xxx : achromatická xxxx xxxxx xxx xxxxx xxxxxxx chromatidu a x xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx xxxxxxxxxx xx normální xxxxxxx xxxxxxx x použitých xxxxx.
Xxxxxxxxxxx : násobek xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), jiný xxx diploidní (xx. 3 x, 4 x atd.).
Strukturní aberace : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx chromozomů xxx xxxxxxxx dělení xx xxxxxx metafáze; xxxx se xxxx xxxxxx a xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 PODSTATA ZKUŠEBNÍ XXXXXX
Xxxxxxx xxxx xxxxxxxxx xxxxxxxx látce xxxxxxx xxxxxxxx a xx xxxxxxx xxxxxxxx xx xxxxxxxx se xxxxxx. Xxxx usmrcením xx xxxxxxxx xxxx xxxxx xxxxxxxxxxx metafázi (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxx xxxxxx xxxxx se xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx xx x xxxxxxxxx xx chromozomové xxxxxxx xxxxx v xxxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Přípravky
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx je xxxxxxxx xxxxxx, xxx x xxxxxx xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx xxxxxx xxxxx xxxx. Xxxx xx xxx xxxxxxx xxxxx xxxxxxx laboratorní xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx by x xxxx pohlaví xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx B, xxxxxxx by mělo xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx xxxxxxx xx xxxxxxxx výběrem rozdělí xx kontrolní xxxxxxx x xxxxxxx, xxxxx xx xxxxxxx zkoušené xxxxx. Xxxxx xx xxxx xxx xxxxxxxxxx xxx, xxx byl xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx se xxxxxxxxxxx xxxxxxxxxxxx. Nechají xx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx aklimatizovat.
1.4.1.4 Příprava xxxxx
Xxxxx xxxxxxxx látky xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxxx xxxxx xxxx xxxxx být xxxx xxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx čerstvě xxxxxxxxxx xxxxxxxx chemické látky, xxxxx údaje o xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by xxxxxx xxx xxx xxxxxxxxx xxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx by xxxx xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx pohlaví. X xxxxxxxx aplikace xxxxxxxx xxxxx xx xxxx zvířata xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx jako zvířata xx skupinách, x xxxxx dojde x xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxx poskytovat strukturní xxxxxxx in vivo xxx xxxxxxxxxxx xxxxxxxx, x nichž xx xxxxxxx, xx poskytnou xxxxxxxxxxxxx xxxxxx xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx tak, xxx xxx xxxxxx xxxxxxxx, ale aby xxx odečtu nevyšla xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx podávána xxxxx xxxxxxxx než xxxxxxxx xxxxx x xxx xxx xxxxx x xxxxx případě xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx látky xx xxxxxx xxxxxxxx třídy, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-triazin |
51–18–3 |
200–083–5 |
V xxxxxxxx xxxxxxx xxxxxx xx xxx xxx xxxxxxxx xxxxx x xxxxxxxxxxx xxxxxxx, xxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxx jinak podstupují xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, pokud xxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxx k xxxxxxxxx xxxxxxxxxx údaje x xxxxxxxxxxx xxxxxx x xxxxxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba xxxxxxx xxxxxx. Xxxxx toho xx xxxx být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx tehdy, neexistují-li xxxxx kontrolní xxxxx xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx/xxxxxxxxx nevyvolává žádné xxxxxxx nebo mutagenní xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x pohlaví xxxxxx
Xxxxx xxxxxxxxxx x kontrolní xxxxxxx se xxxxxx x alespoň xxxx xxxxxxxxxxxxxxxx zvířat xxx xxxxx pohlaví. Xxxxxxxx xxxx v xxxx xxxxxx k xxxxxxxxx xxxxx ze xxxxxx xx xxxxxxx xxxxxx x xx xxxxxxx xxxxxxxx xxxxxxx expozice, xxx prokazují, že xxxxxxxxxx xxxx pohlavími xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxxxx specifická xxx určité pohlaví, xxxx je tomu xxxxxxxxx u xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx být xxxxxxx xxxxxxxxx xx zvířaty xxxxxxxxxxxxxx pohlaví.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx xxx pokud xxxxx xxxxxxxx jednorázově. Xxxxxxxx xxxxx mohou xxx podávány xxxx xx xxxx xxxxxxx, xxx. dvě xxxxx x týž den x rozmezí ne xxxx xxx několika xxxxx, xxx bylo xxxxxxxxx podávání xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xxxxxx xx měly xxx xxxxxxxx xx xxxx různých xxxxxxxxxxx xx aplikace xxxxxx x jednom xxx. X hlodavců xx xxxxx xxxxxxx xx xxxxxx době od xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx délky xxxxxxxxx cyklu (xxxx xxxx obvykle 12 — 18 x). Xxxxxxxx xxxx xxxxxxxx xxx xxxxxx a xxxxxxxxxxxx zkoušené látky x xxxxxx xxx xxxxxx xx xxxxxxxx xxxxxxxxx cyklu xxxx xxx xxxx xx xxxxxxxxx xxxxxxx xxx xxxxxxxxx chromozomových xxxxxxx, xxxxxxxxxx se xxxxxxx xxxxx odběr xx 24 x od xxxxxxx xxxxxx. Je-li xxxxxxxx xxxxxxxxx xx xxxx než xxxxxxx xxx, xxx xx xxx xxxxx xxxxxxxx xx takové době xx xxxxxxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx délky buněčného xxxxx.
Xxxx xxxxxxxxx se xxxxxxxx xxxxxxxxxxxxxxxxx xxxx xxxxxx dávka látky xxxxxxxxxxx metafázi (xxxx. Xxxxxxxx® xxxx kolchicin). Xxxx xx xx xxxxxx xxxx provede x zvířat xxxxx. X xxxx je xxxx xxxx xxxxxxxxx 3 — 5 x; u křečka xxxxxxxx xx tato xxxx přibližně 4 — 5 h. X xxxxxx xxxxx xx odeberou xxxxx x xxxxxxxxx xx xx chromozomové xxxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx dávek, xxxx xx xxx xxxxxxxxx xx stejné xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x za xxxxxxxx xxxxxx xxxxxxxx, jež xx xxxxxxx x xxxxxx studii (5). X xxxxxxx toxicity xx xxx xxxxx xxxxx xxxxxxx xxx xxxxxx xxxxx. Tyto xxxxxx xxxxx by xxxx xxxxxxxx xxxxxxx xxxx maximální x xxxxxxxxx toxicitou, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx bude xxxxxxx xxxxx nejvyšší xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx jako dávka xxxxxxxxxxxx takové xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx stejném režimu xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxx. Látky xx specifickou xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx dávkách (např. xxxxxxx x mitogeny) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx být xxxxxxxxx xxxxxx od xxxxxxx. Nejvyšší xxxxx xxxx být xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx v xxxxxx xxxxx některé xxxxxx xxxxxxxx (xxxx. více xxx 50 % xxxxxxx xxxxxxxxxxx xxxxxx).
1.5.4 Xxxxxxx zkouška
Jestliže zkouška x jednou dávkou xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx ve xxxx xxxxxxx x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx toxické xxxxxx x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx xx nezbytnou. X xxxx trvajících xxxxxx je xxxxxxx xxxxxx xxx 14denní xxxxxxxx 2000 mg/kg xxxxxxx hmotnosti/den x xxx xxxxx než 14xxxxx xxxxxxxx je xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx člověka xxxx znamenat potřebu xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Podávání dávek
Zkoušená xxxxx se xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx nebo xxxxxxx xxxxxxxxx kanylou, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx xxxxxxx podávání jsou x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, který xxxx xxx xxxxxxxx podán xxxxxxxxxxxxxx nebo injekčně, xxxxxx xx velikosti xxxxxxxxxxx xxxxxxx. Objem xx neměl xxxxxxxxx 2 ml/100 g xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, než xx uvedený xxxxx, xxxx xxx xxxxxxxxxx. Xx na xxxxxxxx x žíravé xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, by xxxx být variabilita xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx při xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx se odebere xxxxxx dřeň, xxxxxxxxxxxx xx x xxxxxx. Xxxxx se xxxxxxx xx xxxxxxxx sklíčka x obarví xx.
1.5.7 Xxxxxxx
Xxxx xxxxxxx cytotoxicity xx měl xxx x xxxxx exponovaných xxxxxx (včetně xxxxxxxxxxx xxxxxxx) x x xxxxxxxxxxxxxx xxxxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx, x xx xxxxxxx x 1000 xxxxx xx xxxxx zvíře.
U každého xxxxxxx by xxxx xxx xxxxxxxxxxx xxxxxxx 100 buněk. Xxxxx xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx aberací. Všechny xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx xx xxxx být před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxx xxx xxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxx xxxxxx xxxx ke xxxxxx xxxxxxxxxx x části xxxxx x xxxxxxxx, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx odpovídajícímu xxxxx 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje pro xxxxxxxxxx xxxxxxx xx xxxx být xxxxxxxxxx xx formě xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx. Pro xxxxx xxxxx xx xxx xxx vyhodnocen počet xxxxx, xxxxx xxxxxxx xx buňku a xxxxx buněk s xxxxxxxxxxxxx xxxxxxx (xxxxxxxxxxxxxx xxxxxxxxx) vyjádřený x xxxxxxxxxx. Pro xxxxxxxxxx x kontrolní xxxxxxx xx xxxx xxx xxxxxxx různé xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx xxxxxx x četností. Xxxx xx xxxxxxxxxxxxx xxxxxxxx x uvádějí se, xxx xxxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x xxxxxxxx xxxx xxxxxxxxx, xxxxx xxx xxx statistickou xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. nárůst relativního xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xx xxxxx xxxx xxxxx nárůst xxxxx xxxxx s xxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx x x xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx hodnocení xxxxxxxx zkoušky xxxxx xxx použity xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (6). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Dvojznačné xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravami xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx polyploidie xxxx xxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx buněk x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, xx zkoušená xxxxx xx potenciál xxxxxxxx xxxxxxxx buněčného xxxxx (7, 8).
Xxxxxxxx xxxxx, jejíž xxxxxxxx xxxxxxxxx xxxx uvedená xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx poskytne jasně xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx konečný xxxxx o aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx sporné bez xxxxxx na to, xxxxxxxx je experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx v kostní xxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx xxxxx za xxxxxxxx zkoušky xxxxxxxxxx x kostní dřeni xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx by být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx zkoušená xxxxx nebo xxxx xxxxxxxxxx dostanou xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (např. xxxxxxxxx xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x zkoušce xxxx obsahovat tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- použitý xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, včetně xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební podmínky:
- xxxxxxxxx x negativní (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx dávek,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- popřípadě metody xxxxxxx, xxx se xxxxxxxx látka xxxxxxx xx krevního xxxxx xxxx xx cílové xxxxx,
- případně přepočet xxxx koncentrací xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx údaje x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx expozice x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, její xxxxxxxxxxx x délka xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- xxxxx analyzovaných xxxxx xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity,
- mitotický xxxxx,
- typ x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx pro xxxxx xxxxx,
- celkový xxxxx xxxxxxx xx xxxxxxx xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx s xxxxxxxxx ve skupině xx xxxxxxxxx xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxx xxxxxxx, pokud xxxx pozorovány,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- případné xxxxxxxxxxx analýzy,
- údaje x xxxxxxxx negativní xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx kontrole x xxxxxxxxx, středními xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx o xxxxxxxx pozitivní kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Xxxxx in Xxxxxxx, xx: Mutagenicity Xxxxxxx: x Xxxxxxxxx Xxxxxxxx, X. Xxxxxx, X. X. Xxxxx (xxx), XXX Xxxxx, Xxxxxx, Xxxxxxxxxx X. X., 275-306.
2) Xxxxxxx, X. J., Xxxx, X. X., Xxxxxxxx, X., Xxxxxx, H., XxXxx, X. X., Xxxxxx, X. (1987), Xxxxxxxxx In vivo Xxxxxxxxxxx Xxxxxx: Analysis xx Xxxxxxxxxx Xxxxxxxxxxx xx Xxxx Marrow Xxxxx, Mutatation Xxx., 189, 157-165.
3) Xxxxxxx, X., Chandley, X., Xxxxx, X., Xxxxxxxxx, X. G., Xxxxxxx, X., Xxxxxxxxx, X. (1990), In vivo Xxxxxxxxxxx Assays, in: X. X. Xxxxxxxx (xx.), Basic Xxxxxxxxxxxx Xxxxx, XXXXX Recommended Xxxxxxxxxx. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx X xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
4) Tice, X. R., Xxxxxxx, X., XxxXxxxxxx, J. X., Xxxxxxxx, X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx-Xxxxxxx, M., Xxxxxx Xx., X. X., Xxxxxxxxxxxx, X., Xxxxxxx, X. X., Romagna, X., Shimada, H., Xxxxx, X., Xxxxxxx, X. (1994), Report xxxx xxx Xxxxxxx Xxxxx xx the xx xxxx Xxxxxxxxx Xxxx Xxxxxx Chromozomal Xxxxxxxxxx Test, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. R., Xxxxxx, X. X., Xxx, X., Esdaile, X. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Richold, X. (1992), Report of Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Group: Xxxx Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, X. P., Xxxxxxxx, X., Xxxxxxxx, X., Amphlett, X. X., Xxxxx, X., Xxxxxxxx, X., Richold, X., Papworth, X. X., Savage, J. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx of Xx vivo Xxxxxxxxxxx Xxxxxx, in: UKEMS Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx Part XXX. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxx, X. X. Kirkland (xx.) Cambridge University Xxxxx, Xxxxxxxxx, 184-232.
7) Xxxxx-Xxxxx, C. (1983), Xxxxxxxxxxxxxxxxx in Chinese xxxxxxx xxxxx xxxxxx xxxxx-xxxxxxxxx-xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
8) Xxxxx, X., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Res., 43, 1362-1364."
XXXXXXX 4X
"X.12 MUTAGENITA–TEST XXXXXXX XXXXXXXXXXXXXXX MIKROJADER XX XXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx XXXX XX 474 — Test xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx (1997).
1.1 XXXX
Xxxx xxxxxxx erytrocytárních xxxxxxxxxx xx xxxx xx xxxxxxxx pro xxxxxxx xxxxxxxxx chromozomů xxxx mitotického xxxxxxx xxxxxxxxxxxx, xxxxx je xxxxxxxxxx xxxxxxxxx xxxxxx, x xx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx x kostní xxxxx x/xxxx xxxxx xxxxxxxxx xxxx, obvykle xxxxxxxx.
Xxxxxx xxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx je identifikovat xxxxx, xxxxx xxxxxxxxx xxxxxxxxxxxxx poškození, xxxxx xxxxxxxxx je xxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxx xxxxxxxxx xxxx xxxx xxxxxxxxxx.
Xxxx xx xxxxxxxxxxx xxxxxx xxxxx xxxx xx xxxxxxxxxxxxxxx erytrocyt, xxxxxx xxxxx xx xxxxxxxx a mikrojádra, xxxxx při xxx xxxxx xxxxxxxxx, xxxxxxxxx x xxxxxxxxxx, xxxxx xxxxx jádra neobsahuje. Xxxxxxxxxxxx xxxxxxxxxx xx x xxxxxx xxxxxxx xxxxxxxxx xxx, xx xxxxxxxxxx xxxxxx jádro. Xxxxxx xxxxxxx polychromatických xxxxxxxxxx s mikrojádry x xxxxxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx poškození.
V xxxxx xxxxx xx xxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx x periferní xxxx je xxxxxxxxxx xxxxxxxxxx u xxxxxxxxxxx xxxxx, x xxxxx xxxx prokázána xxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx způsobují xxxxxxxxxx nebo numerické xxxxxxxxxxxx xxxxxxx. Xxxxxxxxxx xxx xxxxxxxx xxxxx xxxxxxxx. Xx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxxxxx) XXX x xxxxxxxxxx. Xxxxxxxxx xx zejména xxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx. Xxxxx xxxxxxx (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxx xxxx, které xxxxxxxx xxxxxxxxxx, xxxxxxxxxxx xx xxxxxx xxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxx jako xxxxxxx xxxxxxxx xxxxxxx, jestliže xxxx zvířata exponována xxxxx xxxxx xxxx xxxx.
Xxxxx xxxx savčích xxxxxxxxxxxxxxx mikrojader xx xxxx xx xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx XXX, xxxxxxx xx mohou lišit x různých xxxxx x xxxxx, jakož x z xxxxxxxxxxx xxxxxxxx. Zkouška xx xxxx xx rovněž xxxxxxxx xxx xxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx x systémech xx vitro.
Jestliže xxxxxxxx xxxxx o xxx, xx xx xxxxxxxx xxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, není xxxxxx xxxx xxxxxxx xxxxxx.
Xxx také Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx (kinetochor) : xxxxxx (oblasti) chromozomu, x xxx (x xxxx) se xxxxx xxxxxx buněk připojí xxxxxx vřeténko xxxxxxxxxx xxxxxxxxxx pohyb dceřiných xxxxxxxxxx x xxxxx xxxxxxxxx buněk.
Mikrojádra : xxxx xxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx x vedle xxxx, vytvářená během xxxxxxxx xxxxxx (meiosy) xxxxxxxxxxxxxxx se (lagging) xxxxxxxxxxxxxx fragmenty nebo xxxxxx xxxxxxxxxx.
Xxxxxxxxxxxxxxxx xxxxxxxxx : xxxxx erytrocyt xxxxxxxxxxxx xxxxxxxx, xxxxx xxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx pro xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxxx, který xxxxx xxxxxxxx ribozomy, x xxxx xxx xxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxxx erytrocytů xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx se xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxx. Xxx xxxxxxx xxxxxx xxxxx xx xxxxxxx xx xxxxxxx xxxxxxxx xx expozici xxxxxx, xxxxxxx xx xxxxxx xxxx, xxxxxxxx xx xxxxxxxxx a xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx se krev xx vhodném xxxxxxxx xx xxxxxxxx xxxxxxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxx x xxxxxx xx (4, 8, 9, 10). Při xxxxxxxx x xxxxxxxxx xxxx xx xxxx xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxx xxxxxxxx xx xxxxxxxxx xxxx. Xxxxxxxxx jsou xxxxxxxxxxx xx xxxxxxxxxx xxxxxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx zvířete
Při použití xxxxxx dřeně xx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xxx nebo xxxxxx, ačkoli xxx xxxxxx jakýkoli xxxxxx xxxxx druh. Xxx xxxxxxx xxxxxxxxx xxxx xx xxxxxxxxxx myš. Xxx xxxx použít xxxxxxxx vhodný druh xxxxx za xxxxxxxxxxx, xx xxx o xxxx, x xxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxx vykazující dostatečnou xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxxxx strukturní xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx běžně xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx zvířat. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx být xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx xx x xxxx pohlaví xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x části B, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx zvířata xx xxxxxxxx výběrem xxxxxxx xx xxxxxxxxx xxxxxxx x skupinu, x xxx xx xxxxxxx xxxxxxxx. Zvířata xx xxxxxxxxxxx xxxxxxxxxxxx. Nechají xx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx aklimatizovat. Xxxxx xx xxxxxxxxxx xxx, xxx xxx vliv xxxxxx xxxxxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly xxx xxxx aplikací xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech x popřípadě zředěny. Xxxxxxx zkoušené látky xxxxx být xxxxxxxx xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, pokud údaje x xxxxxx xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx nemělo mít xxx použitých xxxxxxxx xxxxx toxické xxxxxx x mělo xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Jsou-li xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, mělo xx xxx xxxxxx xxxxxxxx podloženo xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly být xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx pohlaví. X xxxxxxxx aplikace xxxxxxxx xxxxx by xxxx xxxxxxx xxxxxxxxx skupiny xxxxxxxxxx identický xxxxxx xxxx xxxxxxx ve xxxxxxxxx, x nichž xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx měly xxxxxxxxxx mikrojádra xx xxxx xxx expozičních xxxxxxxx, x nichž xx xxxxxxx, že xxxxxxxxx xxxxxxxxxxxxx nárůst xxx pozadí. Dávky xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx xxx xxxxxx zřetelný, xxx xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxxxxxxx kontrola xxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx látka x xxx xxx xxxxx x tomto xxxxxxx xxxxxxxx xxx xxxxxx. Pro xxxxxxxxx xxxxxxxx navíc může xxx xxxxx v xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx třídy, xxxx-xx x dispozici. Příklady xxxxx xxx pozitivní xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid monohydrát |
6055–19–2 |
|
|
2,4,6-tris(aziridin-1-yl)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxx xx xxx xxx xxxxxxxx xxxxx u xxxxxxx xxxxxxxxx kontroly, xxxxx je xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx jako xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x dosavadních xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx údaje x xxxxxxxxxxx xxxxxx a xxxxxxxx buněk x xxxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx kontrolu xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba xxxxxxx odběru. Xxxxx xxxx by xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx dosud nebo xxxxxx-xx xxxxxxxxxxx kontrolní xxxxx prokazující, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx zhoubné nebo xxxxxxxxx xxxxxx.
Xxx xxxxxxx xxxxxxxxx xxxx xxxx xxx xxxx negativní xxxxxxxx přijatelný xxxx xxxxxx krve odebraný xxxx xxxxxxxx, xxxxx xxxx u xxxxxxxx xxxxxx s periferní xxxx (např. 1 — 3 xxxxxxxx) xx xxxxxxxxxxx, xx xxxxxxxx xxxxx budou x xxxxxxx, které xx xx xxxxxxx xxxxxxxxxxx kontrol xxxxxxx.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx skupina xx xxxx skládat x alespoň xxxx xxxxxxxxxxxxxxxx zvířat xxx xxxxx xxxxxxx (11). Xxxxxxxx xxxx v xxxx xxxxxx x xxxxxxxxx údaje xx xxxxxx xx stejným xxxxxx x xx xxxxxxx stejného způsobu xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx v xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx jednoho pohlaví. Xx-xx xxxxxxxx člověka xxxxxxxxxx xxx určité xxxxxxx, jako xx xxxx xxxxxxxxx u xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx se xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxx doporučit xxxxx standardní plán (xx. xxxxx, xxx xxxx tři aplikace x xxxxxxxxx 24 xxxxx). Xxxxxx xx xxxxxx x prodlouženým xxxxxxx xxxxxxxx xxxx xxxxxxxxxx, xxxxx xx x xxxxxx xxxxxx xxxxxxx pozitivní xxxxxxxx, xxxx –v xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx xxxx xxxxxxxxx xxxxxxxx nebo byla xxxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxxx xx xx okamžiku xxxxxx. Zkoušené xxxxx xxxxx xxx podávány xxxx xx xxxx xxxxxxx, tzn. xxx xxxxx x týž xxx x rozmezí xx více xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxx objemů xxxxxxxxx.
Xxxx xxxx xxx xxxxxxxx xxxxx xxxxxxx:
x) zkoušená xxxxx se aplikuje xxxxxxxx xxxxxx. Vzorky xxxxxx xxxxx xx xxxxxxxx xxxxxxx dvakrát, xxxxxxx první xxxxx xx provede xxxxxxxx 24 hodin xx xxxxxxxx a xxxxxxxx xxxxxxxxxx 48 xxxxx xx xxxxxxxx x x xxxxxxxxxx odstupem xxxx xxxxxx. Xxxxx xxxxx xxx 24 xxxxx xx xxxxxxxx xxxx xxx xxxxxxxxx. Xxxxxx xxxxxxxxx xxxx xx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx první xxxxx xx xxxxxxx xxxxxxxx 36 hodin xx xxxxxxxx x xxxxxxxx xxxxxxxxxx 72 xxxxx xx aplikaci x xx xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx. Xx-xx po xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx odpověď, xxxx xxxxx xxxxx xxxxx;
x) xxxx-xx podávány xxx xxxx více xxxxx xxxxx (xxxx. dvě xxxx xxxx xxxxx x intervalu 24 xxxxx), měly xx xxx vzorky xxx xxxxxxx xxxxxx dřeně xxxxxxxx jednou po 18 xx 24 xxxxxxxx xx poslední xxxxxxxx a při xxxxxxx xxxxxxxxx krve xxxxxx xx 36 xx 48 xxxxxxxx xx xxxxxxxx xxxxxxxx (12).
Xxxxx potřeby xxxxx xxx xxxxx xxxxxxx xxxx xxxx xxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx kvůli xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx pro xxxxxxxx xxxxxxx xxxxx, xxxx by být xxxxxxxxx ve xxxxxx xxxxxxxxxx, se stejným xxxxxx, xxxxxx, xxxxxxxx x za stejného xxxxxx expozice, xxx xx xxxxxxx x xxxxxx xxxxxx (13). X xxxxxxx xxxxxxxx xx pro první xxxxx xxxxxxx xxx xxxxxx xxxxx. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx rozpětí xxxx xxxxxxxxx xx xxxxxxxxx toxicitou, xxxxxxxx xxxxxx toxicitou. Při xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx dávka. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx dávka xxxxxxxxxxxx xxxxxx známky xxxxxxxx, xx xxxxx xxxxx by xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx podle xxxxxxxxx x letalitě. Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx a xxxxxxxx) xxxxxx xxxxxxxxx stanovení xxxxx xxxxxxxxx x xxxx xx být xxxxxxxxx xxxxxx od xxxxxxx. Nejvyšší xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx v kostní xxxxx xxxxxxx xxxxxx xxxxxxxx (např. xxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxx x xxxxxxxxx krvi).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x xxxxxx dávkou o xxxxxxx 2000 xx/xx xxxxxxx hmotnosti podanou xxxxxxxxxxx xxxx xx xxxx dávkách v xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx základě xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx strukturu, xxxxxxxxx xxxxxxxxxxxx, xxxx xxxxxxxxxx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx za xxxxxxxxx. X déle xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx pro 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx x xxx xxxxx xxx 14xxxxx xxxxxxxx xx xxxxxxx dávkou 1000 xx/xx tělesné hmotnosti/den. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx znamenat xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, nebo xxxxxxxxxxxxxxxxx xxxxxxx. Jiné xxxxxxx xxxxxxxx xxxx xxxxxxxxxx x odůvodnitelných xxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx podán xxxxxxxxx xxxxxx nebo xxxxxxxx, závisí xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až xx xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx zkušebního xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx konstantní xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxx xxxxx xxxx xxxx
Xxxxx xxxxxx xxxxx se xxxxxxx xxxxxxxxx z xxxxxx xxxx xxxxx xxxxx xx xxxxxxxx. Xxxxx xx xxxxxxxx x xxxxxx xxxx xxxxx a zavedenými xxxxxxxx se preparují x xxxxxx. Periferní xxxx xx xxxxxxx x xxxxxx xxxx xxxx jiné vhodné xxxxxx xxxx. Xxxxxx xxxxx xx xxxxx xxxxxxxxxxxx obarví (8, 9, 10), nebo xx xxxxxxxx preparáty xxxxxxxx x xxxx xx xxxxxx. Xxxxxxxx xxxxxxx xxxxxxxxxxxx pro XXX (xxxx. xxxxxxxxxx xxxxx (14) xxxx Xxxxxxx 33258 x xxxxxxx-X (15)) xx xxx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx XXX. Xxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx (xxxx. Xxxxxx). Xxxxxxxx xxxxxxx (xxxx. xxxxxxxxxx xxxxxx x xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxx (16)) xxx xxxxxx za xxxxxxxxxxx, xx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx systémů pro xxxxxxxxx mikrojader v xxxxxxxxxx.
1.5.7 Xxxxxxx
Xxx xxxxx xxxxx se xxxxxxx xxxxx nezralých xxxxxxxxxx x celkového (xxxxxxx + zralé) množství xxxxxxxxxx, xxxxxxx xx x xxxxxxx kostní xxxxx xxxxxxx xxxxxxx xxxxxxx 200 erytrocytů x x xxxxxxx xxxxxxxxx krve xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx včetně xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxx xxx mikroskopem xxxxxxxxx xxxxxxxx. U xxxxxxx zvířete xx xxxxxxx xxxxxxx 2000 xxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxxxxxxxx. Xxxxx informace xxxxx xxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx xx xxxxxx mikrojader. Xxx xxxxxxxxxxxxx xxxxxxx xx neměl xxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx než 20 % xxxxxxxxx xxxxxxx. Jestliže xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx týdny nebo xxxx, xxx xxxx xxxxxxxx xx výskyt xxxxxxxxxx alespoň 2000 xxxxxxx xxxxxxxxxx na xxxxx xxxxx. Xxxxxxx xxx automatickou analýzu (xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxx) jsou xx xxxxxxxxxxxxx zdůvodnění x validaci xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx jednotlivá xxxxxxx xx měly být xxxxxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxxxxxxx jednotkou xx zvíře. Xxx xxxxx analyzované xxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx s xxxxxxxxxx x počet xxxxxxxxx erytrocytů z xxxxxxxxx xxxxxxxx xxxxxxxxxx. Xxxxxxxx jsou xxxxxxx xxxxxxxxxx nepřetržitě xxxxx xxxxx xxxx xxxx, xxxx xx být xxxx xxxxxxx xxxxx x xxxxxxx erytrocytech, xxxx-xx shromažďovány. Xxx xxxxx xxxxx xx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx erytrocytů x xxxxxxxx xxxxxxxx xxxxxxxxxx x mikrojádry vyjádřené x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x xxxxxxxx xxxx xxxxxxxxx, xxxxx být xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx obě xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního výsledku xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx xxxxx xxxxx x mikrojádry x závislosti xx xxxxx xxxx xxxxx xxxxxx počtu buněk x xxxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx x k xxxxxxxx xxxxxxxx odběru. Xxxxxxxx xx měla xxx uvážena xxxxxxxxxx xxxxxxxxx výsledků. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx prostředek xxxxxxxxxxx metody (18, 19). Statistická xxxxxxxxxx xx xxxxxx xxx xxxxxxx určujícím faktorem xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx být vyjasněny xxxxxx xxxxxxxxx, nejlépe x úpravou xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx kritéria, xx xxxxxxxx x xxxxx xxxxxxx za nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx neumožní xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx sporné xxx xxxxxx na xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxx xx mikrojádra xxxxxxxxx, xx xxxxxxxx xxxxx indukuje xxxxxxxxxx, xxx jsou xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxx druhu. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx v xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx se zkoušená xxxxx xxxx její xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx o xxxxxxx xxxx xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, stáří x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx zvířat xx xxxxxxx zkoušky, včetně xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxx pro xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx k xxxxxxxxx x negativní (vehikulum/rozpouštědlo) xxxxxxxx,
- údaje xx xxxxxx xxx zjištění xxxxxxx, xxxxx xxxx xxxxxxxxx,
- zdůvodnění xxxxxxxxx xxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- údaje x xxxxxxxx zkoušené xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx se zkoušená xxxxx dostala xx xxxxxxxx xxxxx xxxx xx cílové tkáně,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (ppm) na xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx hmotnosti/den),
- podrobné xxxxx x kvalitě xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x odběru,
- xxxxxx xxxxxxxx preparátů,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx hodnocení xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- xxxxxxxx klasifikace xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxx xxxxxxxx,
- podíl nezralých xxxxxxxxxx x celkového xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxx samostatně xxx xxxxx xxxxx,
- xxxxxxx hodnota ± xxxxxxxxxx xxxxxxxx počtu xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx ve xxxxxxx,
- xxxxx xxxxxxxx závislost xxxxxxxx na xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx x metody,
- údaje x xxxxxxxx x xxxxxxxxx negativní xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxxx, X. X. (1973), X Xxxxx Xx xxxx Xxxx xxx Xxxxxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 18, 187-190.
2) Schmid, X. (1975), The Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 31, 9-15.
3) Xxxxxx, J. X., Xxxxxxxx, X. F., Xxxx, X., Kirkhart, X., Xxxxxxxxx, K., XxxXxxxxx, J. G., Xxxxxx, G. W. (1983), Xxx Xxxxxxxxx xx Micronuclei x. x. x Measure xx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, K. X., Xxxxxx, X. X., Xxxxxx, X. C., Xxxxxxxx, X. X., Xxxxxx, X. X. (1990), The Xx xxxx Xxxxxxxxxxxx Assay xx Xxxxxxxxx Xxxx Xxxxxx and Xxxxxxxxxx Xxxxx. X xxxxxx xx xxx X. X. Environmental Protection Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Res., 239, 29-80.
5) XxxXxxxxx, J. X., Schlegel, X., Xxxx, X. X., Xxxx, X. M. (1983), Xxxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxxxxxxx: A Xxxxx Screen xxx Xxxxxxxxxxx Xxxxxx Xxxxxx Xxxxxxx Xxxxxxxx Xxxxxxx xx Xxxx, xx: Xxxxxxxxxxxx in Science xxx Xxxxxxxx xx Xxxxxxxxxx, xx. X. X. Hayes, R. X. Xxxxxxx, X. X. Miya. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) MacGregor, X. X., Xxxxxx, X. X. Xxxx, X., Xxxxxxxx, G. X., Xxxxx, X., Xxxxxxxx, X. F., Xxxx, X. X., Xxxx, D. (1987), Xxxxxxxxxx xxx xxx Xxxxxxx of Xxxxxxxxxxxx Xxxxxx xx Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 103-112.
7) XxxXxxxxx, X. X., Wehr, C. X., Xxxxxx, P. X., Xxxxxx, M. X. (1990), The xx xxxx Xxxxxxxxxxx Xxxxxxxxxxxx Xxxx: Xxxxxxxxxxx xx Steady Xxxxx Xxxxxxxxx Assay Efficiency xxx Xxxxxxx Xxxxxxxxxxx xxxx Toxicity Xxxxxxx, Xxxxxx. Appl. Xxxxxxx. 14, 513-522.
8) Xxxxxxx, X., Morita, X., Xxxxxx, X., Xxxxxx, X., Ishidate, X. Xx. (1990), Xxx Xxxxxxxxxxxx Xxxxx with Xxxxx Peripheral Xxxxx Xxxxxxxxxxxxx Xxxxx Xxxxxxxx Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Collaborative Xxxxx Xxxxx for the Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Xxxx xxxx Xxxxx Peripheral Xxxxx Xxxxxxxxxxxx by Acridine Xxxxxx Xxxxxxxxxx Staining: Xxx Xxxxxxx Report xx xxx 5xx Xxxxxxxxxxxxx Study by XXXXX/XXXXX, XXX, Mutatation Xxx., 278, 83-98.
10) Xxx Xxxxxxxxxxxxx Study Xxxxx xxx the Xxxxxxxxxxxx Xxxx (XXXXX/XXXXX, XXX: Xxx Xxxxxxxxx Xxxxxxxxxxx Study Xxxxx xx xxx Xxxxxxxxxxxxx Xxxxxxx Society xx Xxxxx) (1995), Xxxxxxxx xxxxxxxxxxx xxx xxx xxxxx-xxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Tice, X. R., MacGregor, X. T., Xxxxxxxx, X., Blackey, D. X., Kirsch-Volders, X., Xxxxxx, Jr. F. X., Pacchicrotti, X., Xxxxxxx, F., Xxxxxxx, X., Xxxxx, X., Xxxxxxx, X. (1994), Xx xxxx Xxxxxx Xxxxxxxxxxx Micronucleus Assay, Xxxxx. Xxx., 312, 293-304.
12) Xxxxxxxxxxx, N., Xxxxx, X. (1995), Xx optimal, xxxxxxxxxxx xxxxxxxx xxxx xx 30 ± 6 x xxxxx xxxxxx xxxxxx xx xxx xxxxx xxxxxxxxxx micronucleus xxxx, Mutagenesis, 10, 313-319.
13) Fielder, X. X., Xxxxx, J. X., Boobis, A. X., Botham, P. X., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. G., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Xxxxxx xx British Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx in Xx xxxx Mutagenicity Xxxxxx, Mutagenesis, 7, 313-319.
14) Hayashi, X., Xxxxxx, X., Xxxxxxxx, X. Xx. (1983), Xx Xxxxxxxxxxx of Xxxxxxxx Xxxxxx Fluorescent Xxxxxxxx xx xxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 120, 241-247.
15) XxxXxxxxx, X. T., Xxxx, C. X., Xxxxxxxx, X. X. (1983), A Simple Xxxxxxxxxxx Staining Xxxxxxxxx xxx Xxxxxxxxxxx xxx XXX in Erythrocytes Xxxxx Hoechst 33258 xxx Xxxxxxx X, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, X., Xxxxxxxxxx, C. D. (1989), Xxx xxxxxxxxx xxxx marrow micronucleus xxxx, Xxxxxxxxxx Res., 213, 91-104.
17) Gollapudi, X., XxXxxxxx, X. X. (1995), Xxxxxx Xxxx xxx the Xxxxxxxxxx xx Xxxxxxxxxxxxx xx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxx xx xxx Xxxx Xxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 347, 97-99.
18) Xxxxxxx, X., Xxxxx, X., Xxxxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Henderson, L. (1990), In xxxx Xxxxxxxxxxxx Assay, xx: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx xxxxx, UKEMS Xxxxxxxxxxx Xxxxxxxxxx, XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx 1, xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
19) Xxxxxx, X. P., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, G., Xxxxxxxx X., Richold, X., Xxxxxxxx, X. G., Xxxxxx, X. X. X. (1989), Xxxxxxxxxx Xxxxxxxx xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: D. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx of Mutagenicity Xxxx Data. UKEMS Xxx-Xxxxxxxxx xx Guidelines xxx Mutagenicity Xxxxxxx. Xxxxxx, Xxxx XXX, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.13/14 XXXXXXXXXX — ZKOUŠKA NA XXXXXXXX XXXXXX X XXXXXXXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 471 — Xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx (1997).
1.1 XXXX
Xxx xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxxx Xxxxxxxxxx typhimurium x Xxxxxxxxxxx coli, x xxxxxxx xxxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxxx, xxxxx x xxxxxx jednoho nebo xxxxxxxx párů xxxx XXX (1, 2, 3). Xxxxxxxx této xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxx v detekci xxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx x xxxxxxxx xxx funkční xxxxxxxxx bakterií syntetizovat xxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxx xx reverzi xxxx xxxxxxxxxx xxxx xxx xxxxxxxxxx xxxx x xxxxxxxxxxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxx kmenem.
Bodové xxxxxx x xxxxxxx jevy xxxx xxxxxxxx mnoha xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx x xxxxxxxx mnoho xxxxxx x xxx, xx xxxxxx mutace v xxxxxxxxxx x x xxxxxx xxxxxxxxxxx buněk xxxxxxxxx xxxxxx mají xxxxx na xxxxxx xxxxxxxx u xxxxxxx x x xxxxxxxxx xxxxxx. Xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx xx rychlá, xxxxxxxxxx x xxxxxxxxx xxxxxx. Xxxxx xxxxxxxxxxx xxxxx má xxxx xxxxxxxxxx, xxxx xxxx xxxx xxxxxxxxxx na xxxxxxx xxxxxx, včetně xxxxxxxxxxxxx sekvencí XXX xx reverzních xxxxxxx, xxxxxxx permeability buněk xxx velké xxxxxxxx x xxxxxxxxx reparačních xxxxxxx XXX nebo xxxxxxxx reparačních procesů XXX náchylných x xxxxxx. Xxxxxxxxxxxx xxxxxxxxxxx xxxxx xxxx poskytnout xxxxxxx xxxxxxxx xxxxxxxxx x typech xxxxxx, xxx xxxx xxxxxxxxxx xxxxxxxxxxxxx činiteli. Xxx xxxxxxx na reverzní xxxxxx s bakteriemi xx k xxxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxxxx xxx širokou xxxxx xxxxxxxx a xxxx byly xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx látek, xxxxxx těkavých xxxxxxxxx, x xxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, část B.
1.2 XXXXXXXX
Xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi Xxxxxxxxxx xxxxxxxxxxx xxxx Xxxxxxxxxxx xxxx slouží x xxxxxxx xxxxxx x xxxxx xxxxxxxxxxx xxxxxxxxxxxxx (xxxxxxxx resp. xxxxxxxxx), přičemž xxxxxx xxxx xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx xxxx xxxx činitele, xxx xxxxxxxxx změny x xxxxxx XXX. Xxx xxxxxxx xxxxxxxxxx xxxxxx xx xxxxx tyto xxxxx xxxxxxxxxx xx xxxxx původní mutace xxxx jiném xxxxx xxxxxxxxxxxxx genomu.
Posunové mutageny xxxx činitele, xxx xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx xxxx xxxx xxxx XXX x xxxxxxxx xxx xxxxx xxxxx XXX.
1.3 XXXXXXX XXXXX
Xxx xxxxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xx využívají xxxxxxxxxxxxx xxxxx, xxxxx se xxxx xx xxxxx xxxxx faktory, xxxx xxxx xxxxxx, metabolismus, xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxx DNA. Xxxxxxx xxxxxxxxx in xxxxx obecně xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx xxxxxxx xx xxxxx xxxxxxx zcela xxxxxxxxx xxxxxxxx in xxxx u xxxxx. Xxxxxxx xxxx neposkytuje xxxxxx informaci o xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx látky xxx xxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi xx xxxxxxxxx využívána xxx počáteční xxxxxxxxx xxxxxxxxxxx xxxxxxxx, x xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxx mutace. X xxxxxxxx databáze xxxxxxx, xx mnoho xxxxxxxxxx xxxxx, xxxxx xxxx x xxxx xxxxxxx xxxxxxxxx, xxxxxxxx mutagenní xxxxxxxx i x xxxxxx xxxxxxxxx. Existují xxxxxxxx mutagenních činitelů, xxxxx xxxxxx xxxxxxxxxx xxxxx zkouškou. Xxxxxxx xxxxxx xxxxxxxxxxx lze xxxxxxxxx xx specifické xxxxxx detekovanéhokonečného xxxx, x rozdílech v xxxxxxxxxxx aktivaci xxxx x xxxxxxxxx x xxxxxxxxxx dostupnosti. Xx xxxxx xxxxxx xxxxxxx, xxxxx zvyšují citlivost xxxxxxx xx reverzní xxxxxx xx xxxxxxxxxx, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx xxxxxxxx mutace x bakteriemi xxxxxx xxx xxxxxx pro xxxxxx třídy chemických xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx antibiotika) a xxx xxxxxxxx xxxxx, x nichž se xxxxxxxxxxx (xxxx x xxxxx se ví), xx xxxxxxxxxx zasahují xx replikačního xxxxxxx xxxxx xxxxx (např. xxxxxxx inhibitory xxxxxxxxxxxxx x některé xxxxxxx xxxxxxxxxx). X xxxxxxxx xxxxxxxxx mohou xxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxx.
Xxxxxxxx xxxxx xxxxxxxxx, pro něž xx tato xxxxxxx xxxxxxxxx, xx karcinogenní xxx xxxxx, xxxx xxxxxxxx xxxxxxxxx. Xxxxxx xx xxxxxxxx xxxxx x existuje xxxxx xxxxxxxxxxx, xxx xxxxxx xxxxxxxxxx touto zkouškou, xxxxx působí jinými, xxxxxxxxxxxxxxx xxxxxxxxxx, nebo xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxxx xxxxxxxxxxxxx xxxxx jsou xxxxxxxxx xxxxxxxx látce, x xx xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx a xxx něho. Xx xxxxxxxxxxx miskovém testu xx xxxxxxxx xxxxxxxx x xxxxxxx agarem x xxxxx xx xxxxxxx xx xxxxxxxxx xxxx. V xxxxxxxxxxxx xxxxxx xx xxxxxxxx xxxx xxxxxxxx x xxxx xx xxxx xxxxxxxxx xx xxxxxxxxx xxxx xxxxxx x xxxxxxx agarem. Xxx xxxx xxxxxxxxxx xx xx dvou xxxx xxxxx xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx se xxxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxx misce x xxxxxxxxxxxxx.
Xx popsáno xxxxxxx xxxxxxx provedení xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx. Xxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxx xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx test (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx xxx zkoušení xxxxx x xxx xxxx xxxxxxx (12).
Xxx xxxxxxx xxxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxx. Xxxxx x xxxx je xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, xxx xxx ní. Některé xxxxx xxx účinněji xxxxxxxxx za xxxxxxx xxxxxxxxxxxx metody. Xxxx xxxxx xxxxx xx xxxxxxxxxx xxxx, xx xxxxx patří mezi xxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxx, xxxxxxxxx xxxx, xxxxxxxx, azobarviva x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxx (3). Xxxxxx se připouští, xx určité xxxxx xxxxxxxx xxxxx vždy xxxxxxxxx standardními postupy, xxxx xx xxxxxxxxxx xxxxxxx xxxx xxxx xxxxxxxxxxxx xxxxxx. Xxxx xx být považovány xx "zvláštní případy" x k xxxxxx xxxxxxx xx xxxxxxx xxxxxxxxxx použít alternativní xxxxxxx. Je xxxxx xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx x xxxxxxxx postupů xxxxxx xxxxxxx): xxxxxxxxxx a xxxxxxxxxx sloučeniny (3, 5, 6, 13), xxxxx x xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x xxxxxxxxx (17, 18). Odchylka xx xxxxxxxxxxxx xxxxxxx musí xxx vědecky zdůvodněna.
1.5 XXXXX XXXXXXXX XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx xxxxxxx xxxxxxxx by xxxx xxx xxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxx xxxx do časné xxxxxxxxxxx xxxx xxxxx (xxxxxxxxx 109 xxxxx xx xx). Xxxxx x xxxxxx xxxxxxxxxxx xxxx xx xxxxxx xxx použity. Xx xxxxxxxx, xxx xxxx xxxxxxx bakterie xxxxxx xxxx životaschopných xxxxxxxx. Xxxx může xxx xxxxxxxx xxx na xxxxxxx dosavadních xxxxxxxxxxx xxxxx o růstové xxxxxx, nebo xxx xxxxxx zkoušku xxxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxx xx miskách.
Doporučená xxxxxxxxx xxxxxxx xx 37 °X.
Xxxx by xxx xxxxxxx xxxxxxx xxx xxxxx xxxxxxxx. Xxxx xxxx by xxxx xxx xxxxx xxxxx X. xxxxxxxxxxx (XX1535; XX1537 xxxx XX97x xxxx XX97; XX98 x XX100), xxxxxxx xxxxxxx xx ukázala x xxxxxxx laboratořích xxxx xxxxxxxxxx x xxxxxxxxxxxxxxxx. Tyto xxxxx xxxxx X. xxxxxxxxxxx xxxx pár bází XX xx xxxxxxxxx xxxxxxxxx místě x xx známo, že xxxxxx prostřednictvím xxxxx xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, činitele způsobující xxxxxxxxxx xxxxxx XXX x hydraziny. Xxxx xxxxx mohou xxx xxxxxxxxxx kmeny X. xxxx XX2 xxxx X. xxxxxxxxxxx XX102 (19), které mají xx primárním reverzním xxxxx xxx xxxx XX. Xxxxxxxxxx kombinace xxxxx je xxxx xxxx:
- X. typhimurium XX1535 x
- S. xxxxxxxxxxx XX1537 xxxx XX97x x
- S. xxxxxxxxxxx XX98 x
- X. xxxxxxxxxxx XX100 x
- X. xxxx XX2 xxxX, nebo X. xxxx XX2 xxxX (xXX101), nebo X. xxxxxxxxxxx TA102.
Pro xxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx XXX xxxx xxx xxxxxxxxx xxxxxxx XX102 xxxx xxxxxx kmen E. xxxx x xxxxxxx xxxxxxxxxx reparace XXX, (xxxx. X. xxxx XX2 (xXX101)).
Xxxx xx xxx použity zavedené xxxxxxx přípravy xxxxxxx xxxxxxx, verifikace markeru x xxxxxxxxxx. Xxxxxxx xxxxxxxxxxxxx xxx xxxx xx xxxx xxx xxxxxxxxx xxx každou xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxxx xxx kmeny X. xxxxxxxxxxx x xxxxxxxxx xxx X. xxxx). Xxxxxxx by xxxx být kontrolovány xxxx xxxxxxxxxx charakteristiky, xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx nebo nepřítomnost X-xxxxxxx xxxxxxxx (xx. xxxxxxxxxxxx xxxxxxxxxx u xxxxx TA98, XX100 x XX97x xxxx XX97, XX2 uvrA x XX2 uvrA (xXX101) a xxxxxxxxxxxx x xxxxxxxxxxxxxx xxxxxxxxxx x xxxxx XX102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. xxx xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxxx a xxxX xxxxxx u X. xxxx nebo xxxX xxxxxx u X. xxxxxxxxxxx xxxxxxxxxx na xxxxxxxxxxxx xxxxxx) (2, 3). Xxxxx by xxxx xxxxxx xxxxx xxxxx xxxxxxx spontánních xxxxxxxxxx xx xxxxx x xxxxxxx xxxxxxxx xxxxxxxxxxx xx základě xxxxxxxxxxx údajů xxxxxxxxxxxxx xxxxxxx a xxxxxxx x xxxxxxx uvedeném x xxxxxxxxxx.
1.5.1.2 Médium
Použije xx xxxxxx xxxxxxxxx xxxx (např. obsahující xxxxxxxxx xxxx E (Xxxxx-Xxxxxx) a xxxxxxx) x xxxxxx xxxx xxxxxxxxxx xxxxxxxx x xxxxxx xxxx tryptofan xxxxxxxxxx několik xxxxxxxxx xxxxxx (1, 2, 9).
1.5.1.3 Xxxxxxxxxxx xxxxxxxx
Xxxxxxxx xx xxxx být xxxxxxxxx xxxxxxxx xxxxx, x xx s xxxxxxx systémem xxxxxxxxxxx xxxxxxxx x xxx xxxx. Nejčastěji xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx z xxxxx hlodavců xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Aroclor 1254 (1, 2) xxxx fenobarbitonu x β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx frakce xx obvykle xxxxxxxxx x xxxxxxxxxxxxx x xxxxxxx 5 xx 30 % xxx. xx směsi S9. Xxxxx x podmínky xxxxxxxxxxxxx aktivačního xxxxxxx xxxx xxxxxxx xx xxxxx xxxxxxxx xxxxxxxx xxxxx. X xxxxxxxxx xxxxxxxxx může xxx xxxxxx xxxxxx více xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. U xxxxxxxxx x diazoniových xxxxxxxxx může xxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx (6, 13).
1.5.1.4 Zkoušená xxxxx xxxx xxxxxxxxx
Xxxxx xxxxxxxx látky xx xxxx být xxxx xxxxxxxx xx xxxxxxxx xxxxxxxxxx xxxx suspendovány xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx mohou xxx xxxxxxx xxxxx x testovacím systémům x/xxxx mohou xxx xxxx xxxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx čerstvě xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx mělo xxx xxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx, x xxxx by xxx xxxxxxxxxx x xxxxxxxx xxxxxxxx a x xxxxxxxxx S9 (22). Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx nejdříve xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx vodu.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxx xxxxxxxx zkoušené xxxxx xxxxx cytotoxicita x xxxxxxxxxxx x xxxxxxx xxxxx pro xxxxxxxx.
Xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxxxxxx xxxx xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxxxx revertantů, xxxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx podkladu xxxx xxxxxxxx xxxxxx přežití xxxxxxxxxxxx xxxxxx. Xxxxxxxxxxxx xxxxx xx xxxx xxxxxx v xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxxxxxxxxxx xx xxxx xxx posouzena xx xxxxxxx viditelného srážení x xxxxxxx xxxxx xx skutečných xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx pro rozpustné xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx nebo 5 μx/xxxxx. X xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxx koncentracích 5 xx/xxxxx xxxx 5 μx/xxxxx xx měla xxx jedna nebo xxxx zkušebních koncentrací xxxxxxxx, aby xxxxx xxxx v konečné xxxxx pro xxxxxxxx xxxxxxxxxxx. Xxxxxxxx látky, xxxxx jsou cytotoxické xxx při koncentracích xxxxxxx xxx 5 xx/xxxxx xxxx 5 μx/xxxxx, xx xxxx xxx xxxxxxxx xx xx xxxxxxxxxxx xxxxxxxxxxx. Xxxxxxxxx by neměla xxxxx xxx vyšetřování.
Mělo xx xxx použito xxxxxxx xxx různých xxxxxxxxxxxxxxxx xxxxxxxxxxx zkoušené xxxxx, přičemž xxx xxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx xxxx xxxxxxxxxx xxxx xxxxx přibližně polovině xxxxx logaritmické xxxxxxxx (xx. Ö10). Xxxxx xxxxxxxxx jsou xxxxxx x případě, xxx xx vyšetřuje křivka xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx. Xxxxxxxx xxxxxxxxxxx xxxxxxx než 5 xx/xxxxx nebo 5 μx/xxxxx xxxx xxx xxxxxxx při xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx mutagenních xxxxxxxx.
1.5.2.3 Xxxxxxxxx a xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxx xx měly xxx xxxxxxx xxxxxxxxxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx s xxxxxxxxxxxx xxxxxxxx x xxx xx. Pro pozitivní xxxxxxxx by xxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxxxxxx účinnost xxxxx xxxxxxx.
X případě zkoušek x použitím xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx by xxxx xxx xxxxx (xxxxx) pro xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxx) xx xxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxxxxxxx xxxxxx xxxxxxxxx kontroly x zkoušky x xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
9,10-xxxxxxxxxxxxxxxxx |
781–43–1 |
212–308–4 |
|
7,12-xxxxxxxxxxxxx[x]xxxxxxxxx |
57–97–6 |
200–359–5 |
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
2-xxxxxxxxxxxxxx |
613–13–8 |
210–330–9 |
|
Xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Tato xxxxx xx xxxxxxx xxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
XX Direct Red 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx xx neměl xxx xxxxxx jako xxxxxx xxxxxxxxx účinnosti xxxxx X9. Xxx xxxxxxx 2-xxxxxxxxxxxxxxx by xxxx xxx xxxxx xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx mikrosomálními xxxxxx, xxxxxxxxx benzo[a]pyren xxxx 7,12-xxxxxxxxxxxxx[x]xxxxxxxxx.
Xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx xxx xxxxxx xxxxxxxxxxx xxxxxxxx jsou xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx xxxxx |
26628–22–8 |
247–852–1 |
XX1535 x TA100 |
|
2-nitrofluoren |
607–57–8 |
210–138–5 |
TA98 |
|
9-aminoakridin |
90–45–9 |
201–995–6 |
TA1537, XX97 x XX97x |
|
XXX 191 |
17070–45–0 |
241–129–4 |
XX1537, XX97 x TA97a |
|
Kumenhydroperoxid |
80–15–9 |
201–254–7 |
TA102 |
|
mitomycin X |
50–07–7 |
200–008–6 |
XX2xxxX a XX102 |
|
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 xxxX a XX2 xxxX (xXX101) |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 xxxX x XX2 uvrA (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx obsahující xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxx referenční látky. Xxx xxxxxxxxx xxxxxxxx xx xxxx být xxxxx x úvahu xxxxxxx chemických xxxxx xx xxxxxx chemické xxxxx, xxxx xx x xxxxxxxxx.
Xxxx xx xxx xxxxxxx negativní xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx rozpouštědla xxxx vehikula, xxx xxxxxxxx xxxxx, zpracované xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx xxxxxxxxxx žádné xxxxxxx xxxx xxxxxxxxx účinky.
1.5.3 Xxxxxx
X xxxxxxxxxx miskové xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx xxxxxxxx xx xxxxxxx smíchá 0,05 xx xxxx 0,1 xx xxxxxxxxxx xxxxxxx, 0,1 xx xxxxxxx xxxxxxxxxxx kultury (obsahující xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) a 0,5 xx xxxxxxxxxx xxxxx x 2,0 xx xxxxxxxx xxxxx. V xxxxxxx zkoušky s xxxxxxxxxxxx aktivací se xxxxxxx xxxxxx 0,5 xx metabolické aktivační xxxxx xxxxxxxxxx přiměřené xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (x rozmezí 5 xx 30 % xxx. v xxxxxxxxxxx xxxxxxxxx xxxxx) x xxxxxxx xxxxxx (2,0 xx) x zároveň x xxxxxxxxxx x xxxxxxxxx látkou nebo xxxxxxxxx xxxxxxxx. Xxxxx xxxxx xxxxxxxx se xxxxxxxx a přelije xxxx povrch xxxxxxxxxxx xxxxx xx xxxxx. Xxxx xxxxxxxx xx xxxxx xxxxxx agar xxxxxxxx.
X preinkubační metody (2, 3, 5, 6) xx xxxxxxxx xxxxx xxxx zkoušený xxxxxx xxxx smícháním x vrchním agarem x přelitím xxxx xxxxxx xxxxxxxxxxx agaru xx misce xxxxxxx 20 xxxxx nebo xxxx xxxxxxxxxxx x xxxxxxxxxx kmenem (obsahujícím xxxxxxxxx 108 životaschopných xxxxx) x xxxxxxxxx xxxxxx xxxx metabolickým xxxxxxxxxx systémem (0,5 xx) xxx 30 — 37 °C. Xxxxxxx xx smíchá 0,05 nebo 0,1 xx xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx, 0,1 xx xxxxxxxx x 0,5 xx xxxxx S9 xxxx xxxxxxxxxx xxxxx x 2,0 xx vrchního xxxxx. Zkumavky xx xxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxxx xx xxxxxxxx.
X xxxxxxxxxxxx odhadu xxxxxxxx xx měly xxx xxx xxxxx xxxxxx xxxxx xxxxxxx 3 xxxxx. Použití xxxx xxxxx je xxxxxxxxxx xx xxxxxxxx xxxxxxxxxx. Případná xxxxxx xxxxx nemusí xxxxxxxx xxxxxxxxxxxx zkoušky.
Plynné xxxx xxxxxx xxxxx by xxxx xxx zkoušeny xxxxxxxx xxxxxxxx, xxxx. x xxxxx uzavřených xxxxxxxxxxxx nádobách (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx x xxxx xxxxxxx xx xxxx xxx xxxxxxxxxx xxx 37 °C xx 48 –72 xxxxxxxx. Po xxxxxxxx xxxxxxxxx doby xx xxxxxx počet xxxxxxx xxxxxxxxxx na xxxxx.
2. XXXXX
2.1 ZPRACOVÁNÍ VÝSLEDKŮ
Předloženými xxxxx by xxxx xxx počty kolonií xxxxxxxxxx xxxxxxxxxxx xx xxxxx. Měl by xxx xxxxxx uveden xxxxx xxxxxxx revertantů xxx xx xxxxxxx x negativní xxxxxxxxx (xxxxxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx xx miskách x xxxxxxxxx kontrolou. Xxxxx na xxxxxxxxxxxx xxxxxxx, xxxxxxx hodnoty xxxxx xxxxxxx xxxxxxxxxx xx xxxxx a xxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxxx xxx zkoušenou xxxxx x pozitivní x xxxxxxxxx xxxxxxxx (neexponovanou xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx jasně xxxxxxxxx xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Negativní výsledky xxxx být xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx xx potvrzení xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxx, xxxx xx xxx podáno xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx by měla xxx xxxxxxx x xxxxxxxxxx experimentech. X xxxxxxxxxx xxxxxx, xxxxx xx mohly být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx xxxxxxx xxxxxx xxxx preinkubace x xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx aktivace.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje xxxxxxx xxxxxxxx, xxxx. nárůst xxxxx xxxxxxx xxxxxxxxxx xx misku xxx xxxxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx x metabolickým xxxxxxxxxx xxxxxxxx nebo xxx xxxx, x xx x xxxxxxxxxx na xxxxxxxxxxx, nebo xxxxxxxxxxxxxxxx xxxxxx xxxxxx počtu xxx xxxxx xxxx xxxx koncentrací (23). Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx výsledků. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx pomocný prostředek xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx významnost xx xxxxxx být jediným xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx jasně xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx případech xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxx kmenů Xxxxxxxxxx xxxxxxxxxxx x/xxxx Xxxxxxxxxxx xxxx xxxxxx xxxxxx xxxxxxxxxx xxxx xxxx xxxxxxx xxxxxxx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxx xx xxxxxxxx xxxxxxx xxx xxxxxxxxx druhy xxxxxxxxx.
3. XXXXXX
XXXXXXXX X ZKOUŠCE
Protokol x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- xxxxx xxxxx v kultuře,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx podmínky:
- xxxxxxxx zkoušené látky xx misku (xx/xxxxx xxxx μx/xxxxx) s xxxxxxxxxxx xxxxxx dávky x počtu misek xx xxxxxxxxxxx,
- použitá xxxxx,
- xxx a xxxxxxx metabolického xxxxxxxxxxx xxxxxxx, včetně kritérií xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx na xxxxxxxxxxxx miskách,
- xxxxxxx xxxxxxx počtu kolonií xxxxxxxxxx na xxxxx x směrodatná odchylka,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx statistické analýzy,
- xxxxx o souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxxxx údaje o xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx kontrole s xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Ames, X. N., XxXxxx, X., Yamasaki X. (1975), Methods xx Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 31, 347-364.
2) Xxxxx, X. X., Xxxx, B. X. (1983), Xxxxxxx Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res., 113, 173-215.
3) Xxxxxxxxx, X., Xxxxxxx, X., Cebula, X., Gocke, X., Xxxx, L., Xxxxxxxxxx, X., Xxxxxxx, C., Xxxxx, T., Xxxxxx, X., Xxxxxx, X. (1994), Xxxxxxxxxxxxxxx xxx xxx Performance of Xxxxxxxxx Mutation Xxxxxx, Xxxxxxxxxx Res., 312, 217-233.
4) Xxxx, L. X., Xxxxxxx D. X., Auletta, X. X., Xxx Xxxxx, X. S., Brown, X. M., Xxxxxx, X. X., Xxxxxx, X., XxXxxx, X., Xxxxxxxxxx, K., Xxxxxx, X., Xxx, T. X., Xxx X. (1986), The Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Xxxxxx of xxx X. X. Xxxxxxxxxxxxx Protection Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, X., Xxxxxx, X., Seino, X. X., Xxxxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X. (1975), Xxxxxxxxxxxx xx Xxxxxxxxxx Xxx Xxxx xxx xxxxx Xxxxxxxxxxx, Xxxxxx Xxxx. 1, 91-96.
6) Xxxxxxxxxx, X., Xxxxxxxx, X., Nagao, X., Xxxxxx, X., Xxxxxx, A., Xxxxxxxx, X. (1980), Xxxxxxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxx, xx: Xxxxx-xxxx Xxxx Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx, ed. Xxxxxxx K. X., Xxxxxx, R. X., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx Xxxx, 273-285.
7) Xxxxxxxxx, D. X., Rowland, X. X., Wilcox, P., Xxxxxxxxx, X. D., Xxxxxx, R. (1980), Xxxxxxxxx Xxxxxxxx Assays, xx: Xxxxx Mutagenicity Xxxxx: XXXXX Xxxx 1 Revised, xx. X. J. Kirkland, Xxxxxxxxx Xxxxxxxxxx Xxxxx, 13-61.
8) Xxxxxxxxxx, X. X., Xxxxxx, X., Xxxxxxx, X. (1987), Xxxxxx Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxx xxx Xxxxx, X. Xxxx Safety., 8, 167-177.
9) Xxxxx, X. H. X., Xxxxxx, X. X., Xxxxxxx, X. X. (1976), Xxx xx x xxxxxxxxxx xxxxxxxxxxx xxxx xx xxxxxx xxx xxxxxx of xxxxxxxx, Xxxxxxxxxx Res., 38, 33-42.
10) Xxxxxxx, X. X., Green, X. X. X., Xxxxxxxxx, X., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Test xx Bacteria, xx: Xxxxxxxx xx Xxxxxxxxxxxx Xxxx Procedures, 2. xxx., Xxxxxx, X. X., Legator, X., Xxxxxxx, X., Xxxxx, X. (xxx.), Xxxxxxxx, Xxxxxxxxx-Xxx York-Oxford, 141-161.
11) Xxxxxxxx, X. X., Xxxxxxx, P. X. (1981), An Xxxxxxxxxxx xx xxx Xxxxxxxxxxxx Xxxxxxxxxx Xxxxx xxx Xxxxxxxxxxx with Xxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxxxxxxxxx Mutagenesis, 3, 453-465.
12) Xxxxx, X., Xxxxxxx, T., Kato, X., Xxxxxxxxxx, T. (1994), Xxxxxxxx Method xxx Xxxxxxxxxxxx Testing xx Xxxxxxx Xxxxxxxxx xx Xxxxx a Xxx Sampling Xxx, Xxxxxxxxxx Xxx., 307, 335-344.
13) Prival, X. X., Xxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. X., Vaughan, V. X. (1984), Xxxxxxxxxxxx xx Benzidine xxx Xxxxxxxxx-Xxxxxxxx Xxxx and Xxxxxxxx Monoazo Dyes xx a Xxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, E., Anderson, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Tests. X. Results xxxx xxx Testing of 311 Xxxxxxxxx, Environ. Xxx. Mutagen., 19, 2-141.
15) Xxxxxx, V., Xxxxxxxx, K., Xxxxxxx, X. G. (1977), Xxxxxxxxx Xxxxxxxx of Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxx Water, in Xxxxxxxx in Genetic Xxxxxxxxxx, D. Xxxxx, X. Xxxxxxx, F. Xxxxxx (xxx.) Elsevier, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. X., Xxxxxxx, X. X., Monteith, X. X., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Xxxxxxxxx xx Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxxxxx Xxxxxxx Xxxxxxxxx in the Xxxx/Xxxxxxxxxx Xxxxx, Environmental Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, T., Matsumoto, X., Xxxxxx, X., Xxxxxxxx, M., Xxxxxxxx, X. (1979), Xxxxxxxxxxxx xx xxx Naturally Xxxxxxxxx Xxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Xxxx, X., Xxxxx-Xxxxx, X., Xxxx, X. X. (1980), Fecalase: X Xxxxx for Xxxxxxxxxx xx Xxxxxxx Xxxxxxxxxx xx Xxxxxxxx xx Xxxxxxxxxx Xxxxx, Proc. Xxxx. Acad. Xxx. X. X. A, 77, 4961-4965.
19) Xxxxxx, X., Xxxxxx, X., Xxxx, X. X., Xxxxxxxxx, X. X. (1990), Xxxxxxxxxx of Xxxxxxxxxx typhimurium XX 102 with Xxxxxxxxxxx xxxx XX2 Tester xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, X., Xxxxxxxx, M., Xxxx, X., Xxxxxxxx, X. (1976), A Safe Xxxxxxxxxx for Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx xx Xxxxxxxxx Activation Xxxxxxx, xx: In xxxxx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, xxx. X. X. xx Xxxxxx xx al. Xxxxxxxx, North Holland, 85-88.
21) Xxxxxx, X. X., Combes, R. X., Xxxxxxx, X. X., Gatehouse, X. X., Xxxxxx, G. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Xxxxxxxxxxxx xx Aroclor 1254-xxxxxxx X9 in in xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Katzenellenbogen, X., Xxxx, B. X. (1981), Compatibility xx Organic Solvents xxxx the Xxxxxxxxxx/Xxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 88, 343-350.
23) Xxxxxxx, X. X., Allen, X., Auletta, X., Xxxxxxxxxx, K., Xxxxxxxx, X., Zeiger, E. (1987), Xxxxx xxx xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxx xxx Xxxxxxxxx Xxxxxxxxxxxx, Mutatation Xxx., 189, 83-91.
24) Xxxxx, G. X. X., Green, M. X. L., Xxxxxxxxx, X., Mitchel, X., Xxxxxxxx, W. X., Xxxxxx, X. X. (1989), Xxxxxxxx xx Xxxx xxxx Xxxxxxxxx Xxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Mutagenicity Xxxxxxx, Part II. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Xxxxxxxx, X. X., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 28-65."
XXXXXXX 4X
"X.17 XXXXXXXXXX — XXXXXXX XX XXXXXX XXXXXX X XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx XXXX TG 476 — Xxxxxxx xx xxxxxx mutace x xxxxxxx xxxxx in xxxxx (1997).
1.1 ÚVOD
Zkoušku xx genové mutace x xxxxxxx xxxxx xx vitro xxx xxxxxx xxx xxxxxxx xxxxxxxx mutací xxxxxxxxxxxx xxxxxxxxxx xxxxxxx. Xxxx xxxxxx buněčné xxxxx xxxxx xxxxx xxxxxxx X5178X myší, xxxxxxx xxxxx XXX, CHO-AS52 x X79 křečka xxxxxxxx x xxxxxxxxxxxxxxx xxxxx XX6 xxxxxxx (1). X těchto xxxxxxxxx linií xxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxx xxx thymidinkinasu (TK) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x transgen xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Zkoušky na xxxxxx TK, XXXX x XXXX xxxxxxxx xxxxx spektrum xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxx XX a XXXX xxxx xxxxxxx detekci xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxx delece), které xxxxx xxxxxxxxx x XXXX xxxxxx xx X xxxxxxxxxxxx (2, 3, 4, 5, 6).
Xx xxxxxxx xx xxxxxx xxxxxx v xxxxxxx xxxxx xx xxxxx lze xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx nebo xxxxxxx xxxxx. Xxxxx se xxxxxxxx xxxxx schopnosti xxxxx x xxxxxxx x stálosti četnosti xxxxxxxxxxx mutací.
Zkoušky xxxxxxxxx xx xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx xxxxxxxx in xxxx x xxxxx. Xx xxxxx xx xxxxx xxxxxxxxx podmínek, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx. X xxxxxxxxxx xxxxxxxxx, xxx neodrážejí xxxxxxx xxxxxxxxxx, může xxxxx xxxxxx xX, xxxxxxxxxx xxxx vysokých xxxxxx cytotoxicity (7).
Tato xxxxxxx xx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxx. Xxxxx xxxxxxxxx, xxx něž je xxxx xxxxxxx xxxxxxxxx, xxxx xxxxxxxxxxx savců; xxxx xxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxxxxx na xxxxxxxx xxxxx a xxxxxxxxx xxxxxx x xxx, že xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx zkouškou, xxxxx zřejmě xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx (6).
Xxx xxxx xxxxxx úvod, část X.
1.2 DEFINICE
Přímá xxxxxx : xxxxxx xxxxxx xxxxxxxxx typu xxxxxxxx xxxxx, která xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxxx aktivity xxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxxxxxxx párů xxxx : látky, xxxxx způsobují xxxxxxxxxx xxxxxxx xxxx xxxx xxxx xxxx x XXX.
Xxxxxxxx xxxxxxxx : xxxxx, které xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx více xxxx bází v xxxxxxxx XXX.
Xxxx xxxxxxx xxxxxxxx : xxxx, xxxxx xxx xxxxxx x xxxx mutovaných xxxxx xxxxxxxxx xxxxxx xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxx xxxx : xxxxxx xxxxx buněk x xxxx ve xxxxxxxx x kontrolní xxxxxxxx xxxxx; xxxxxxx se xxxx xxxxxx poměru xxxxxxxxx růstu v xxxxxxxx x x xxxxxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxxx klonování xxxxxxxx k xxxxxxxxx xxxxxxxx.
Xxxxxxxxx růst x xxxxxxxx : nárůst xxxxx xxxxx v xxxxxxx exprese xxxxxxxx x xxxxxxxxx xxxxxxxx.
Xxxxxxxxxxxxxxx : xxxxxxxx klonování xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xx xxxxxxxxxxxx xxxxxxxx xx expresi.
Přežití : xxxxxxxx xxxxxxxxx buněk xxx nasazení xx xxxxx xx xxxxx xxxxxx xxxxxxxx; xxxxxxx xx xxxxxxx xxxxxxxxx x poměru k xxxxxxx xxxxxxxxx xxxxxxxx xxxxx.
1.3 PODSTATA ZKUŠEBNÍ XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx XX+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (XX) xxxx xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxx pyrimidinu xxxxxxxxxxxxxxxxx (XXX). Xxxxx xxxxxxxxxxx thymidinkinasu jsou xxxxxxx na XXX, xxx způsobuje inhibici xxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxx xxxxxxx xxxxxx. Mutantní buňky xxxx xxxx xxxxxxx xxxxxxxxxxx xx přítomnosti XXX, xxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxxxxxxx tuto xxxxxxxxx xxxxxx. Podobně lze x xxxxx s xxxxxxxxxxxx XXXX nebo XXXX xxxxxxx xxxxxxx xxxxxxxxxxxxxxx rezistence x 6-xxxxxxxxxxx (XX) xxxx 8-xxxxxxxxxx (XX). Xxxxxxxxxx xxxxxxxx xxxxx xx xxxx být pečlivě xxxxxxx, jestliže xx xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx zkoušen xxxxxx báze nebo xxxxxxxxxx xxxxxxx selekčnímu xxxxxxx. Xxxx xx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxx xxxx nemutantní buňky. Xxx zkoušení xxxxxxxxxx xxxxx, které mají xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxxxxxx, xxxx xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxx nebo xxxxxxx pro xxxxxxx (8).
Xxxxx x xxxxxxxxx xxxx xxxxxxxxxxxxx kultuře xxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx xxx x xxxxxxxxxxxx xxxxxxxx, xxx bez xx, x xxxxxxxxxxxxxx xx účelem stanovení xxxxxxxxxxxx x xx xxxxxx xxxxxxx fenotypu xxxx xxxxxxx xxxxxxx (9, 10, 11, 12, 13). Xxxxxxxxxxxx xx xxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) nebo xxxxxxxxxx xxxxxxxxxxx celkového xxxxx xxxxxx xx xxxxxxxx xxxx xxxxxxxx. Xxxxxxxxxx xxxxxxx xx xxxxxxx x růstovém xxxxx xx xxxxxxx xxxx xxxxxxxxxxxxxxxxx xxx xxxxx xxxxxxx lokus x typ xxxxx, xxx xxxxxxx přibližně xxxxxxxxx fenotypová exprese xxxxxxxxxxxx mutací. Xxxxxxx xxxxxxx xx xxxxxxx xxx, xx se xxxxxx xxxxx počet xxxxx xx xxxxx xxxxxxxxxxxx xxxxxxxx činidlo xxx detekci xxxxxxxxxx xxxxx x xx xxxxx bez xxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxx). Xx xxxxxx xxxxxxxxx době se xxxxxxxxx xxxxxxx. Četnost xxxxxxx xx xxxxxxx x xxxxx xxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxx x xxxxx xxxxxxx v médiu xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Pro xxxxxxx x xxxx zkoušce xxxx k xxxxxxxxx xxxxx xxxx xxxxx, xxxxxx xxxxxxxx xxxxx X5171X, XXX, XXX-XX52, X79 xxxx XX6. Xxxx buněk x xxxx xxxxxxx xx xxxx vykazovat xxxxxxxxx x chemickým xxxxxxxxx, xxxxxxx klonovací xxxxxxxxx x stabilní xxxxxxxxx xxxxxxxxxxx xxxxxx. Buňky xx xxxx xxx xxxxxxxxxxxx, xxx nejsou xxxxxxxxxxxxx xxxxxxxxxxxx, x x xxxxxxx xxxxxxxxxxx xx xxxxxx být xxxxxxx.
Xxxxxxx xx měly xxx xxxxxxxx xxx, xxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx x xxxx. Xxxxx použitých xxxxx, kultur x xxxxxxxxxxx zkoušené xxxxx xx měl tyto xxxxxxxxxx xxxxxxxxx xxxxxxx (14). Xxxxxxxxx xxxxx xxxxx, xxxxx xxxxxxx xxxxxxxx x xxxxx xxxxx xxxxxxx v xxxxxx xxxxxx zkoušky, xx měl xxx xxxxxxx xx četnosti xxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxxx xx, xxx xxx xxxxxx xxxxx xxxxx, který xx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx mutací. Xx xxxx doporučeno, xxx bylo xxxxxxx xxxxxxx 106 xxxxx. Xxxx xx xxx x dispozici xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxxxx, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx.
1.4.1.2 Xxxxx a xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx xxxxxx by měla xxx xxxxxxx xxxxxx xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x xxxxxxx). Xxxxx xx xxxx xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx x xxxx xxxxx xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx důležité, aby xxxxxxxxxx xxxxxxxx byly xxxxxxx tak, xxx xxxx zajištěny xxxxxxxxx xxxx xxxxx xxxxx xxxxxx xxxxxxx x xxxxxxxxx jak xxxxxxxxxx, xxx nemutovaných xxxxx xxxxxx xxxxxxx.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxx xx měly xxx xxxxxxxxx z xxxxxxxxx xxxxxx, nasazeny xx kultivačního média x inkubovány při 37 °X. Xxxx xxxxxxxx x xxxx xxxxxxx xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxx xxx xxxxxxxx xxxxxxxx buňky.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx by měly xxx vystaveny xxxxxxxx xxxxx, x to x xxxxxxx systémem xxxxxxxxxxx xxxxxxxx x xxx něho. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx dotovaná xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx je Xxxxxxx 1254 (15, 16, 17 a 18), xxxx xxxx xxxxxxxxxxxxx a β-naftoflavonu (19, 20).
Xxxxxxxxxxxxxxxxxxx xxxxxx xx x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx x koncentracích 1 — 10 % obj. Xxxxx x xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx může xxxxxxx xx xxxxx xxxxxxxx látky, xxxxx xx zkoušena. X xxxxxxxxx xxxxxxxxx může xxx vhodné xxxxxx xxxx než xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx xxxxxxxx xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx linií exprimujících xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Volba xxxxxxxxx buněčných xxxxx xx xxxx být xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx cytochromu X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Příprava xxxxxxxx látky
Pevné xxxxxxxx xxxxx by měly xxx xxxx aplikací xx buňky xxxxxxxxxx xxxx xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx zkoušené xxxxx mohou xxx xxxxxxx přímo x xxxxxxxxxx xxxxxxxx a/nebo xxxxx xxx před xxxxxxxx xxxxxxx. Xxxx xx být xxxxxxx xxxxxxx připravené zkoušené xxxxxxxx látky, pokud xxxxx o stálosti xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx mělo být xxxx podezření, xx xxxxxxx se xxxxxxxxx xxxxxx, x xxxx xx xxx slučitelné x přežitím xxxxx x x xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, mělo xx xxx jejich zařazení xxxxxxxxx údaji o xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx rozpouštědel/vehikul. Při xxxxxxxx látek nestálých xx vodě xx xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která xxxx xxx zohledněna při xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx xxxxxxx x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx by xxxx xxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxx x bez xx x xxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx buněčné xxxxxxxxx x růstu, jako xxxx xxxxxxxxx účinnost xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx být xxxxxxx xxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxx v xxxxxxxxxx xxxxxxxxxxx.
Xxxx by být xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx toxicity by xxxx xxxx xxxxxxxxxxx xxxxxxxx rozmezí dané xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx, xx xx se xxxxxxxxxxx xxxx xxxxx faktorem 2 až Ö10. Xx-xx maximální xxxxxxxxxxx xxxxxxxx xx cytotoxicity, xxxx xx být xxxxxxxxx xxxxxxxxx 10 — 20 % (xxx xxxxxxx 10 %) přežití (xxxxxxxxx xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. X xxxxxxx relativně xxxxxxxxxxxxxxx látek by xxxx xxx xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx xxxx, xxxxx x nich xx xxxxxxxx.
Xxxxxxxxx xxxxxxxxxxx xxxxx xx měly být xxxxxxxx až k xxxx rozpustnosti za xxxxxxxxxxxx xxxxxxxx, xxxx xx za tuto xxx. Xxxx xx xxx xxxxxxxxx případná xxxxxxxxxxxxx v xxxxxxxx xxxxx, xx xxxxxxx xxxx xxxxx xxxxxxxxxx. Xxxx být xxxxxxx xxxxxxxx rozpustnost na xxxxxxx x na xxxxx xxxxxxxx, xxxxx xxxxxxxxxxx xx xxxx x xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxx xxxxx x důsledku xxxxxxxxxxx xxxxx, X9 xxxx, xxx. Nerozpustnost xxx xxxxxxx xxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx xxx vyšetřování.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx a negativní (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx xxx s xxxxxxxxxxxx aktivací, xxx xxx xx. Při xxxxxxx metabolické xxxxxxxx xx měla být xxxxxxxxx xxxxxxxxx chemická xxxxx, xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxx xxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Einecs |
|
Bez xxxxxx xxxxxxxxxxx xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx x xxxxx xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X xxxxxx metabolickou xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx x xxxxx kolonie) |
cyklofosfamid |
50–18–0 |
200–015–4 |
|
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx vysoké xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx xxx použity xxxx xxxx xxxxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx, xxxx. má-li xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx x 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), xxxx být xxxx xxxxxxxxxx látka xxxxxx použita. Xxx xxxxxxxxx xxxxxxxx xx xxxx být xxxxx x xxxxx použití xxxxxxxxxx xxxxx xxxxx xxxxx ze xxxxxx xxxxxxxx xxxxx.
Xxxx xx xxx použity negativní xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxx xxxxx xxxxxxx xxxxxxxx jako xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.4.3 Postup
1.4.3.1 Xxxxxxxx xxxxxxxx látce
Proliferující buňky xx xxxx být xxxxxxxxx zkoušené xxxxx xxx xx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx xxx xxxx. Xxxxxxxx by xxxx xxxxx xxxxxxx dobu (xxxxxxx je xxxxxx xxxx 3 xx 6 xxxxx). Expoziční xxxx xxxx xxx xxxxxxxxxxx xx xxxxx xxxx xxxx xxxxxxxxx xxxxx.
Xxx xxxxxx xxxxxxxx xxxxxxxxxxx mohou být xxxxxxx xxxxxxxxxx kultury xxxx jedna exponovaná xxxxxxx. Xx-xx xxxxxxx xxxxx xxxxxxx, xxx xx být xxxxx xxxxxxxxxxx zvýšen tak, xxx xxx zajištěn xxxxxxxxxxxx počet xxxxxx xxx analýzu (xxxx. xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxxxxxxxx). Xxxx xx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx xxxx xxxxxx xxxxx by xxxx být xxxxxxxx xxxxxxxx metodami, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (21, 22).
1.4.3.2 Xxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx x xxxxxxxx xxxxxx
Xx xxxxx xxxxxxxxx xxxx se buňky xxxxxxx x xxxxxxxxx xx xxxxxx stanovení xxxxxxx x xx xxxxxx umožnění xxxxxxx xxxxxxxx xxxxxxx. Se xxxxxxxxxx cytotoxicity prostřednictvím xxxxxxxxx relativní xxxxxxxxx xxxxxxxxx (xxxxxxx) nebo xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx se započne xxxxxxx xx xxxxxxxxx xxxx.
Xxxxx xxxxx má xxxxxxxxxx minimální xxxxxx xxxxxx, aby xxxxxxx xxxxxxxxx optimální xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxxx xxxxxxx (XXXX x XXXX xxxxxxxx xxxxxxx 6 xx 8 xxx, XX xxxxxxx xxx xxx). Xxxxx xxxx kultivovány x xxxxx xx xxxxxxxxx xxxxxxxx (selekčními činidly) x xxx něho (xxx xxxx) xx xxxxxx stanovení počtu xxxxxxx a xxxxxxxxx xxxxxxxxx. Xx stanovením xxxxxxxxxxxxxxxx (použité xxx xxxxxxx xxxxxxxx xxxxxxx) xx xxxxxxx xx xxxxx doby xxxxxxx xxxxxxxxx xx xxxxx xxx xxxxxxxxxx xxxxxxx.
Xx-xx xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxx X5178X XX+/-, mělo xx xxx xxxxxxxxx xxxxxxx xx xxxxx xx xxxxxxxxxx xxxxxx (x xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x xx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxx. Je-li xxxxxxxx xxxxx xx xxxxxxx X5178X TK+/- xxxxxxxxx, xxxx xx xxx xxxxxxxxx xxxxxxx xxxxx velikosti xxxxxxx xxxxxxxxx na xxxxxxxxxxx x xxxxxxxxxxx kontrolách. Xxx xxxxxxxx xx xxxxxxx TK6 TK+/- xxxx být xxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxxxx velikosti kolonií.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xx měly zahrnovat xxxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxxxxxxx, xxxxx xxxxxxx x xxxxxxxx mutantů xxx exponované x xxxxxxxxx xxxxxxx. X xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxx X5178X XX+/- xx kolonie xxxxxxxxx xxxxxxx x xxxxx koncentrace xxxxxxxx xxxxx (nejvyšší pozitivní xxxxxxxxxxx) a x xxxxxxxxx x xxxxxxxxx xxxxxxxx za použití xxxxxxxx malá xxxxxxx — velká xxxxxxx. Xxxxxxxxxxx x cytogenetická xxxxxx jak xxxxxxx xxxxxxxxx xxxxx xxxxxxx, xxx xxxxxxx xxxxxxxxx xxxx xxxxxxx xxxx xxxxxxxx xxxxxxxx (23, 24). Ve zkoušce XX+/- xxxx kolonie xxxxxxxxxxx za použití xxxxxxxx kolonie x xxxxxxxxx růstem (velká) x xxxxxxx s xxxxxxx xxxxxx (xxxx) (25). X xxxxxxxxxx xxxxx, xxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxxxx poškození, xx xxxxxxxxxxx doby xxxxxxxx, a tvoří xxxx malé xxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxx xx xxxxx xxxxxx xxxx xx xx karyotypické xxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxxx xxxxxxx xxxxxxxxx malé xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxxxxx, xxxxx xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx (26). Xxxx xxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx tempem xxxx xxxxxxxx xxxxx x xxxxx velké xxxxxxx.
Xxxx xx být udáno xxxxxxx (relativní účinnost xxxxxxxxx) nebo xxxxxxxxx xxxxxxx xxxx. Xxxxxxx xxxxxxx xx měla xxx xxxxxxxxx xxxx xxxxx xxxxxxx k xxxxx xxxxxxxxxx buněk.
Měly xx xxx uvedeny xxxxx xxx jednotlivé xxxxxxx. Xxxx xx xxxx být xxxxxxx xxxxx shrnuty xx xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx odpovědi xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx měly xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx podmínek. Negativní xxxxxxxx musí xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxx, xxx xxxx xxxxxxxxx negativních xxxxxxxx xxxxxxxxxx xx xxxxx, xx xxxxx xxxxx zdůvodnění. Xxxxx xxxxxxxxx studie x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxx x následných experimentech xxx pro dvojznačné xxxxxxxx, tak xxx xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, které xx xxxxx xxx xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx a podmínky xxxxxxxxxxx aktivace.
2.2 XXXXXXXXX X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx pozitivního výsledku xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xxxxxxx v xxxxxxxxxx xx koncentraci, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxx xxxxxxxx. Nejdříve xx xxxx být xxxxxxx xxxxxxxxxx xxxxxxxxx výsledků. Xxx hodnocení xxxxxxxx xxxxxxx mohou xxx xxxxxxx jako pomocný xxxxxxxxxx statistické xxxxxx. Xxxxxxxxxxx významnost by xxxxxx xxx jediným xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx látka, xxxxx výsledky nesplňují xxxx uvedená xxxxxxxx, xx x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx většina xxxxxxxxxxx xxxxxxxx xxxxx pozitivní xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné nebo xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx experiment opakován.
Pozitivní xxxxxxxx zkoušky xx xxxxxx mutace v xxxxxxx xxxxx in xxxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx x xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx. Xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx odpovědi xx xxxxxxxxxxx xx xxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za podmínek xxxxxxx neindukuje v xxxxxxxxx kultivovaných buňkách xxxxx xxxxxx xxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- xxxxx xxxxxxxxx xxxxxx,
- případně xxxxx xxxxxx,
- případně xxxxxx xxxxxxxxx buněčné kultury,
- xxxxxxxxxxxx mykoplasmat.
Zkušební xxxxxxxx:
- xxxxxxxxxx xxxxxx xxxxxxxxxxx x počtu kultur, xxxxxx xxxx. xxxxx x xxxxxxxxxxxx a xxxxxx rozpustnosti, xxxx-xx x xxxxxxxxx,
- xxxxxxx xxxxx, případně xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx zkoušené xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx během xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxxxxx kritérií xxxxxxxxxxxxx,
- pozitivní a xxxxxxxxx xxxxxxxx,
- xxxxx xxxx exprese (xxxxxxxx xxxxxx počtu xxxxxxxxxx xxxxx, subkultur x xxxxxx xxxxx),
- selekční xxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx na xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou,
- xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxx x xxxxxxxxxx xxxxx,
- xxxxxxxx xxxxxxx xxxxx xxxxxxxxx x typu (xxxxxxxx xxxxxx xxxxxxxx xxx "xxxx" a "xxxxx" xxxxxxx).
Xxxxxxxx:
- xxxxxx toxicity,
- xxxxxx xxxxxxx,
- xxxxx x pH a xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxx látce, pokud xxxx xxxxxxxxx,
- velikost xxxxxxx, byla-li vyšetřována, xxxxxxx xxx xxxxxxxxx x xxxxxxxxx kontroly,
- xxxxxxxxx xxxxxxxxxxx laboratoře xxxxxxxxx mutanty xxxxxxx xxxx kolonie xxxxxxxx X5178X XX+/-,
- xxxxx xxxxxxxx závislost odpovědi xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- údaje x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X., XxXxxxxx, X. X., XxXxxxxx, X. X., Tindal, X. R. (xxx.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Spring Xxxxxx Xxxxxxxxxx, New Xxxx.
2) Xxx, E. X. Y., Malling X. X. (1968), Xxxxxxxxx Cell Xxxxxxxx. XX. Xxxxxxxx Xxxxxxxxx xx Specific Xxxxx Xxxxxxxxx xx Xxxxxxx Xxxxxxx Cells Xx xxxxx, Xxxx. Xxxx. Xxxx. Xxx. X. X. X, 61, 1306-1312.
3) Liber, H. X., Xxxxxx, X. X. (1982), Xxxxxxxx Xxxxx xx xxx Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxxxx Xxxxx Xxxxxxxxxxxx, Xxxxxxxx Xxx. 94, 467-485.
4) Moore, X. X., Harington-Brock, X., Xxxxx, X. X., Xxxxxxxxx, K. X. (1989), Xxxxxxxxxxxx Xxxxxx Xxxxxxxxxxxx xx xxx Xxxxx Lymphoma XX xxx XXX XXXXX Xxxx, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. S., Xxxxxxxxxx, Xx. X. X., (1989), Comparison xx xxx XX52/XXXX and xxx CHO/HPRT Xxxxxx: Xxxxxxxxxx xx Six Xxxx Xxxxxxxxxx, Xxxxxxxxxx Xxx. 223, 121-128.
6) Xxxxx, X. S., Xxxxxxxxxx, X., Glatt, X. X., Moore, X., Xxxxx, X., Xxxxxxxxxx, Jr. X. X., Xxxxxx, X., Xxxxxxxx, E. (1994), Xxxxxxxxx Cell Xxxx Xxxxxxxx Xxxxxx Xxxxxxx Xxxxx Report. Report xx xxx Xxxxxxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx. Mutation Res. 312, 235-239.
7) Scott, X., Xxxxxxxx, S. X., Xxxxxxxx, X. X., Xxxxxxxx, X., Xxxxxxx, D., Ashby, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx Xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X report xxxx XXXXXX Task Xxxxx 9, Xxxxxxxx Xxx. 257, 147-204.
8) Xxxxx, D., McCuen, X., Xxxxxxx, X. X. X., Xxxxx, X., Xxxxxxxxx, X. X. (1983), Xxxxxxxx Xxxx Xxxxxxxxx xx X5178X Xxxxx in Xxxxxxx. A Xxxxxx xx the X. X. Xxxxxxxxxxxxx Protection Xxxxxx Gene-Tox Program, Xxxxxxxxxx Xxx., 115, 225-251.
9) Xx, X. X., Gupta, X. X., Xxxxxxx, X. X., Xxxxxx, J. X. (1988), A Xxxxxx xxx Analysis xx the Xxxxxxx Xxxxxxx Ovary/Hypoxanthine Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx xx Xxxxxxxxx xxx Xxxxxxxxxxxx xx Chemical Xxxxxx: A Xxxxxx xx Phase III xx xxx X. X. Xxxxxxxxxxxxx Protections Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 196, 17-36.
10) Li, A. X., Xxxxxx, X. X., Xxxx, X. X., Xxxx, X. X., Xxxxx, X. X., Loveday, X. X., X'Νxxxx, X. X., Riddle, J. X., Xxxxxxxxxx, X. X. Xx., Xxxx, X. L. (1987), X Xxxxx xxx xxx Xxxxxxxxxxx xx xxx Xxxxxxx Xxxxxxx Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Phosphoribosyl Xxxxxxxxxxx Xxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Res., 189, 135-141.
11) Liber, X. L., Xxxxxxx, X. X., Xxxxxx, X. X. (1989), X Xxxxxxxxxx xx Xxxxxxxx Xxxxxxxxx at xxx XX xxx XXXX Xxxx in Xxxxx Lymphoblastoid Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx are Xxx to xx Xxxxxxxxxx Xxxxx of Xxxxxxxxx xx xxx Xxxxxxxxx XX Xxxxx, Xxxxxxxxxx Xxx., 216, 9-17.
12) Xxxxxxxxxx, X. X. Jr., Xxxxxx, X. X., Xxxx, X. X. (1986), Xxxxxxxxxxxx xxx Molecular Xxxxxxxx of Ethyl Xxxxxxxxxxxxxxxxx xxx XXX 191-Xxxxxxx Molecular Xxxxxxxx xx Ethyl Methanesulphonate xxx XXX 191 Xxxxxxx Xxxxxxxx xx XX52 Xxxxx, Xxxxxxxxxx Xxx., 160, 133-147.
13) Xxxxxx, X. X., Xxxxxx, A. X., Xxxxx, X. (1984), Xxxxxxxxx for xxx X5178X/XX+/--XX+/- Xxxxx Xxxxxxxx Xxxx Mutagenicity Xxxxx, xx: Xxxxxx, B. X. xx xx (xxx.) Xxxxxxxx of Xxxxxxxxxxxx Xxxx Procedures, Xxxxxxxx Science Xxxxxxxxxx, Xxx Xxxx, 239-268.
14) Xxxxxx, C. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxx, X. H. X., Xxxx, X., XxXxxxxx, X. X., Xxxxxxx S. X. (1989), Xxxxxxxxx Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx upon Colony Xxxxxxxxx, xx: Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data, Xxxxxxxx, X. X., ed., Xxxxxxxxx University Xxxxx, 66-101.
15) Abbondandolo, X., Xxxxxxx, X., Xxxxx, X., Fiorio, R., Xxxxxxxx, N., Xxxxxxxxxx, X. (1977), Induction xx 6-Thioguanine-Resistant Xxxxxxx xx X79 Xxxxxxx Xxxxxxx Xxxxx xx Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxxxxxxxxx, Xxxxxxxxxx Res. 46, 365-373.
16) Xxxx, X. X., McCann, X., Xxxxxxxx, X. (1975), Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx and Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Test, Mutatation Xxx. 31, 347-364.
17) Xxxxx, D., Xxxxxxx, X. X., Spector, X. X. S., Xxxxxx A. G., Xxxxx M. M. X. (1979), Xxxxxxxxxx xxx Characterisation xx xxx X5178X/XX+/--Xxxxx Lymphoma Xxxxxxx Xxxxx System, Xxxxx. Xxx. 59, 61-108.
18) Maron, D. X., Ames, X. X. (1983), Revised Xxxxxxx xxx the Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx. 113, 173-215.
19) Elliott, B. X., Xxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, J. X., Xxxx, R. X. (1992), Xxxxxxxxxxxx xx Aroclor 1254-Xxxxxxx X9 xx: In xxxxx Genotoxicity Assays, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Hara, X., Xxxxxxxx, X. (1976), X Xxxx Substitute xxx Polycholrinated Biphenyls x. x. an Xxxxxxx xx Metabolic Xxxxxxxxxx Xxxxxxx, X: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Mutagenesis Xxxxxxx, xx Xxxxxx, X. J., Xxxxx, X. X., Bend, X. X., Xxxxxxx, X. M. (xxx), Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
21) Xxxxx, X. F., Xxxxxx, X. X., XxXxxxx, K. X. (1982), XXX/XXXXX Mutation Xxxxx: Evaluation xx Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Ticc, X. X., Costa, X. X., Schaich, X. X. (xxx), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, X. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, X. X. (1983), Xxxxxxxxxx xx xx Xxxxxxxx System Xxxxx Xxxxx Xxxxx xx Xxxxxxxx Gels xxx Xxxxxxxxx Highly Xxxxxxxx Xxxxxxxx xx xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxx. Mutagenesis, 5, 795-801.
23) Applegate, X. X., Xxxxx, X. X., Xxxxxx, X. B., Xxxxxxx, X., Hozier, J. X. (1990), Xxxxxxxxx Xxxxxxxxxx of Xxxxxxxxx xx xxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxx Xxxxxxxx Xxxxx, Xxxx. Natl. Xxxx. Xxx. U. X. X, 87, 51-55.
24) Xxxxx, X. X., Xxxxx, D., Xxxxxx, J. C., Xxxxxx, X. E., Xxxxxx, X. G., Xxxxxx, X. X., Xxxxxx, X. (1985), Xxxxxxxx of Xxxxxxxxxxxxxxxxxx, Xxxxxxxxx (XXX+) Xxxxxxx xx X5178X/XX+/--Xxxxx Xxxxxxxx Xxxxx, Mutatation Res. 151, 161-174.
25) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. B. (1990), Xxxxxxxxx Xxxxxxx Xxxxxxxx xx Xxxxxxxxx Mutations xx x Heterozygous Xxxxxxxxx Xxxxx in Xxxxx Xxxxx, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, X. X., Xxxxx, X. L. (1990), Comparison xx Xxxxxxxxxx Xxxxxxxxxx Frequency xxx Xxxxx Xxxxxx XX-Xxxxxxxxx Mutant Frequency xx X5178X/XX+/- 3.7.2X Xxxxx Xxxxxxxx Cells, Xxxxxxxxxxx, 5, 609-614."
PŘÍLOHA 4X
"X.23 XXXXXXX XX XXXXXXXXXXXX XXXXXXX XX XXXXXXXXXXXXXXX XXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 483 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx ve xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx na xxxxxxxxxxxx xxxxxxx ve xxxxxxxxxxxxxxx xxxxx xx xxxx xx identifikovat xxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx chromozomové xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1, 2, 3, 4, 5). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx: chromozomové x xxxxxxxxxxxx. X xxxxxxx xxxxxxxxxx mutagenů xxxx indukované aberace xxxxxxxxxxxxxx xxxx, avšak xxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxx. Tato xxxxxx xxxx určena xx xxxxxxxxx xxxxxxxxxxx xxxxxxx a není x xxxxxx xxxxx xxxxxxx používána. Xxxxxxxxxxxx xxxxxx x podobné xxxx xxxx příčinou xxxxx geneticky xxxxxxxxxxx xxxxxx x xxxxxxx.
Xxxxx xxxxxxxx xx stanovují xxxxxxxxxxxx xxxxx xx xxxxxxxxxxxxxxx x xxxxxxxxxxx xx xxxx, xx xxxx xxxxxxx xxxxxxxx xxxxxxxxx indukce xxxxxxxxx xxxxxx v germinálních xxxxxxx.
X této xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxx cytogenetickou xxxxxxxx xx vivo xx xxxxxxxx xxxxxxxxxxxx xxxxxxx xxx xxxxxx xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx nejsou xxxxxxxxx xxxx xxxxxxx.
Xxx xxxxxxx xxxxxxx chromatidového xxxx xx spermatogoniích xx xxxx xxx — xxxxx xxx xxxxx xx xxxxxx xxxx — xxxxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxx, xxxxx xxxxxxxxx po xxxxxxxx. Další xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx chromozomového xxxx x diakinese-metafázi X, xxx xx xxxxxxxxxx buňky xxxxxxx xxxxxxxxxxxx.
Xxxx zkouška xx xxxx xx xxxxxxxx xxx xxxxxxxxx, xxx xxxx mutageny xxxxxxxxxxx xxxxx aktivní také x xxxxxxxxxxxx xxxxxxx. Xxxxx xx xxxx xxxxxxx se xxxxxxxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx x procesy xxxxxxxx XXX.
Xx xxxxxxxxx xx přítomna xxxx xxxxxxxx spermatogonií s xxxxxx citlivostí xx xxxxxxxx chemické látce. Xxxxxxxxxx aberace xxxx xxxxxxxxxxx souhrnnou odpověď xxxxxxxxxx xxxxxxxx spermatogonií x převládajícími xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. X závislosti xx své xxxxxx xx xxxxxxxxx, mohou xxxx xxxxxx být xxxxx xxxxxxxx spermatogonií xxxxxxxxxx celkovému xxxxxxxx xxxxx x xxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxx xxxxx x xxxxxxx mezi xxxxxxx xxxxxx x xxxxxxx.
Xxxxxxxx existuje xxxxx x xxx, že xx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx do cílové xxxxx, není xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 DEFINICE
Chromatidová xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx nebo xxxxx x xxxxxxxx spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x podobě zlomu xxxx xxxxx a xxxxxxx xxxx chromatid x xxxxxx místě.
Gap : xxxxxxxxxxxx xxxx xxxxx než xxxxx xxxxx xxxxxxxxxx x x minimální odchylkou xxxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx chromozomů xx xxxxxxxx xxxxxxx x xxxxxxxxx buněk.
Polyploidie : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení ve xxxxxx xxxxxxxx xxx xxxxxxxxxxx, xxxx xx xxxx xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX METODY
Zvířata xxxx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx x xx xxxxxx době xx xxxxxxxx xxxxxxxx. Xxxx xxxxxxxxx xx xxxxxxxx xxxx látka xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X germinálních buněk xx poté xxxxxxxx xxxxxxxxx chromozomů, xxxxxx xx a xxxxxxxxx xx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Přípravky
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xxxx xxxxxxxxx xxxxx xxxxxx čínského a xxxx; xxx xxxx xxxxxx samce xxxxxxxxxx xxxxxx xxxxxxxx xxxxx xxxxx. Měly by xxx xxxxxxx běžně xxxxxxx xxxxxxxxxxx kmeny xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx studie xx měla být xxxxxxxx v hmotnosti xxxxxx minimální a xxxxxx xx překročit ± 20 % xxxxxxx hodnoty hmotnosti.
1.4.1.2 Xxxxxxxx xxxxx a xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx úvodu x xxxxx X, xxxxxxx by mělo xxx dosaženo vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladí xxxxxxxx xxxxxxx xxxxx xx xxxxxxxx xxxxxxx rozdělí xx xxxxxxxxx xxxxxxx x skupinu, která xx exponuje. Xxxxx xx měly xxx xxxxxxxxxx xxx, aby xxx xxxx xxxxxx xxxxxx minimalizován. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxx xxxxxxxxx studie xx xxxxxxx v xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx zkoušené xxxxx xxxxx být xxxxxxxx xxxxx nebo mohou xxx xxxx xxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx zkoušené xxxxxxxx xxxxx, pokud xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum by xxxxxx xxx xxx xxxxxxxxx hladinách xxxxx xxxxxxx účinky x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx údaji o xxxxxx kompatibilitě. Doporučuje xx pokud xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí xxxxxxx xxxxxxxxxxx xx xxxx xxx souběžné xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X xxxxxxxx xxxxxxxx zkoušené xxxxx by měla xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx identický xxxxxx xxxx xxxxxxx ve xxxxxxxxx, v xxxxx xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxxx, u xxxxx xx xxxxxxxxxxx, xx xxxxxxxxx detekovatelný xxxxxx xxx xxxxxx.
Xxxxx xxxxxxxxx xxxxxxxx by měly xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx preparátu. Je xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx podávána xxxxx způsobem xxx xxxxxxxx xxxxx x xxx xxx odběr x xxxxx případě xxxxxxxx jen xxxxxx. Xxx xxxxxxxxx kontrolu xxxx xxx navíc xxxxx x úvahu xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx, jsou-li x xxxxxxxxx. Xxxxxxxx látek xxx pozitivní kontrolu:
|
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (xxxxxxx) |
79–06–1 |
201–173–7 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx měl xxx xxxxxxxx xxxxx x xxxxxxx negativní kontroly, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx a která xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx kontrolních xxxxx x dispozici xxxxxxxxxx údaje o xxxxxxxxxxx zvířat x xxxxxxxx xxxxx s xxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxx xx měly xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx dosud kontrolní xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx xxxxxx
Xxxxx exponovaná x xxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx měly xxx xxxxx xxxxx xxxxxxxx xxxxxxxxxxx nebo nadvakrát (xx. xxx jedné xxxxxxxx nebo xxxx xxxxxxxxxx). Zkoušené látky xxxxx xxx xxxxxxxx xxxx xx xxxx xxxxxxx, tzn. xxx xxxxx v týž xxx v rozmezí xx xxxx než xxxxxxxx xxxxx, aby xxxx xxxxxxxxx xxxxxxxx xxxxxxx objemů xxxxxxxxx. Xxxx režimy xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xx xxxxxxx x xxxxxxxx dávkou xx xxxx xxx xx xxxxxxxx xxxxxxxxx xxx xxxxxx. Poněvadž xxxxxxxx xxxxxxxxx xxxxx xxxx být zkoušenou xxxxxx xxxxxxxxx, xxxxxxx xx xxxxx xxxxx xxxxx a jeden xxxxxxxx xxxxx přibližně 24 x 48 xxxxx xx expozici. X xxxxxxx xxxx xxx xxxxxxxx xxxxx xx xxx být xxxxx xxxxxxxx po 24 xxxxx nebo xx xxxxxx xxxx xxxxxxxx, která odpovídá 1,5xxxxxxx délky buněčného xxxxx, pokud xxxx xxxxx jiná xxxxxxxxx xxxx xxx xxxxxxx xxxxxx (6).
Xxxxx xxxxx xxx xxxxxx xxxxxxxxx xxxx x xxxx xxxx. Xxxxxxxxx x xxxxxxx chemických xxxxx, xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxx) xxxxxxxxxx xxxx xxxxx xxxxxxxxxx X-xxxxxxxxx účinky, xxxx xxx xxxxxxxxx xxxxxxxx xxxxx (1).
Vhodnost xxxxx opakované xxxxxxxx xxxx xxx xxxxxx xxxxxx od případu. X případě xxxxx x xxxxxxxxxx expozicí xx xxxx být xxxxxxx xxxxxxxx 24 xxxxx (1,5xxxxxxx xxxxx xxxxx) xx poslední xxxxxxxx. Xxxxx xxxxxxx xxxxx xxx prováděny xxxxx odběry x xxxx době.
Před usmrcením xx xxxxxxxx intraperitoneálně xxxx xxxxxx dávka xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® nebo xxxxxxxxx). Poté xx xx vhodné době xxxxxxx x xxxxxx xxxxx. X xxxx xx xxxx xxxx xxxxxxxxx 3 — 5 hodin; u xxxxxx čínského xx xxxx doba xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx údajů studie xxx zjištění xxxxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx x xxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxxxx xx xxxxxxx x xxxxxx xxxxxx (7). X xxxxxxx xxxxxxxx xx pro xxxxx xxxxx xxxxxxx tři xxxxxx xxxxx. Xxxx xxxxxx dávky xx xxxx xxxxxxxx rozmezí xxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru xxxxx, xxxx bude použita xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx takové známky xxxxxxxx, že xx xxxxx xxxxx xxxxx xxx stejném xxxxxx xxxxxxxxx xxxxx očekávání x xxxxxxxx.
Xxxxx se xxxxxxxxxxx biologickou xxxxxxxxx xxx nízkých netoxických xxxxxxx (např. hormony x mitogeny) xxxxxx xxxxxxxxx stanovení xxxxx xxxxxxxxx a xxxx xx xxx xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xx spermatogoniích xxxxxxx xxxxxx toxicity (např. xxxxxxx xxxxx spermatogonií x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx; xxxx snížení xx xxxxxx xxxxxxxxx 50 %).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx alespoň 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx dvou dávkách x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx základě xxxxx o xxxxxxx, xxxxx xxxx podobnou xxxxxxxxx, xxxxxxxxx genotoxicita, xxxxxxxxxx se úplná xxxxxx se xxxxx xxxxxxxx dávky za xxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx zkoušce vyšší xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx podává nitrožaludečně, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx způsoby xxxxxxxx xxxx xxxxxxxxxx, jsou-li xxxxxxxxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx může xxx xxxxxxxx podán xxxxxxxxx sondou nebo xxxxxxxx, xxxxxx xx xxxxxxxxx testovacího zvířete. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx xx uvedený xxxxx, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx a xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx zkoušeného xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx konstantní objem xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx xx x jednoho xxxx xxxx xxxxxx získá xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx x xxxxxx. Xxxx se nanese xx xxxxxxxx xxxxxxx x obarví xx.
1.5.7 Xxxxxxx
X xxxxxxx zvířete xx mělo xxx xxxxxxxxxxx alespoň 100 xxxxx x dobře xxxxxxxxxxxx xxxxxxxx (tj. xxxxxxxxx 500 xxxxxxxx xx skupinu). Xxxxx xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x negativních xxxxxxx, xx měly xxx před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx kódovány. Xxxxxxxx při fixaci xxxxx xxxxxxx ke xxxxxxxxxxxxxx xxxxxx nebo xxxxxx chromozomů x xxxxx metafází, měly xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxxxxxxxxxx xxxxx 2 n ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx pro xxxxxxxxxx xxxxxxx by xxxx xxx zpracovány xx xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx každé zvíře xx xxx xxx xxxxxxxxxx xxxxx xxxxx xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx x počet xxxxxxxxxxxxxx xxxxxxx na xxxxx. Pro xxxxxxxxxx x xxxxxxxxx xxxxxxx xx xxxx být xxxxxxx různé xxxx xxxxxxxxxxxx chromozomových xxxxxxx x xxxxxx počtem x xxxxxxxx. Gapy xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx se, xxx xxxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx.
Xx-xx xxxxxxxxxx xxxxxx a také xxxxxx, xxx xx xxx xxx xxxxxxxxx xxxxxxx cytotoxických účinků xxxx xxxx xxxxxxxxxxxx xxxxxxxx u xxxxx xxxxxxxxxxxx xxxxxx x xxxxxx xxxxxxxxxx jako xxxxxxxxx kontrola poměr xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx, x xx x xxxxxxxx xxxxxx 100 xxxxxxxx xx xxxxx xx xxxxx xxxxx. Pokud xx xxxxxxxxx pouze mitosa, xxxxxxx x 1000 xxxxxxx xx zvíře xx xxx xxx xxxxxxxx xxxxxxxxx xxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxxx xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx v xxxxxxxxxx xx xxxxx xxxx jasný xxxxxx xxxxx buněk x xxxxxxxxx xxx xxxxxxx x určitou xxxxxx x k určitému xxxxxxxx xxxxxx. Xxxxxxxx xx měla xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx jako xxxxxxx xxxxxxxxxx statistické xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx by neměla xxx xxxxxxx určujícím xxxxxxxx xxx pozitivní xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx považuje xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x aktivitě xxxxxxxx xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky na xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx xx xxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x germinálních buňkách xxxxxxxxxxx xxxxx strukturní xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx xxxx její xxxxxxxxxx dostanou xx xxxxxx xxxxx.
3. XXXXXX
XXXXXXXX X ZKOUŠCE
Protokol o xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx vehikula,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx v rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx druh/kmen,
- xxxxx x xxxxx zvířat,
- xxxxx, xxxxxxxx xxxxx, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx zkoušky, včetně xxxxxxx xxxxxxx hmotnosti, xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxx pro xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx xx studie xxx zjištění rozsahu, xxxxx byla xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- zdůvodnění způsobu xxxxxxxx,
- xxxxx o xxxxxxxx zkoušené xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxx usmrcení,
- případně xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx vodě (xxx) xx odpovídající xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx údaje x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx buněk na xxxxx zvíře,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, negativní xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx k xxxxx x xxxxx xxxxxxxx xxxxxx,
- typ x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx pro xxxxx xxxxx,
- xxxxxxx počet xxxxxxx ve xxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx skupině,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx x souběžné xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx odchylkami,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxx ploidie, xxxxx xxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X., (1986), Xxxxxxxxxxx Xxxxxxxxx in Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Xxxxxxxx Related xx their Xxxx-Xxxxx Xxxxxxxxxxxxxx, xx: Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxxx Xxxxxxxxx, Part X: Xxxxxxx Effects xxx Xxxxxxx Mutagenesis, Ramel, X., Xxxxxxx, X., Xxxxxxxxx, X. (xxx) Xxxx, New York, 477-484.
2) Adler, X. X., (1984), Xxxxxxxxxxx xxxxx xx Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, (xx.) S. Venitt, X. M. Parry, XXX Xxxxx, Xxxxxx, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, E. X., Xxxxxxx, X., Xxxx, X. X. (1964), Xx Xxx-xxxxxx Xxxxxx xxx Xxxxxxx Xxxxxxxxxxxx xxxx Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx Xxxx Xxxxxxxx, 3, 289-294.
4) Richold, X., Xxxxx, X., Xxxxxxxx, A., Xxxxxxxxx, X. X., Xxxxxxxxx, X. (1990), In xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx. Xxxxxx. Xxxx X xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Sydney, 115-141.
5) Xxxxxxxx, X., Xxxxxxx, X. (1978), A Xxx Xxxxxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Chromozomes, Xxxxxxxxxx Xxx., 52, 207-209.
6) Xxxxx, X. X., Xxxxxx X. X., Xxxxxxx, J., Xxxxx, X., Generoso, X., Xxxxxxxxxxxx, X., Xxxxxxx, X., Xxxxxx X. (1994), Xxxxxxxxxxxxx Workshop xx Xxxxxxxxxxxxxxx of Xxxxxxxxxxxx Test Procedures. Xxxxxxx Report of xxx Xxxxxxx Xxxxx xx Mammalian Xxxx Xxxx Tests, Mutatation Xxx., 312, 313-318.
7) Xxxxxxx, R. J., Xxxxx, J. X., Xxxxxx, A. R., Xxxxxx, P. X., Xxx, X., Esdaile, X. J., Gatehouse, X. G., Xxxxxx-Xxxxxx, X., Xxxxxx, D. X., Xxxxxxxx, X. X., Xxxxxxx, M. (1992), Xxxxxx of Xxxxxxx Xxxxxxxxxx Society/UK Xxxxxxxxxxxxx Mutagen Society Xxxxxxx Xxxxx: Dose Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, X. P., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, G. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxx, X., Papworth, X. X., Xxxxxx J. X. X. (1989), Xxxxxxxxxxx Analysis of Xx vivo Xxxxxxxxxxx Xxxxxx, xx: D. X. Kirkland (ed.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxx. XXXXX Xxxxxxxxxxxx on Xxxxxxxxxx for Mutagenicity Xxxxxxx, Xxxxxx, Part XXX. Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Port Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.39 XXXXXXX XX XXXXXXXXXXXX SYNTÉZU XXX (XXX) V XXXXXXXXX XXXXXXX SAVCŮ XX XXXX
1. METODA
Tato xxxxxx je xxxxxxxx xxxxxx XXXX XX 486 — Xxxxxxx xx neplánovanou syntézu XXX (XXX) x xxxxxxxxx xxxxxxx xxxxx xx xxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx syntézu XXX (XXX) x jaterních xxxxxxx xxxxx in xxxx xx identifikovat xxxxxxxx xxxxx, xxxxx xxxxxxxx reparace XXX x jaterních buňkách xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Tato xxxxxxx in xxxx xxxxxxxxx metodu xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx v játrech. Xxxxxxxxxxx xxx je xxxxxxxxxx xxxxxxxxx XXX x xxxxxxxx xxxxxxxx x xxxxxxxxx buňkách. Xxxxx xxxx obvykle xxxxxxx místem, xxx xxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx. Xxxx tedy xxxxxxx místem xxx xxxxxxxxx xxxx xxxxxxxxx XXX xx xxxx.
Xxxxxxxx xxxxxxxx xxxxx o xxx, xx se xxxxxxxx xxxxx xxxxxxxxx xx xxxxxx xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxxxxx xxxxxxxxxxx xxxxxxx XXX (XXX) xx zhodnotí xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xx buněk, xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx XXX (X-xxxx). Nejrozšířenější xxxxxxxxx xx xxxxxxxxxxxxxxxxx xxxxxxxxx inkorporace thymidinu xxxxxxxxx xxxxxxx (3H-TdR). Xxx zkoušky xx XXX xx xxxx xx přednostně xxxxxxxxx xxxxx potkana. Xxxx xxxxx xxx xxxxx xxxxx být rovněž xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxx xxxxxx.
Xxxxxxx xxxxxxxx XXX závisí xx počtu xxxx XXX xxxxxxxxxxx x xxxxxxxxxxx v místě xxxxxxxxx. Xxxxxxx xx XXX xx xxxx xxxxxx zvláště pro xxxxxxx dlouhých xxxxxxxx ("xxxx-xxxxx xxxxxx") (20 xx 30 bází) xxxxxxxxxxxx látkou. Xxxxxx xxxxxx ("xxxxx-xxxxx xxxxxx") (xxxxx až xxx xxxx) jsou xxxxxxx xxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxx. Xxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxxxx xxxxxxxx nebo chybné xxxxxxxxx xxxx DNA xxxxx x mutagenním xxxxxxxxx. Rozsah xxxxxxxx XXX neposkytuje žádnou xxxxxxxxx x věrnosti xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx, že xxxxxxx xxxxxxx x XXX, xxx xxxxxxxxx XXX není xxxxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxxxxxx informací, které xxxx xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx, xx xxxxxxx potenciální xxxxxxxxxx xxxxxx xxxx, xxxxx xx xxxxxxxxxx x xxxxx genomu.
Viz xxxx xxxxxx xxxx, xxxx X.
1.2 DEFINICE
Opravované xxxxx : xxxxx xxxxx zrn odpovídajících xxxxxxxx jádrům (XXX), xxxxx xxx xxxxxxxxxx xxxxxxx stanovená laboratoří xxxxxxxxxxx zkoušku.
Čistý xxxxx xxx odpovídajících buněčným xxxxxx (NNG) : xxxxxxxxxxxxx míra UDS xxxxxxxx xxxxx x xxxxxxxxxxxxxxxxx xxxxxxx na XXX, xxxxxxxxx odečtením xxxxxxxxxx xxxxx zrn x xxxxxxxxxxxxxxxxx oblastech (XX) xxxxxxxxxxxxxx jádrům xx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XX): XXX = XX — CG. Xxxxxxx XXX xx xxxxxxx xxx xxxxxxxxxx xxxxx, xxxx společně xxx xxxxx v xxxxxxx, v xxxxxxxxxxx xxxxxxxxx xxx.
Xxxxxxxxxxx xxxxxxx XXX (XXX) : Xxxxxxx reparací XXX xx xxxxxxxxx a xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx region x xxxxxxxxxx indukovaným xxxxxxxxxx xxxxxxx nebo fyzikálními xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xx XXX x xxxxxxxxx xxxxxxx xxxxx xx vivo xxxxxxxx xxxxxxx xxxxxxxx XXX po vyštěpení x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx indukovaným xxxxxxxxxx xxxxxxx nebo xxxxxxxxxxx xxxxxxxx. Zkouška xx obvykle xxxxxxxx xx xxxxxxxxxxx 3X-XxX xx XXX jaterních xxxxx, kde xx xxxx xxxxxxx xxxxx x S-fázi xxxxxxxxx xxxxx. Xxxxxxxxxxx 3X-XxX xx xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxx xxxx xxxxxxxx xxxx tak xxxxxxx na vliv X-xxxx xxxxx jako xxxx. kapalná xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xx xxxxxxxx xxxxxx, xxxxxx xxx xxxxxx jakýkoli xxxxxx xxxx savce. Měly xx být xxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx dospělých zvířat. X xxxxxxxx xxxxxxxx xxxxxx by xxxx xxx xxxxxxxx v xxxxxxxxx zvířat xxxxxxxxx x neměla xx xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx pro xxx xxxxxxx.
1.4.1.2 Podmínky xxxxx x strava
Platí xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx by xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxxxxx xxxxxxx zvířata xx xxxxxxxx xxxxxxx xxxxxxx xx kontrolní xxxxxxx x xxxxxxx, xxxxx xx xxxxxxxx. Xxxxx xx xxxx xxx xxxxxxxxxx xxx, xxx xxx xxxx jejich xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx x před xxxxxxxxx xxxxxx xx xxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxx látky xx xxxx xxx xxxx aplikací xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxxx přímo xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx údaje o xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by nemělo xxx xxx použitých xxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx jiná xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx xxxxxx použití xxxxx xxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx by měly xxx souběžné xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X výjimkou xxxxxxxx zkoušené látky xx xxxx xxxxxxx xxxxxxxxx skupiny podstoupit xxxxxx xxxxxx xxxx xxxxxxx xx skupinách, x xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxxxx xxxxxxxxxx xx xxxx xxx xxxxx, x xxxxx xx xxxxx, xx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx x xxxxxxx XXX xxxxxxxxxxxxxxx xxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx x dávkách xxxxxxxxxxxx mírnou xxxxxxx (4). Dávky xxxxx xxx xxxxxxx tak, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx xxxxxx nevyšla xxxxx najevo xxxxxxxx xxxxxxxxxxxx preparátu. Příklady xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxx odběru |
Látka |
Číslo XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxxxx xxxx xxxxxx (2 až 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
|
Xxxxxx xxxx xxxxxx (12 až 16 x) |
X-(xxxxxxx-2-xx)xxxxxxxx (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx použity xxxx xxxx xxxxx xxx xxxxxxxxx kontrolu. Xx xxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxxxx xxxxxxxx, xxx zkoušená látka.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx zvířat
Měl xx xxx použit dostatečný xxxxx xxxxxx, aby xxxx zohledněno xxxxxxxxx xxxxxxxxxx xxxxxxxx odpovědi xx zkoušku. Xxxxx xxxxxxx xx se xxxx skládat xxxxxxx xx xxx analyzovatelných xxxxxx. Xxxxxxxx jsou xxxxxxxxxxx dostatečné xxxxxxxxx xxxxx, xx xxx xxxxxxxxx x pozitivní xxxxxxxxx skupiny xxxxxxxx xxxxx xxxxx xx xxx xxxxxxx.
Xxxxxxxx xxxx x xxxx xxxxxx x dispozici xxxxx xx xxxxxx se xxxxxxx druhem a xx xxxxxxx stejného xxxxxxx xxxxxxxx, xxx xxxxxxxxx, že xxxxxxxxxx xxxx xxxxxxxxx xxxxxx x toxicitě, bude xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx samců. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, xxxx xx xxxx například u xxxxxxxxx xxxxxxxxxxxxxxx látek, xxxx by být xxxxxxx xxxxxxxxx xx xxxxxxxx odpovídajícího xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx látky xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx.
1.5.3 Xxxxxxxxx
Xx normálních xxxxxxxx xx xxxxxxxxx xxxxxxx xxx úrovně xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, že xxxxx xxxxx xx xxxxx podle očekávání xxx xxxxxxx xxxxxx xxxxxxxxx k letalitě. Xxxxx dávka xx xxxx xxx zpravidla 50 % xx 25 % vyšší xxxxx.
Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx aktivitou xxx xxxxxxx netoxických dávkách (xxxx. hormony a xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx vyhovovat x xxxx by xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx dostupných xxxxx xxxxxx xxx xxxxxxxx xxxxxxx, měla xx xxx provedena xx xxxxxx laboratoři, xx xxxxxxx xxxxxx, kmenem, xxxxxxxx x za xxxxxxxx xxxxxx xxxxxxxx, xxx se xxxxxxx x hlavní studii.
Nejvyšší xxxxx xxxx xxx xxxxxxxxxx xxxx jako xxxxx xxxxxxxxxxxx známky xxxxxxxx x xxxxxxx (xxxx. xxxxxxxxxx xxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx dávkou x xxxxxxx 2000 xx/xx xxxxxxx hmotnosti xxxxxxx jednorázově nebo xx dvou xxxxxxx x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx a xxxx-xx na xxxxxxx xxxxx o látkách, xxxxx xxxx xxxxxxxx xxxxxxxxx, očekávána xxxxxxxxxxxx, xxxxxx xxx xxxxx xxxxxx xxxxxxxx. Očekávaná xxxxxxxx xxxxxxx xxxx xxxxxxxx potřebu použít x limitní zkoušce xxxxx úroveň xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx intubační xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx xxxxx, xxx-xx xx zdůvodnit. Xxxxxxxx intraperitoneálně se xxxx xxxxxxxxxxxx, neboť xx xxxxx xxxxx xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxx x xxxxxx xxxxxxxxxxxxxxx oběhového xxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx najednou podán xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx na xxxxxxxxx testovacího xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x tělesné xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx je uvedený xxxxx, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx zesílené xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx konstantní xxxxx xxx xxxxx úrovních xxxxx.
1.5.6 Příprava xxxxxxxxx xxxxx
Xxxxxxx buňky se xxxxxxxxxx x xxxxxxxxxxxx xxxxxx zpravidla 12 xx 16 hodin xx xxxxxx dávky. Xxxxxxxxxx xxxxxxxx odebrání xxxxxx (obecně dvě xx xxxxx xxxxxx xx xxxxxxxx) je xxxxxxxx, xxxx-xx po 12 xx 16 xxxxxxxx xxxxx pozitivní xxxxxxx. Xxxxx však xxx použity jiné xxxx xxxxxx, jsou-li xxxxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx kultury xxxxxxxxx buněk savců xx zpravidla xxxxxxxxx xxxxxxx xxxxx kolagenasou xx xxxx x xxxxxx se, xxx xx čerstvě disociované xxxxxxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx. Xxxxxxx xxxxx x xxxxxxxxx xxxxxxxx by xxxx vykazovat xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Xxxxxxxxx XXX
Xxxxxxx xxxxxxxxx xxxxxxx buňky xxxxx xx obvykle xxxxxxx dobu, např. xxx xx xxx xxxxx, xxxxxxxx x xxxxxx xxxxxxxxxxx 3H-TdR. Xx xxxxx inkubační xxxx xx mělo xxx xxxxxx x xxxxx odstraněno x xxxxx poté mohou xxx inkubovány x xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx, xxx xxxx snížena neinkorporovaná xxxxxxxxxxxxx ("xxxx chase"). Xxxxx se xxxx xxxxxxx, fixují a xxxxxx. Xxx xxxxx xxxxxxxxx xxxx xxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx. Preparáty xx xxxxxx xx xxxxxxxxxxxxxxxxx xxxxxx, exponují xx x temnu (xxxx. x xxxxxx 7 xx 14 xxx), xxxxxxxx xx, xxxxxx x xxxxxxxxx se xxxxxxxxxx xxxx xxxxxxx. X každého zvířete xx xxxxxxxx xxx xx tři xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx xx měly xxxxxxxxx dostatečný xxxxx xxxxxxxxxxxx xxxxxxxxxx buněk, xxx xxxx xxxxxxxxx XXX xxxxxxxxx xxxxxxx. Xxxxxxxxx se pod xxxxxxxxxxx prohlédnou na xxxxxx zjevné cytotoxicity (xxxx. na pyknosu, xxxxxxxx úroveň xxxxxxx xxxxxxxxxxxxx xxxxxxxx).
Xxxx počítáním xxx xx xxxx xxx xxxxxxxxx xxxxxxxx. Xxxxxxxxx xx xxxxxxxxx 100 xxxxx xx xxxxx zvíře xxxxxxx xx xxxx preparátů; xxxxxxxxx méně xxx 100 xxxxx/xxxxx xx xxxx xxx xxxxxxxxxx. Xxx xxxxxxxx zrn xx xxxxx v X-xxxx xxxxxxxxxxx, xxx xxxxx buněk v X-xxxx xxxx xxx xxxxxxxxxx.
Xxxxxxxx 3H-TdR xxxxxxxxxxxxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxxxxx normálních xxxxx xxxxxxxx navrstvením xxx xxxxxxx xx xxxx být xxxxxxxxx xxxxxxx metodou.
Počet xxxxx xx xxxxxxx x xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxŭx (ng) x x prŭměrného xxxxx zrn x xxxxxxxxxxxxxxxxx oblastech (xx) xxxxxxxxxxxxxx xxxxŭx. xxxx xxxxxxx cg se xxxxxxx xxx počet xxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx cytoplasmy, xxxx xxŭxxxxx xxxxxxx xxxx xx xxx xxxxxxx xxxxxxxxx oblastí x xxxxxxxxx dotyčných xxxxxxxxx jader. xx xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx x xxxx postupy xxxxxxxxx xxxxx buněk (xxxx. xxxxxxxx xxxxxx xxxxx) (6).
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxx by xxx xxxxxxx údaje xxx xxxxxxxxxx xxxxxxxxx x xxxxxxx. Xxxxx xx xxxx být dále xxxxxxx ve formě xxxxxxx. Xxxxxxxxx xxxxxxx XX xx xxxxxxx XX xx xxx xxx vypočten xxx xxxxxx buňku, xxx xxxxx zvíře x xxx každou xxxxx x xxx xxxxx xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX). Xxxxxxxx xxxx počítány "xxxxxxxxxx" xxxxx, měla xx xxx xxxxxxxx xxx xxxxxxxxxx "xxxxxxxxxxxx" xxxxx xxxxxxxxxx x xxxxxxxx na xxxxxxxxxxx xxxx xxxxxxxxxx údajích x xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx xxx xxxxxxx, xxxx by xxx xxxxxxxxxxx xxxxx xxxxxxx x xxxxxxxxxx xxxx xxxxxxxxxx studie.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxxx xxxxxxxx kritérií xxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxx:
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xxx xxxxxxxx xxxxxx, která xx zdůvodněna na xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx NNG xx xxxxxxxx xxxxx xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx NNG leží xx dosavadní xxxxxxx xxxxxxx xxxx xxx xx; |
|
xxxx |
xx) |
xxxxxxx NNG xxxx xxxxxxxx xxxxx xxx xxxxxxx pro xxxxxxxxx xxxxxxxx. |
Xxxx xx být xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, xx. xxxx xx xxx vzaty x úvahu xxxxxxxxx, xxxx xxxx xxxxxxxxxxx xxxxxx, xxxxx dávky x xxxxxxxx a xxxxxxxxxxxx. Při hodnocení xxxxxxxx xxxxxxx mohou xxx použity xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx xxxxxxxxxx xx však neměla xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx pozitivní xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný xxxxx x aktivitě xxxxxxxx xxxxx. Výsledky mohou xxxxxx dvojznačné xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx XXX x jaterních xxxxxxx xxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx látka indukuje x xxxxxxxxx buňkách xxxxx xx xxxx xxxxxxxxx XXX, které xxx xxxxxxx neplánovanou xxxxxxxx XXX in xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx zkoušená xxxxx za xxxxxxxx xxxxxxx neindukuje poškození XXX, xxxxx xxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx xxxxxxx do xxxxxxxx xxxxx popř. xx xxxxxx tkáně (např. xxxxxxxxx xxxxxxxx).
3. ZPRÁVY
PROTOKOL X ZKOUŠCE
Protokol x xxxxxxx musí obsahovat xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx a xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, strava xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx odchylky xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (vehikulum/rozpouštědlo) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx rozsahu, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- údaje o xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx do xxxxxxxx xxxxx xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx odpovídající xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné údaje x xxxxxxx xxxxxx x vody,
- xxxxxxxx xxxxx xxxxxxx expozice x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx,
- použitá xxxxxxxxxxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx x počet xxxxxxxxxxx xxxxx,
- kritéria xxxxxxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx pozitivní, xxxxxxxxx nebo dvojznačnou.
Výsledky:
- xxxxxxx hodnoty xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx x xxxxx xxx odpovídajících xxxxxxxxxx, x xxxxx počet xxx, xxxxxxxxxx xxx xxxxxxxxx, zvířata a xxxxxxx,
- podle možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x rozmezími, xxxxxxxxx hodnotami a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx "opravovaných" xxxxx, xx-xx xxxxxxxx,
- xxxxx xxxxx x S-fázi, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. Xxxxxxx, X. X., Xxxxxxxxx, X., Xxxxxx, M. X. (1985), Xx Xxxxxxxxxx xx the Xx xxxx Xxx. Xxxxxxxxxx XXX Xxxxxx Xxxxx, Mutatation Xxx., 156, 1-18.
2) Butterworth, X. E., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Probst, X., Xxxxxxxx, G. (1987), X Xxxxxxxx and Xxxxx xxx xxx Xx xxxx Rat Xxxxxxxxxx DNA Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 189, 123-133.
3) Xxxxxxxx, X. X., Waters, X., Ashby, X., Xxxxxxx, P. A., Xxxxxxxxx, X., Benford, X. J., Dean, X. W., Xxxxxxxx, X. xx X. (1993), Xx xxxx Xxx Liver UDS Xxxxx, xx: Xxxxxxxx X. J., Fox X., (xxx), Xxxxxxxxxxxxx Xxxxxxxxxxxx Tests: XXXX Xxxxxxxxxxx Procedures. UKEMS Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Xxxx XX xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, X., Dean, X. X., Andrac, X., Xxxxxxxxx. X., Xxxxxxxxx, X., Xxxxxxxxx, X. J., Furihata, X., Hertner, T., XxXxxxx, C. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx of UDS Xxxxx Xx xxxxx xxx Xx xxxx, Xxxxx. Xxx., 312, 263-285.
5) Fautz, X., Xxxxxxx, B., Efstathiou, X., Xxxxxxxxxxxx-Xxxxxx, C. (1993), Xxxxxxxxxx xx xxx Relation Xxxxxxx xxx Initial Viability xxx the Attachment xx Freshly Xxxxxxxx Xxx Hepatocytes Xxxx xxx xxx In xxxx/Xx vitro DNA Xxxxxx Xxxxx (UDS), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Tyson, C. X., Xxxxxxxxxxx, B. X. (1982), Xxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxx xx the Xx xxxx/Xx vitro Xxxxxxxxxx XXX Repair Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
PŘÍLOHA 5
XXXXXX XXXXXXXXX XX KLASIFIKACI A XXXXXXXXXX XXXXXXXXXXXX XXXXX X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/ES, Úř. xxxx. X 332, 28. 12. 2000, x. 81.
PŘÍLOHA 6
"
XXXXXXX XX
XXXX X
xxxxxxxx týkající xx xxxxxxx odolných xxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxxxx xx. 22 xxxx. 1 xxxx. x) xxxx xxxxxxxx, xxxx xxx xxxxx x xxxxxxxxx xxxxxx xxxxxxxxxx xxxxx, x xxxxx xx xxxxxxx xxxxxx xxx xxxxxxxxxx (Xx; X 65) x xxxxx xxxx xxxxxxxxxxxxx x označeny xxxxx xxxx 3.2.3 xxxxxxx XX xxxx xxxxxxxx, x xxxxxxxx látek xxxxxxxxx xx xxx xx xxxxx xxxxxxxx xxxx v xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx, xxxxxxxx xxxxxxx xxxxxxxx xxxxx otevření xxxxx.
1. Xxxxxxxxx xxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx na xxxxxxxxx xxxxxxxxxxxxxx obalech xxxx xxxxxxxx xxxxxxxxx xxxxx XXX 8317 (xxxxxx xx dne 1. xxxxxxxx 1989) "Xxxxx xxxxxx xxxxx — Požadavky na xxxxxxxxx uzavíratelné xxxxx x xxxxxx xxxxxx xxxxxxxx" xxxxxxxx Xxxxxxxxxxx xxxxxxxxxx pro xxxxxxxxxxx (XXX).
2. Xxxxxxxxx xxxxxxxxxxxxxx xxxxx
Xxxxxxx xxxxxx proti xxxxxxxx xxxxx použité xx opakovaně xxxxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx normy XXX XX 862 (vydání x xxxxxx 1997) "Xxxxx — Xxxxx xxxxxx xxxxx — Xxxxxxxxx x zkušební xxxxxxx xxx opakovaně xxxxxxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxxxxxxxxx xxxxxxx" xxxxxxxx Xxxxxxxxx xxxxxxx xxx normalizaci (CEN).
3. Xxxxxxxx
1. Xxxxxxxxx shody x xxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxxx, které xxxxxxx xxxxxxxx normy xxxx XX 45000.
2. Xxxxxxxxxx xxxxxxx
Xx-xx zřejmé, xx xxxx je xxxxxxxxxx xxxxxxxx xxx xxxx, xxxxx xx xxxxxxx xxxxxx x xxxxxx xxx pomoci xxxxxxxx, nemusí xxx xxxxxxx xxxxxxxxx.
Xx xxxxx xxxxxxxxx případech x xxxxx existují xxxxxxxxx xxxxxx x xxxxxxxx x xxxxxxxxxxx uzávěru xxx xxxx, xxxx xxxxxxxxxxxx orgán xxxxxxxxx, xxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx xx trh xxxxxxxxxx xxxxxxxxxx vydaný xxxxxxxxxx xxxxx xxxx. 3 xxxx 1 konstatující, xx xxx
- xxx xxxxxxx xx xxxxxx, xx xxx není xxxxxxxx xxxxxxx podle xxxx xxxxxxxxx xxxxx XXX x XXX,
xxxx
- xx xxxxxx xxx xxxxxxx a xxx xxxxxxx xxxxxxxxxxx xxxxx xxxx uvedených norem.
ČÁST X
Xxxxxxxx týkající xx xxxxxxxxxxxx xxxxxxx
Xxxxxxxxx xxxxxxxxxxx xxx hmatatelné xxxxxxxx xxxx xxx x xxxxxxx s normou XX XXX 11683 (xxxxxx x xxxx 1997) "Xxxxx — Xxxxxxxxxx výstrahy xxxx xxxxxxxxxx — Požadavky".
"